BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor A Pathway and Receptor Tyrosine Kinases Involved in Tu

Cancer Research

64, 7099-7109

DOI: 10.1158/0008-5472.can-04-1443

Citation Report

#	Article	IF	Citations
1	Kinase Inhibition with BAY 43â€“9006 in Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 6388S-6392S.	3.2	232
2	Primary intracranial myxopapillary ependymomas: report of two cases and review of the literature. Acta Radiologica, 2004, 45, 344-347.	0.5	25
3	Update on angiogenesis inhibitors. Current Opinion in Oncology, 2005, 17, 578-583.	1.1	70
4	Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti-Cancer Drugs, 2005, 16, 709-717.	0.7	54
5	Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 499-515.	2.0	31
6	"Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 25-34.	2.0	28
7	A critical function for B-Raf at multiple stages of myelopoiesis. Blood, 2005, 106, 833-840.	0.6	28
8	Oncogenes as molecular targets in lymphoma. Blood, 2005, 106, 1911-1923.	0.6	23
9	Cancer Targets in the Ras Pathway. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 461-467.	2.0	95
10	Angiogenesis inhibitors in the treatment of cancer. Expert Opinion on Pharmacotherapy, 2005, 6, 1701-1711.	0.9	49
11	Raf Kinase Inhibitors in Oncology. Oncology Research and Treatment, 2005, 28, 101-107.	0.8	31
12	Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU International, 2005, 96, 286-290.	1.3	51
13	Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. British Journal of Cancer, 2005, 92, 1855-1861.	2.9	321
14	Role of novel targeted therapies in the clinic. British Journal of Cancer, 2005, 92, S21-S27.	2.9	12
15	Killing time for cancer cells. Nature Reviews Cancer, 2005, 5, 573-580.	12.8	79
16	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene, 2005, 24, 6646-6656.	2.6	354
17	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 2005, 24, 6861-6869.	2.6	254
18	Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell, 2005, 7, 179-191.	7.7	252

#	Article	IF	Citations
19	Focus on lymphangiogenesis in tumor metastasis. Cancer Cell, 2005, 7, 121-127.	7.7	291
20	A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell, 2005, 8, 111-118.	7.7	219
21	K-ras as a target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1756, 127-144.	3.3	137
22	2005 Highlights From: 41st Annual Meeting of ASCO Orlando, FL, May 2005 6th International Lung Cancer Congress Kauai, Hawaii, June 2005 11th World Conference on Lung Cancer Barcelona, Spain, July 2005. Clinical Lung Cancer, 2005, 7, 81-86.	1.1	0
23	The Emerging Role of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. Seminars in Oncology, 2005, 32, 23-29.	0.8	23
24	Advances in Prostate Cancer Chemotherapy: A New Era Begins. Ca-A Cancer Journal for Clinicians, 2005, 55, 300-318.	157.7	146
25	Sorafenib: Scientific Rationales for Single-Agent and Combination Therapy in Clear-Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2005, 4, 167-174.	0.9	33
26	Targeting Angiogenesis with Vascular Endothelial Growth Factor Receptor Small-Molecule Inhibitors: Novel Agents with Potential in Lung Cancer. Clinical Lung Cancer, 2005, 7, S31-S38.	1.1	23
27	Targeting Multiple Signal Transduction Pathways in Lung Cancer. Clinical Lung Cancer, 2005, 7, S39-S44.	1.1	18
28	BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis, 2005, 26, 2553-2561.	1.3	25
29	Targeted agents for the treatment of advanced renal cell carcinoma. Cancer, 2005, 104, 2323-2333.	2.0	105
30	Small-Molecule Kinase-Inhibitor Target Assessment. ChemBioChem, 2005, 6, 523-526.	1.3	24
32	Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents. Current Oncology Reports, 2005, 7, 116-122.	1.8	6
33	The role of B-RAF in melanoma. Cancer and Metastasis Reviews, 2005, 24, 165-183.	2.7	143
34	Cortactin Overexpression Inhibits Ligand-Induced Down-regulation of the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 3273-3280.	0.4	77
35	Melanoma genetics and the development of rational therapeutics. Journal of Clinical Investigation, 2005, 115, 813-824.	3.9	152
36	Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. Current Cancer Drug Targets, 2005, 5, 229-248.	0.8	48
37	Expression genomics and drug development: Towards predictive pharmacology. Briefings in Functional Genomics & Proteomics, 2005, 3, 303-321.	3.8	9

#	Article	IF	Citations
38	From Traditional Biomarkers to Transcriptome Analysis in Drug Development. Current Molecular Medicine, 2005, 5, 29-38.	0.6	36
39	Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype. Journal of Clinical Oncology, 2005, 23, 8232-8241.	0.8	135
40	Targeting Signal Transduction Pathways in Colorectal Cancerâ€"More Than Skin Deep. Journal of Clinical Oncology, 2005, 23, 5374-5385.	0.8	71
41	Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Annals of Oncology, 2005, 16, 1688-1694.	0.6	270
42	Angiogenic inhibitors: a new therapeutic strategy in oncology. Nature Clinical Practice Oncology, 2005, 2, 562-577.	4.3	186
43	Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation. Journal of Biological Chemistry, 2005, 280, 35217-35227.	1.6	266
44	p21-activated Kinase 1 (Pak1)-dependent Phosphorylation of Raf-1 Regulates Its Mitochondrial Localization, Phosphorylation of BAD, and Bcl-2 Association. Journal of Biological Chemistry, 2005, 280, 24698-24705.	1.6	130
45	Targeting the Cell Cycle: A New Approach to Cancer Therapy. Journal of Clinical Oncology, 2005, 23, 9408-9421.	0.8	703
46	Raf kinase as a target for anticancer therapeutics. Molecular Cancer Therapeutics, 2005, 4, 677-685.	1.9	235
47	Mechanisms of Lymphangiogenesis: Targets for Blocking the Metastatic Spread of Cancer. Current Cancer Drug Targets, 2005, 5, 561-571.	0.8	23
48	Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway. Current Cancer Drug Targets, 2005, 5, 345-356.	0.8	17
49	Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors. Clinical Cancer Research, 2005, 11, 5472-5480.	3.2	332
50	Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13147-13152.	3.3	269
51	Molecularly targeted therapy in renal cell carcinoma. Expert Review of Anticancer Therapy, 2005, 5, 1031-1040.	1.1	33
52	BRAF mutation in thyroid cancer. Endocrine-Related Cancer, 2005, 12, 245-262.	1.6	1,114
53	Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncology, The, 2005, 6, 491-500.	5.1	527
54	Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. Journal of Clinical Oncology, 2005, 23, 965-972.	0.8	830
55	The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy. Urologic Clinics of North America, 2005, 32, 217-230.	0.8	9

#	Article	IF	Citations
56	Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications. Journal of Clinical Oncology, 2005, 23, 3243-3256.	0.8	244
57	Raf: A Strategic Target for Therapeutic Development Against Cancer. Journal of Clinical Oncology, 2005, 23, 6771-6790.	0.8	256
58	Anti-Angiogenic Treatment of Gastrointestinal Malignancies. Cancer Investigation, 2005, 23, 712-726.	0.6	19
60	Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opinion on Investigational Drugs, 2005, 14, 607-628.	1.9	17
61	Genomics and the second golden era of cancer drug development. Molecular BioSystems, 2005, 1, 17.	2.9	48
62	Emerging drugs for renal cell carcinoma. Expert Opinion on Emerging Drugs, 2005, 10, 773-795.	1.0	6
63	Role of Tyrosine Kinase Inhibitors in Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 971-979.	1.3	846
64	The promise of molecular targeted therapies: Protein kinase inhibitors in the treatment of cutaneous malignancies. Journal of the American Academy of Dermatology, 2005, 53, 291-302.	0.6	48
65	B-RAF and melanocytic neoplasia. Journal of the American Academy of Dermatology, 2005, 53, 108-114.	0.6	61
66	Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Current Opinion in Pharmacology, 2005, 5, 350-356.	1.7	198
67	Renal cell carcinoma: Current status and future prospects. Cancer Treatment Reviews, 2005, 31, 536-545.	3.4	120
68	Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. Drug Resistance Updates, 2005, 8, 75-83.	6.5	113
69	Molecularly targeted agents: Their promise as cancer chemopreventive interventions. European Journal of Cancer, 2005, 41, 2003-2015.	1.3	28
70	Improving Outcomes in Advanced Malignant Melanoma. Drugs, 2005, 65, 733-743.	4.9	35
71	Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, 188-196.	1.0	107
72	Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 6066-6083.	2.9	153
74	Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy. Journal of Clinical Oncology, 2005, 23, 5386-5403.	0.8	191
75	Biology and Clinical Development of Vascular Endothelial Growth Factorâ€“Targeted Therapy in Renal Cell Carcinoma. Journal of Clinical Oncology, 2005, 23, 1028-1043.	0.8	380

#	Article	IF	Citations
76	Therapeutic options to target angiogenesis in human malignancies. Expert Opinion on Emerging Drugs, 2006, 11, 635-650.	1.0	68
77	Kidney cancer therapy: new perspectives and avenues. Expert Opinion on Pharmacotherapy, 2006, 7, 2481-2493.	0.9	14
79	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics, 2006, 5, 2378-2387.	1.9	102
80	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology, 2006, 3, 24-40.	4.3	968
81	Sorafenib (BAY 43â€9006, NexavarÂ®), a Dualâ€Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. Methods in Enzymology, 2006, 407, 597-612.	0.4	387
82	Sorafenib. Expert Opinion on Pharmacotherapy, 2006, 7, 453-461.	0.9	86
83	Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885. Cancer Research, 2006, 66, 11100-11105.	0.4	257
84	Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC. Oncologist, 2006, 11, 274-284.	1.9	86
85	Novel Bis(1H-indol-2-yl)methanones as Potent Inhibitors of FLT3 and Platelet-Derived Growth Factor Receptor Tyrosine Kinase. Journal of Medicinal Chemistry, 2006, 49, 3101-3115.	2.9	46
86	Tyrphostins and Other Tyrosine Kinase Inhibitors. Annual Review of Biochemistry, 2006, 75, 93-109.	5.0	205
87	Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006). American Journal of Pathology, 2006, 169, 1875-1885.	1.9	139
88	Targeting the Expression of Platelet-Derived Growth Factor Receptor by Reactive Stroma Inhibits Growth and Metastasis of Human Colon Carcinoma. American Journal of Pathology, 2006, 169, 2054-2065.	1.9	93
89	Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer. Journal of Surgical Research, 2006, 133, 203-206.	0.8	64
90	Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nature Clinical Practice Oncology, 2006, 3, 564-574.	4.3	86
91	Novel Inhibitors of B-RAF Based on a Disubstituted Pyrazine Scaffold. Generation of a Nanomolar Lead. Journal of Medicinal Chemistry, 2006, 49, 407-416.	2.9	54
92	Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions. Oncologist, 2006, 11, 753-764.	1.9	245
93	Targeted therapy of renal cell carcinoma. Community Oncology, 2006, 3, 419-420.	0.2	0
94	Improving survival of patients with advanced renal cell carcinoma: a new paradigm. Community Oncology, 2006, 3, 422-425.	0.2	0

#	Article	IF	Citations
95	Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions. European Urology Supplements, 2006, 5, 619-626.	0.1	1
96	Tumor-induced lymphangiogenesis: A target for cancer therapy?. Journal of Biotechnology, 2006, 124, 224-241.	1.9	89
97	New Targets in the Management of Prostate Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 985-999.	0.9	1
98	Novel Therapies Targeting Signaling Pathways in Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 379-396.	0.4	12
99	Novel Therapies for the Treatment of Small-Cell Lung Cancer. Drugs, 2006, 66, 1919-1931.	4.9	16
100	Sorafenib: Recent Update on Activity as a Single Agent and in Combination with Interferon-Î±2 in Patients with Advanced-Stage Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2006, 4, 246-248.	0.9	16
101	Targeting Growth Factor and Antiangiogenic Pathways in Clear-Cell Renal Cell Carcinoma: Rationale and Ongoing Trials. Clinical Genitourinary Cancer, 2006, 5, S31-S39.	0.9	5
102	Targeting the ERK signaling pathway in cancer therapy. Annals of Medicine, 2006, 38, 200-211.	1.5	357
103	Yeast Screens for Inhibitors of Rasâ€“Raf Interaction and Characterization of MCP Inhibitors of Rasâ€“Raf Interaction. Methods in Enzymology, 2006, 407, 612-629.	0.4	5
104	Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5. Cancer Research, 2006, 66, 11851-11858.	0.4	1,315
105	KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Research, 2006, 66, 9134-9142.	0.4	189
106	Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treatment Reviews, 2006, 32, 9-27.	3.4	59
107	Targeted therapies in melanoma. Cancer Treatment Reviews, 2006, 32, 524-531.	3.4	20
108	Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?. Drug Resistance Updates, 2006, 9, 1-18.	6.5	46
109	Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. European Journal of Cancer, 2006, 42, 548-556.	1.3	173
110	Multiple targeted tyrosine kinase inhibition in the clinic: All for one or one for all?. European Journal of Cancer, 2006, 42, 1351-1356.	1.3	48
111	To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. European Journal of Cancer, 2006, 42, 2472-2479.	1.3	160
112	Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 42-52.	2.9	69

#	Article	IF	Citations
113	Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Review of Anticancer Therapy, 2006, 6, 1559-1568.	1.1	59
114	Mitogen-Activated Protein Kinases and Chemoresistance in Pancreatic Cancer Cells. Journal of Surgical Research, 2006, 136, 325-335.	0.8	70
115	Molecular genetics and targeted therapies for cutaneous melanoma. Update on Cancer Therapeutics, 2006, 1, 59-64.	0.9	0
116	Angiogenesis inhibitors in clinical oncology. Update on Cancer Therapeutics, 2006, 1, 429-434.	0.9	2
120	Sorafenib is a potent inhibitor of FIP1L1-PDGFRÎ± and the imatinib-resistant FIP1L1-PDGFRÎ± T674I mutant. Blood, 2006, 108, 1374-1376.	0.6	128
121	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 582-587.	0.5	10
122	Development of Small-Molecule Inhibitors of Raf. Recent Patents on Anti-infective Drug Discovery, 2006, 1, 241-246.	0.5	2
123	Mitogen Activated Protein (MAP) Kinases: Development of ATP and Non- ATP Dependent Inhibitors. Medicinal Chemistry, 2006, 2, 213-222.	0.7	18
124	Sorafenib (BAY 43-9006): Review of Clinical Development. Current Clinical Pharmacology, 2006, 1, 223-228.	0.2	26
125	Angiogenesis Inhibitors for Lung Cancer: Clinical Developments and Future Directions. Journal of Thoracic Oncology, 2006, 1, 744-748.	0.5	7
126	Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Current Opinion in Oncology, 2006, 18, 341-346.	1.1	40
127	New approaches to primary brain tumor treatment. Anti-Cancer Drugs, 2006, 17, 1003-1016.	0.7	45
128	Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells. Molecular Cancer Therapeutics, 2006, 5, 809-817.	1.9	18
129	Sorafenib. Current Opinion in Oncology, 2006, 18, 615-621.	1.1	66
130	New molecular targeted therapies in thyroid cancer. Anti-Cancer Drugs, 2006, 17, 869-879.	0.7	21
131	Renal cell carcinoma. Current Opinion in Oncology, 2006, 18, 289-296.	1.1	32
132	Assessing the Utility of a Mutational Assay for B-RAF as an Adjunct to Conventional Fine Needle Aspiration of the Thyroid Gland. Advances in Anatomic Pathology, 2006, 13, 228-237.	2.4	16
133	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. Topics in Medicinal Chemistry, 2006, , 83-132.	0.4	1

#	Article	IF	Citations
134	Relational Database Driven Two-Dimensional Chemical Graph Analysis. Chemical Biology and Drug Design, 2006, 68, 135-138.	1.5	1
135	Embryogenesis meets tumorigenesis. Nature Medicine, 2006, 12, 882-884.	15.2	15
136	Turning neurogenesis up a Notch. Nature Medicine, 2006, 12, 884-885.	15.2	17
137	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery, 2006, 5, 835-844.	21.5	1,525
138	Targeted therapy for metastatic renal cell carcinoma. British Journal of Cancer, 2006, 94, 614-619.	2.9	151
139	The place of VEGF inhibition in the current management of renal cell carcinoma. British Journal of Cancer, 2006, 94, 1217-1220.	2.9	19
140	Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British Journal of Cancer, 2006, 95, 581-586.	2.9	608
141	Mechanisms of drug inhibition of signalling molecules. Nature, 2006, 441, 457-462.	13.7	281
142	Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 2006, 25, 3787-3800.	2.6	367
143	Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein. Oncogene, 2006, 25, 6262-6276.	2.6	70
144	Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. Critical Reviews in Oncology/Hematology, 2006, 59, 150-158.	2.0	30
145	Kinase inhibitors in the treatment of renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2006, 60, 216-226.	2.0	34
146	Targeting VEGF in Cancer Therapy. Current Problems in Cancer, 2006, 30, 7-32.	1.0	26
147	Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4326-4330.	1.0	23
148	Targeting Renal Cell Carcinoma. Clinical Oncology, 2006, 18, 511-512.	0.6	1
149	Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 5601-5608.	0.8	336
150	Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Research and Treatment, 2006, 99, 23-33.	1.1	20
151	Molecular mechanisms of metastasis. Cancer and Metastasis Reviews, 2006, 25, 203-220.	2.7	92

#	Article	IF	Citations
152	Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer and Metastasis Reviews, 2006, 25, 279-292.	2.7	25
154	Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 788-796.	1.4	83
155	Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. International Journal of Clinical Oncology, 2006, 11, 90-107.	1.0	14
156	Molecular targeting therapy for renal cell carcinoma. International Journal of Clinical Oncology, 2006, 11, 209-213.	1.0	22
157	Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World Journal of Urology, 2006, 24, 565-578.	1.2	10
158	Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology, 2006, 59, 183-195.	1.1	79
159	Back to the roots: the remarkable RAF oncogene story. Cellular and Molecular Life Sciences, 2006, 63, 1314-1330.	2.4	94
161	New antiangiogenetic agents and non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 76-86.	2.0	22
162	Hypertension and targeted therapy. Targeted Oncology, 2006, 1, 104-108.	1.7	9
163	Hypertension and targeted therapy. Targeted Oncology, 2006, 1, 172-178.	1.7	10
164	VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices. Current Oncology Reports, 2006, 8, 85-89.	1.8	11
165	Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents. Current Urology Reports, 2006, 7, 16-22.	1.0	9
166	Grape seed proanthocyanidins inhibit UV-radiation-induced oxidative stress and activation of MAPK and NF-Î²B signaling in human epidermal keratinocytes. Free Radical Biology and Medicine, 2006, 40, 1603-1614.	1.3	184
167	Understanding the Importance of Smart Drugs in Renal Cell Carcinoma. European Urology, 2006, 49, 633-643.	0.9	83
168	New Therapies in the Treatment of Breast Cancer. Seminars in Oncology, 2006, 33, 3-8.	0.8	16
169	Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway. Seminars in Oncology, 2006, 33, 392-406.	0.8	319
170	New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors. Seminars in Oncology, 2006, 33, 407-420.	0.8	242
171	The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma. Seminars in Oncology, 2006, 33, 596-606.	0.8	34

#	Article	IF	Citations
172	Hepatocellular Carcinoma: Molecular Biology and Therapy. Seminars in Oncology, 2006, 33, 79-83.	0.8	41
173	Clinical Activity of Sorafenib and Sunitinib in Renal Cell Carcinoma Refractory to Previous Vascular Endothelial Growth Factorâ€"Targeted Therapy: Two Case Reports. Clinical Genitourinary Cancer, 2006, 5, 78-81.	0.9	16
174	Adjuvant Therapy of Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2006, 5, 120-130.	0.9	14
175	Pathways of Dysregulation in Renal Cell Carcinoma: Rational Approaches to Development of Novel Treatment. Clinical Genitourinary Cancer, 2006, 5, S7-S18.	0.9	3
176	Emerging Antiangiogenic Agents in Lung Cancer. Clinical Lung Cancer, 2006, 7, 304-308.	1.1	20
177	Toxicities of Antiangiogenic Therapy in Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2006, 8, S23-S30.	1.1	46
178	Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry Part B - Clinical Cytometry, 2006, 70B, 107-114.	0.7	49
179	Molecularly targeted therapy for melanoma. Cancer, 2006, 107, 2317-2327.	2.0	50
180	Raf kinases: Oncogenesis and drug discovery. International Journal of Cancer, 2006, 119, 2261-2271.	2.3	94
181	Anti-angiogenic drugs: from bench to clinical trials. Medicinal Research Reviews, 2006, 26, 483-530.	5.0	146
182	Regulation of ERK3/MAPK6 expression by BRAF. International Journal of Oncology, 2006, 29, 839.	1.4	5
183	The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells. Cancer Research, 2006, 66, 1611-1619.	0.4	161
184	Genetic and Pharmacologic Dissection of Ras Effector Utilization in Oncogenesis. Methods in Enzymology, 2006, 407, 195-217.	0.4	21
185	Sorafenib for the Treatment of Renal Cell Carcinoma. Journal of Pharmacy Technology, 2006, 22, 281-288.	0.5	0
187	Is BRAF the Achilles' Heel of Thyroid Cancer?. Clinical Cancer Research, 2006, 12, 1661-1664.	3.2	23
188	Targeting Mitogen-Activated Protein Kinase/Extracellular Signalâ€"Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases. Cancer Research, 2006, 66, 8200-8209.	0.4	108
189	Structure Selection for Protein Kinase Docking and Virtual Screening:Homology Models or Crystal Structures?. Current Protein and Peptide Science, 2006, 7, 437-457.	0.7	51
190	Protein Kinases as Drug Targets in Cancer. Current Cancer Drug Targets, 2006, 6, 623-634.	0.8	76

#	Article	IF	Citations
191	Recent Advances in the Research and Development of RAF Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2006, 6, 1071-1089.	1.0	51
192	Caffeic acid suppresses UVB radiation-induced expression of interleukin-10 and activation of mitogen-activated protein kinases in mouse. Carcinogenesis, 2006, 27, 1803-1811.	1.3	64
193	Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development. Current Pharmaceutical Design, 2006, 12, 2609-2622.	0.9	147
194	Sorafenib for the Treatment of Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2006, 12, 7271-7278.	3.2	415
195	Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology. Current Pharmaceutical Design, 2006, 12, 2623-2630.	0.9	51
196	Targeted Therapy for Renal Cell Carcinoma: A New Therapeutic Paradigm. Cancer Investigation, 2006, 24, 640-656.	0.6	9
197	New targets and non-cytotoxics in ovarian cancer. Annals of Oncology, 2006, 17, x247-x250.	0.6	5
198	Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma: Table 1.. Clinical Cancer Research, 2006, 12, 2366s-2370s.	3.2	137
199	Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma: Fig. 1.. Clinical Cancer Research, 2006, 12, 2371s-2375s.	3.2	100
200	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 2505-2512.	0.8	1,002
201	Advances in the Therapy of Chronic Idiopathic Myelofibrosis. Oncologist, 2006, 11, 929-943.	1.9	31
202	Targeting angiogenesis with oral agents. Annals of Oncology, 2006, 17, x71-x75.	0.6	4
203	Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1070-1080.	1.3	97
204	Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics, 2006, 5, 995-1006.	1.9	202
205	Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma: Fig. 1.. Clinical Cancer Research, 2006, 12, 7215-7220.	3.2	159
206	Targeted Therapies in Combination with Chemotherapy in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 4451s-4457s.	3.2	20
207	Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen. Journal of Biomolecular Screening, 2006, 11, 145-154.	2.6	19
208	BAY 43-9006 Inhibition of Oncogenic RET Mutants. Journal of the National Cancer Institute, 2006, 98, 326-334.	3.0	458

#	Article	IF	Citations
209	Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis, 2006, 27, 1729-1738.	1.3	150
210	Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition: Fig. 1.. Clinical Cancer Research, 2006, 12, 4446s-4450s.	3.2	37
211	Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer. Clinical Cancer Research, 2006, 12, 144-151.	3.2	182
212	Identification of RAS-Mitogen-Activated Protein Kinase Signaling Pathway Modulators in an ERF1 RedistributionÂ® Screen. Journal of Biomolecular Screening, 2006, 11, 423-434.	2.6	15
213	Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models. Cancer Research, 2006, 66, 999-1006.	0.4	204
214	Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Annals of Oncology, 2006, 17, 866-873.	0.6	127
215	Extracellular Signal-regulated Kinase-dependent Proliferation Is Mediated through the Protein Kinase A/B-Raf Pathway in Human Uveal Melanoma Cells. Journal of Biological Chemistry, 2006, 281, 9238-9250.	1.6	52
216	Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy. Current Cancer Drug Targets, 2006, 6, 207-227.	0.8	12
217	The ABCs of Targeting Raf: Novel Approaches to Cancer Therapy. Current Cancer Therapy Reviews, 2006, 2, 305-314.	0.2	4
218	Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. Molecular Cancer Therapeutics, 2006, 5, 80-88.	1.9	8
219	Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers. Current Cancer Drug Targets, 2006, 6, 455-489.	0.8	36
220	Targeted Therapies in Gynecologic Cancers. Current Cancer Drug Targets, 2006, 6, 333-363.	0.8	38
221	Multi-target inhibitors in non-small cell lung cancer (NSCLC). Annals of Oncology, 2006, 17, ii55-ii57.	0.6	6
222	Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opinion on Emerging Drugs, 2006, 11, 153-165.	1.0	21
223	Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. , 2006, , 223-268.		61
224	New treatment strategies for malignant gliomas. Expert Review of Anticancer Therapy, 2006, 6, 1087-1104.	1.1	117
225	Nouvelles tentatives mÃ©dicamenteuses. , 2006, , 535-546.		0
226	Molecular Targets in Melanoma from Angiogenesis to Apoptosis. Clinical Cancer Research, 2006, 12, 2376s-2383s.	3.2	46

#	Article	IF	Citations
227	Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Annals of Oncology, 2006, 17, 1185-1196.	0.6	68
228	Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006. Journal of Clinical Oncology, 2006, 24, e48-e48.	0.8	102
229	BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma. Clinical Cancer Research, 2006, 12, 1623-1629.	3.2	160
230	AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma. Cancer Research, 2006, 66, 8722-8730.	0.4	54
231	Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Molecular Cancer Therapeutics, 2006, 5, 1007-1013.	1.9	62
232	Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2006, 24, 4293-4300.	0.8	1,144
233	Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors. Oncologist, 2007, 12, 426-437.	1.9	386
234	Sorafenib and Sunitinib in the Treatment of Advanced Nonâ€Small Cell Lung Cancer. Oncologist, 2007, 12, 191-200.	1.9	109
235	The selectivity of protein kinase inhibitors: a further update. Biochemical Journal, 2007, 408, 297-315.	1.7	2,287
236	Oncogenes in Myeloproliferative Disorders. Cell Cycle, 2007, 6, 550-566.	1.3	153
237	Emerging drugs for the treatment of metastatic renal cancer. Expert Opinion on Emerging Drugs, 2007, 12, 605-618.	1.0	16
238	Recent advances in the therapy of renal cancer. Expert Opinion on Biological Therapy, 2007, 7, 233-242.	1.4	8
239	Phase II Trial of Sorafenib Plus Interferon Alfa-2b As First- or Second-Line Therapy in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology, 2007, 25, 3288-3295.	0.8	171
240	Dietary grape seed proanthocyanidins inhibit UVB-induced oxidative stress and activation of mitogen-activated protein kinases and nuclear factor-ÎºB signaling in in vivo SKH-1 hairless mice. Molecular Cancer Therapeutics, 2007, 6, 995-1005.	1.9	205
241	Cell Cycleâ€"Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation. Cancer Research, 2007, 67, 9443-9454.	0.4	125
242	A Selective Cellular Screening Assay for B-Raf and c-Raf Kinases. Journal of Biomolecular Screening, 2007, 12, 818-827.	2.6	3
243	Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?. Clinical Cancer Research, 2007, 13, 6545-6548.	3.2	62
244	Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting. Journal of Biological Chemistry, 2007, 282, 29230-29240.	1.6	90

#	Article	IF	Citations
245	The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents: Figure 1.. Molecular Cancer Therapeutics, 2007, 6, 1180-1185.	1.9	37
246	New targets for non-small-cell lung cancer therapy. Expert Review of Anticancer Therapy, 2007, 7, 1423-1437.	1.1	35
247	Targeted therapies in small-cell lung cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 1033-1041.	1.5	2
248	Novel therapeutic targets in mantle cell lymphoma. Expert Opinion on Therapeutic Targets, 2007, 11, 929-940.	1.5	4
249	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. Expert Review of Dermatology, 2007, 2, 179-190.	0.3	0
250	Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy. Expert Opinion on Therapeutic Targets, 2007, 11, 771-782.	1.5	5
251	Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 753s-757s.	3.2	25
252	Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy. Current Pharmaceutical Design, 2007, 13, 3368-3377.	0.9	60
253	Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma. Japanese Journal of Clinical Oncology, 2007, 37, 755-762.	0.6	143
254	Therapy of metastatic bladder carcinoma. Annals of Oncology, 2007, 18, vi153-vi156.	0.6	13
255	Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. Annals of Oncology, 2007, 18, x32-x41.	0.6	18
256	Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. Expert Review of Endocrinology and Metabolism, 2007, 2, 225-238.	1.2	1
257	Strategies for the management of hepatocellular carcinoma. Nature Clinical Practice Oncology, 2007, 4, 424-432.	4.3	253
258	Sorafinib in kidney cancer. Annals of Oncology, 2007, 18, ix90-ix93.	0.6	7
259	CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 3765-3770.	3.2	61
260	Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Î² Gatekeeper Mutants. Clinical Cancer Research, 2007, 13, 3363-3369.	3.2	70
261	Rap1/B-Raf Signaling Is Activated in Neuroendocrine Tumors of the Digestive Tract and Raf Kinase Inhibition Constitutes a Putative Therapeutic Target. Neuroendocrinology, 2007, 85, 45-53.	1.2	35
262	Induction of Apoptosis and Inhibition of Cell Migration and Tube-Like Formation by Dihydroartemisinin in Murine Lymphatic Endothelial Cells. Pharmacology, 2007, 80, 207-218.	0.9	31

#	Article	IF	Citations
263	Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma. Oncology, 2007, 73, 204-209.	0.9	30
264	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. Expert Opinion on Drug Discovery, 2007, 2, 335-348.	2.5	5
265	Novel inhibitors in the treatment of metastatic melanoma. Expert Review of Anticancer Therapy, 2007, 7, 715-724.	1.1	26
266	Drug Insight: advances in renal cell carcinoma and the role of targeted therapies. Nature Clinical Practice Oncology, 2007, 4, 470-479.	4.3	35
267	Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Annals of Oncology, 2007, 18, vi22-vi25.	0.6	25
268	The new paradigm in the treatment of colorectal cancer: are we hitting the right target?. Expert Opinion on Investigational Drugs, 2007, 16, 311-324.	1.9	9
269	Toward a Molecular Classification of Melanoma. Journal of Clinical Oncology, 2007, 25, 1606-1620.	0.8	234
270	Nitric Oxide Inactivates the Retinoblastoma Pathway in Chronic Inflammation. Cancer Research, 2007, 67, 9286-9293.	0.4	40
271	New drug therapies for advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2007, 7, 57-71.	1.1	3
272	Drug resistance in cancer â€“ searching for mechanisms, markers and therapeutic agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 805-817.	1.5	51
273	The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation. Molecular Pharmacology, 2007, 72, 788-795.	1.0	61
274	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4712-4718.	1.8	95
275	Protein Kinases and Protein Phosphatases in Signal Transduction Pathways. , 2007, , 959-992.		2
276	Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease. Clinical Cancer Research, 2007, 13, 1029-1035.	3.2	7
277	Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Molecular Cancer Therapeutics, 2007, 6, 1785-1792.	1.9	129
278	The Potential of Antiangiogenic Therapy in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 1961-1970.	3.2	64
279	Sorafenib in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 747s-752s.	3.2	49
280	Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy. Clinical Cancer Research, 2007, 13, 2068-2074.	3.2	158

#	Article	IF	Citations
281	Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation. Clinical Cancer Research, 2007, 13, 4280-4290.	3.2	63
282	Mutant V600E BRAF Increases Hypoxia Inducible Factor-1Î± Expression in Melanoma. Cancer Research, 2007, 67, 3177-3184.	0.4	127
283	Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions. Clinical Cancer Research, 2007, 13, 1098-1106.	3.2	161
284	Phase I Trial of Sorafenib in Combination with IFN Î±-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma. Clinical Cancer Research, 2007, 13, 1801-1809.	3.2	136
285	Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2007, 25, 3766-3773.	0.8	230
286	Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies. Oncologist, 2007, 12, 1404-1415.	1.9	115
287	Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 4849-4857.	3.2	90
288	Signal Transduction Inhibitors in Chronic Myeloid Leukemia. , 2007, , 75-102.		0
289	Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Molecular Cancer Therapeutics, 2007, 6, 2220-2229.	1.9	30
290	The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress. Molecular and Cellular Biology, 2007, 27, 5499-5513.	1.1	209
291	IB05204, a dichloropyridodithienotriazine, inhibits angiogenesis in vitro and in vivo. Molecular Cancer Therapeutics, 2007, 6, 2675-2685.	1.9	18
292	Current Status and Future of Target-Based Therapeutics. Current Cancer Drug Targets, 2007, 7, 273-284.	0.8	6
293	Combination of Anti-EGFR Drugs with Anti-Angiogenic or Other Signal Transduction Inhibitors as a Rational Approach to Cancer Therapy. Current Cancer Therapy Reviews, 2007, 3, 284-291.	0.2	0
294	Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 226-235.	0.2	0
295	Chromosomes, Hypoxia, Angiogenesis, and Trial Design: A Brief History of Renal Cancer Drug Development. Clinical Cancer Research, 2007, 13, 1630-1633.	3.2	9
296	Sorafenib Inhibits the Imatinib-Resistant KIT T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 4874-4881.	3.2	144
297	Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma. Oncology Research and Treatment, 2007, 30, 519-524.	0.8	24
299	Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation. International Journal of Molecular Medicine, 0, , .	1.8	24

#	Article	IF	Citations
300	Differential Responses of Human Papillary Thyroid Cancer Cell Lines Carrying the RET/PTC1 Rearrangement or a BRAF Mutation to MEK1/2 Inhibitors. JAMA Otolaryngology, 2007, 133, 810.	1.5	22
301	Acute Pancreatitis Associated with Sorafenib. Southern Medical Journal, 2007, 100, 909-911.	0.3	27
302	Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases. Current Drug Targets, 2007, 8, 217-235.	1.0	16
303	Renal Cell Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 282-286.	1.0	21
304	Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia. Current Drug Targets, 2007, 8, 715-725.	1.0	39
305	Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2007, 41, 839-854.	1.1	15
306	New therapies in renal cell carcinoma. Current Opinion in Supportive and Palliative Care, 2007, 1, 174-179.	0.5	7
307	Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Current Opinion in Oncology, 2007, 19, 98-102.	1.1	20
308	Targeted Molecular Therapy for Renal Cell Carcinoma. Urology, 2007, 69, 3-10.	0.5	54
309	Targeted therapies for kidney cancer in urologic practice. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 420-432.	0.8	13
310	Targeted therapies in bladder cancerâ€"an update. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 433-438.	0.8	77
311	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	6.5	74
312	Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. European Journal of Cancer, 2007, 43, 55-63.	1.3	87
313	The l-isoform but not d-isoforms of a JNK inhibitory peptide protects pancreatic Î²-cells. Biochemical and Biophysical Research Communications, 2007, 354, 227-233.	1.0	19
314	Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Current Opinion in Pharmacology, 2007, 7, 339-343.	1.7	55
315	Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treatment Reviews, 2007, 33, 1-8.	3.4	16
316	Renal cell carcinoma: Current status and emerging therapies. Cancer Treatment Reviews, 2007, 33, 299-313.	3.4	84
318	Sorafenib-induced erythema multiforme. Journal of the American Academy of Dermatology, 2007, 56, 527-528.	0.6	50

#	Article	IF	Citations
319	New Perspectives: An Oral Multikinase Inhibitor in Patients with Advanced RCC. European Urology Supplements, 2007, 6, 499-504.	0.1	4
320	Kidney Cancer: Highlights from 2006. European Urology Supplements, 2007, 6, 745-753.	0.1	1
321	Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. Expert Review of Anticancer Therapy, 2007, 7, 1193-1202.	1.1	14
322	Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets, 2007, 11, 1587-1609.	1.5	63
323	Alkynylpyrimidine Amide Derivatives as Potent, Selective, and Orally Active Inhibitors of Tie-2 Kinase. Journal of Medicinal Chemistry, 2007, 50, 627-640.	2.9	28
324	Sorafenib-Induced Pancreatitis. Mayo Clinic Proceedings, 2007, 82, 521.	1.4	25
325	Acute Myelogenous Leukemia. , 2007, , .		0
326	Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. Expert Opinion on Investigational Drugs, 2007, 16, 467-476.	1.9	25
327	The ability of sorafenib to inhibit oncogenic PDGFRÂ and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica, 2007, 92, 27-34.	1.7	98
328	Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 2684-2691.	3.2	94
329	Future options for imatinib mesilate-resistant tumors. Expert Opinion on Investigational Drugs, 2007, 16, 1549-1560.	1.9	7
330	The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy. Journal of Urology, 2007, 177, 1978-1984.	0.2	81
331	Sorafenib: delivering a targeted drug to the right targets. Expert Review of Anticancer Therapy, 2007, 7, 617-626.	1.1	58
332	Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. Journal of Translational Medicine, 2007, 5, 38.	1.8	35
333	Sorafenib. Drugs, 2007, 67, 475-483.	4.9	19
334	The Direct Effects of Antiâ€“Vascular Endothelial Growth Factor Therapy on Tumor Cells. Clinical Colorectal Cancer, 2007, 6, 564-571.	1.0	10
335	A Randomized Phase II Study of Sorafenib/Gemcitabine or Sorafenib/Erlotinib for Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients or Patients with a Performance Status of 2: Treatment Rationale and Protocol Dynamics. Clinical Lung Cancer, 2007, 8, 396-398.	1.1	24
336	Discovery ofN-(4-(3-Amino-1H-indazol-4-yl)phenyl)-Nâ€˜-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor. Journal of Medicinal Chemistry, 2007, 50, 1584-1597.	2.9	179

#	Article	IF	Citations
338	Mechanisms of Disease: the PI3Kâ€“Aktâ€“PTEN signaling nodeâ€”an intercept point for the control of angiogenesis in brain tumors. Nature Clinical Practice Neurology, 2007, 3, 682-693.	2.7	93
339	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. New England Journal of Medicine, 2007, 356, 125-134.	13.9	4,569
340	Protein kinases as targets for cancer treatment. Pharmacogenomics, 2007, 8, 1005-1016.	0.6	68
341	New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Review of Anticancer Therapy, 2007, 7, 701-713.	1.1	33
342	Targeted Therapy for Renal Cell Carcinoma: A New Treatment Paradigm. Baylor University Medical Center Proceedings, 2007, 20, 244-248.	0.2	19
343	Targeting the tumor microenvironment. Frontiers in Bioscience - Landmark, 2007, 12, 3468.	3.0	181
344	The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma. Scientific World Journal, The, 2007, 7, 800-807.	0.8	4
345	Combination of Target Agents: Challenges and Opportunities. Journal of Thoracic Oncology, 2007, 2, S4-S6.	0.5	5
346	The Role of the Endothelium in Normal and Pathologic Thyroid Function. , 2007, , 1386-1396.		0
347	Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMOâ€“PCV chemotherapy. International Journal of Cancer, 2007, 121, 2279-2283.	2.3	12
348	Ciliary neurotrophic factor receptor Î± subunit-modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications. Hepatology, 2008, 47, 1298-1308.	3.6	19
349	Are MAP Kinases Drug Targets? Yes, but Difficult Ones. ChemMedChem, 2007, 2, 1116-1140.	1.6	40
350	Chemotherapy for metastatic melanoma. Cancer, 2007, 109, 455-464.	2.0	196
351	A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer, 2007, 110, 955-964.	2.0	30
352	Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma. Cancer, 2007, 110, 2293-2303.	2.0	69
353	Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorganic and Medicinal Chemistry, 2007, 15, 2187-2197.	1.4	29
354	Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 250-254.	1.0	49
355	Novel treatment strategies for malignant melanoma: A new beginning?. Critical Reviews in Oncology/Hematology, 2007, 62, 16-22.	2.0	30

#	Article	IF	Citations
356	Angiogenesis inhibitors in the treatment of lung cancer. Critical Reviews in Oncology/Hematology, 2007, 62, 93-104.	2.0	41
357	Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. Journal of Pathology, 2007, 212, 124-133.	2.1	85
358	Classifying protein kinase structures guides use of ligandâ€selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex. Proteins: Structure, Function and Bioinformatics, 2008, 70, 1451-1460.	1.5	71
359	MKK signaling and vascularization. Oncogene, 2007, 26, 1290-1296.	2.6	25
360	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26, 3291-3310.	2.6	2,421
361	Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer, 2007, 7, 475-485.	12.8	468
362	Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia, 2007, 21, 439-445.	3.3	152
363	Targeting BRAF in thyroid cancer. British Journal of Cancer, 2007, 96, 16-20.	2.9	88
364	A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. British Journal of Cancer, 2007, 97, 1480-1485.	2.9	100
365	Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Modern Pathology, 2007, 20, 779-787.	2.9	91
366	Melanoma biology and new targeted therapy. Nature, 2007, 445, 851-857.	13.7	1,161
367	Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU International, 2007, 99, 274-280.	1.3	56
368	Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. British Journal of Dermatology, 2007, 156, 1204-1213.	1.4	111
369	Recent Progress in the Management of Advanced Renal Cell Carcinoma. Ca-A Cancer Journal for Clinicians, 2007, 57, 112-125.	157.7	147
370	What Is Standard Initials Systemic Therapy in Metastatic Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2007, 5, 256-263.	0.9	2
371	Key Signaling Pathways and Targets in Lung Cancer Therapy. Clinical Lung Cancer, 2007, 8, S52-S60.	1.1	12
372	Chemotherapy and Antiangiogenic Agents in Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2007, 8, S68-S73.	1.1	8
373	Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer. Pharmacotherapy, 2007, 27, 1125-1144.	1.2	97

#	Article	IF	Citations
374	Raf kinases: Function, regulation and role in human cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1196-1212.	1.9	249
375	Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death. Cancer Cell, 2007, 12, 66-80.	7.7	241
376	Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling, 2007, 19, 2003-2012.	1.7	841
377	Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental Hematology, 2007, 35, 1522-1526.	0.2	47
378	A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discovery Today, 2007, 12, 622-633.	3.2	170
379	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecologic Oncology, 2007, 104, 768-778.	0.6	64
380	The RTK/RAS/BRAF/PI3K Pathways in Melanoma: Biology, Small Molecule Inhibitors, and Potential Applications. Seminars in Oncology, 2007, 34, 546-554.	0.8	56
381	Sunitinib: From Rational Design to Clinical Efficacy. Journal of Clinical Oncology, 2007, 25, 884-896.	0.8	813
382	Critical Roles of the Raf/MEK/ERK Pathway in Apoptosis and Drug Resistance. , 2006, , 101-134.		2
383	Molecular mechanisms in chronic obstructive pulmonary disease. Cell Biochemistry and Biophysics, 2007, 47, 131-147.	0.9	39
384	Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World Journal of Urology, 2007, 25, 59-72.	1.2	9
385	A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2007, 60, 81-89.	1.1	19
386	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemotherapy and Pharmacology, 2007, 59, 561-574.	1.1	419
387	Challenges for patient selection with VEGF inhibitors. Cancer Chemotherapy and Pharmacology, 2007, 60, 151-170.	1.1	77
389	Recent discoveries in the genetics of melanoma and their therapeutic implications. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 363-372.	1.0	19
390	The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. Molecular and Cellular Biochemistry, 2007, 295, 19-26.	1.4	53
391	Pancreatic cancer â€" Outlook: targeted therapy. Chinese-German Journal of Clinical Oncology, 2007, 6, 176-180.	0.1	0
393	Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology, 2007, 8, 15-27.	1.3	115

#	Article	IF	Citations
394	Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer. Current Treatment Options in Oncology, 2007, 8, 211-226.	1.3	10
395	The platelet-derived growth factor receptor as a therapeutic target. Current Oncology Reports, 2007, 9, 89-95.	1.8	11
396	Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Current Oncology Reports, 2007, 9, 115-119.	1.8	191
397	Adjuvant therapy for high-risk renal cell carcinoma patients. Current Urology Reports, 2007, 8, 19-30.	1.0	27
398	Sorafenib TARGET Trial results in Spanish patients. Clinical and Translational Oncology, 2007, 9, 671-673.	1.2	3
399	Renewed hope in the treatment of renal cell carcinoma. Targeted Oncology, 2007, 2, 1-2.	1.7	0
400	Targeted therapies for renal cell carcinoma. Targeted Oncology, 2007, 2, 7-16.	1.7	0
401	VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology, 2007, 2, 153-164.	1.7	10
402	Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology, 2007, 2, 199-210.	1.7	6
403	New angiogenic agents and non-small cell lung cancer: current results and future development. Targeted Oncology, 2007, 2, 211-223.	1.7	3
404	Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Reviews in Oncology/Hematology, 2007, 62, 179-213.	2.0	515
405	Safety and anti-tumor activity of sorafenib (NexavarÂ®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemotherapy and Pharmacology, 2008, 61, 535-548.	1.1	131
406	Targeted therapy in renal cell carcinoma. World Journal of Urology, 2008, 26, 135-140.	1.2	43
408	Current status of studies on targeted therapy for renal cell carcinoma. Chinese Journal of Clinical Oncology, 2008, 5, 294-298.	0.0	0
410	The impact of new data in the treatment of advanced hepatocellular carcinoma. Current Oncology Reports, 2008, 10, 199-205.	1.8	25
411	Adjuvant therapy for renal cell carcinoma. Current Oncology Reports, 2008, 10, 245-252.	1.8	10
412	The future of tyrosine kinase inhibitors: Single agent or combination?. Current Oncology Reports, 2008, 10, 264-270.	1.8	9
413	Pediatric developmental therapies: Interesting new drugs now in early-stage clinical trials. Current Oncology Reports, 2008, 10, 477-490.	1.8	18

#	Article	IF	Citations
414	Angiogenesis and angiogenic inhibitors in renal cell carcinoma. Current Urology Reports, 2008, 9, 26-33.	1.0	13
415	Systemic therapy of hepatocellular carcinoma: Are we making progress?. Advances in Therapy, 2008, 25, 1089-1104.	1.3	79
416	Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. Medical Oncology, 2008, 25, 323-330.	1.2	21
417	Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology, 2008, 10, 198-203.	1.2	2
418	Hepatocarcinoma: from pathogenic mechanisms to target therapy. Oncology Reviews, 2008, 2, 214-222.	0.8	2
420	Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. Journal of Gastroenterology, 2008, 43, 905-911.	2.3	42
422	Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer, 2008, 112, 250-259.	2.0	122
423	Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkers. Cancer, 2008, 113, 450-460.	2.0	83
424	Systemic cancer therapy: Evolution over the last 60 years. Cancer, 2008, 113, 1857-1887.	2.0	43
425	Sunitinibâ€induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer, 2008, 113, 1309-1314.	2.0	42
426	Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance. Journal of Cellular Biochemistry, 2008, 103, 691-708.	1.2	36
427	7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3777-3787.	2.9	46
428	Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development. Clinical Cancer Research, 2008, 14, 3571-3581.	3.2	120
429	Axitinib for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 741-748.	1.9	60
430	Sorafenib: advances in targeted therapy for renal cell carcinoma. Future Prescriber, 2008, 7, 11-13.	0.1	0
431	Recent Advances in Angiogenesis Drug Development. , 2008, , 421-430.		0
432	Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib^{Â®} treatment. Acta Ophthalmologica, 2008, 86, 456-458.	0.6	33
433	Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells. Journal of Investigative Dermatology, 2008, 128, 2013-2023.	0.3	129

#	Article	IF	Citations
434	Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia, 2008, 22, 1226-1233.	3.3	93
435	Thyroid carcinoma: molecular pathways and therapeutic targets. Modern Pathology, 2008, 21, S37-S43.	2.9	331
436	BRAFE600 in benign and malignant human tumours. Oncogene, 2008, 27, 877-895.	2.6	251
437	PI3K pathway alterations in cancer: variations on a theme. Oncogene, 2008, 27, 5497-5510.	2.6	1,621
438	A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology, 2008, 26, 127-132.	9.4	2,186
439	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics, 2008, 40, 600-608.	9.4	514
440	Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer, 2008, 8, 473-480.	12.8	1,064
441	Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia, 2008, 22, 808-818.	3.3	162
442	Role of magnetic resonance cholangiopancreatography and other non-invasive imaging modalities in assessing bile duct stones. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 684-686.	1.4	1
443	Chemotherapy for advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 682-684.	1.4	14
444	Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Ecological Management and Restoration, 2008, 21, 514-521.	0.2	17
445	Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Science, 2008, 99, 1492-1498.	1.7	110
446	Azaspirene, a fungal product, inhibits angiogenesis by blocking Rafâ€1 activation. Cancer Science, 2008, 99, 1853-1858.	1.7	36
447	A distinct cutaneous reaction to sorafenib and a multikinase inhibitor. International Journal of Dermatology, 2008, 47, 767-769.	0.5	16
448	New Options for Integrating Antiangiogenic Therapy and Platinum-Based First-Line Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2008, 9, S100-S108.	1.1	3
449	Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis. European Urology, 2008, 54, 1373-1378.	0.9	91
450	Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390.	13.9	12,004
451	Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells. Advances in Experimental Medicine and Biology, 2008, 615, 81-104.	0.8	36

#	Article	IF	Citations
452	Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs, 2008, 17, 511-522.	1.9	18
453	Sorafenib. Drugs, 2008, 68, 251-258.	4.9	39
454	What Role Do Combinations of Interferon and Targeted Agents Play in the First-Line Therapy of Metastatic Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2008, 6, S14-S21.	0.9	4
455	Vascular Endothelial Growth Factor Pathwayâ€"Targeted Therapy as Initial Systemic Treatment of Patients with Renal Cancer. Clinical Genitourinary Cancer, 2008, 6, S22-S28.	0.9	7
456	Biological Approaches to Therapy of Pancreatic Cancer. Pancreatology, 2008, 8, 431-461.	0.5	24
457	Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 7049-7052.	2.9	73
458	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. Journal of Hematology and Oncology, 2008, 1, 18.	6.9	50
459	RAS: Target for Cancer Therapy. Cancer Investigation, 2008, 26, 948-955.	0.6	65
460	Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Review of Molecular Diagnostics, 2008, 8, 83-95.	1.5	259
461	Targeted therapeutic strategies in malignant melanoma. Drug Discovery Today Disease Mechanisms, 2008, 5, e63-e68.	0.8	6
462	Target therapy in metastatic renal cell carcinoma. European Journal of Cancer, Supplement, 2008, 6, 38-41.	2.2	1
463	Novel Inhibitors of the v-raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) Based on a 2,6-Disubstituted Pyrazine Scaffold. Journal of Medicinal Chemistry, 2008, 51, 3261-3274.	2.9	31
464	From Anti-Angiogenesis to Anti-Lymphangiogenesis: Emerging Trends in Cancer Therapy. Lymphatic Research and Biology, 2008, 6, 165-172.	0.5	52
465	Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 6779-6788.	0.4	589
466	ThÃ©rapeutiques antiangiogÃ©niques en cancÃ©rologie. , 2008, , .		0
468	Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of Hepatology, 2008, 48, S20-S37.	1.8	739
469	Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. Journal of Hepatology, 2008, 49, 1-5.	1.8	35
470	Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 2008, 58, 545-570.	0.6	231

#	Article	IF	Citations
471	Solid tumor physiology and hypoxia-induced chemo/radio-resistance: Novel strategy for cancer therapy: Nitric oxide donor as a therapeutic enhancer. Nitric Oxide - Biology and Chemistry, 2008, 19, 205-216.	1.2	181
472	Somatic genetics and targeted therapies for cutaneous melanoma. Update on Cancer Therapeutics, 2008, 3, 81-87.	0.9	0
473	Preoperative Tyrosine Kinase Inhibition as an Adjunct to Debulking Nephrectomy. Urology, 2008, 72, 864-868.	0.5	86
474	A Peptoid â€œAntibody Surrogateâ€•That Antagonizes VEGF Receptor 2 Activity. Journal of the American Chemical Society, 2008, 130, 5744-5752.	6.6	220
475	Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. European Journal of Cancer, 2008, 44, 2152-2161.	1.3	58
476	Therapeutic strategies for inhibiting oncogenic BRAF signaling. Current Opinion in Pharmacology, 2008, 8, 419-426.	1.7	72
477	Targeted therapy for uveal melanoma. Cancer Treatment Reviews, 2008, 34, 247-258.	3.4	90
478	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Seminars in Diagnostic Pathology, 2008, 25, 232-244.	1.0	9
479	Breast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting Secretome. Journal of Proteome Research, 2008, 7, 1379-1387.	1.8	61
480	Treatment Approaches in Renal Cell Carcinoma: Past, Present, and Future Perspectives. European Urology Supplements, 2008, 7, 36-45.	0.1	5
481	European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?. European Urology Supplements, 2008, 7, 46-54.	0.1	4
482	New Treatment Options for Renal Cell Cancerâ€”Critical Evaluation. European Urology Supplements, 2008, 7, 443-446.	0.1	3
483	Effectively targeting BRAF in melanoma: a formidable challenge. Pigment Cell and Melanoma Research, 2008, 21, 410-411.	1.5	11
484	Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncology, The, 2008, 9, 117-123.	5.1	358
485	Highlights from: The 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Orlando, FL; January 25-27, 2008. Clinical Colorectal Cancer, 2008, 7, 165-171.	1.0	3
487	Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics. Dermatologic Clinics, 2008, 26, 121-159.	1.0	29
488	Early Clinical Studies of Novel Therapies for Thyroid Cancers. Endocrinology and Metabolism Clinics of North America, 2008, 37, 511-524.	1.2	47
489	Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America, 2008, 17, 279-301.	0.6	12

#	Article	IF	Citations
491	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3041-3046.	3.3	1,206
492	Successful targeted therapies for hepatocellular carcinoma: are we really getting there?. Expert Review of Anticancer Therapy, 2008, 8, 499-505.	1.1	1
493	Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncology, 2008, 4, 793-802.	1.1	103
494	Sorafenib in Liver Cancer â€" Just the Beginning. New England Journal of Medicine, 2008, 359, 420-422.	13.9	103
495	Potential role of sorafenib in the treatment of acute myeloid leukemia. Leukemia and Lymphoma, 2008, 49, 2246-2255.	0.6	48
496	Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 5705-5712.	0.8	1,540
497	BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy. Cancer Research, 2008, 68, 4774-4782.	0.4	929
498	Novel drugs for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 1501-1516.	1.9	5
499	Phase II Trial of Sorafenib in Advanced Thyroid Cancer. Journal of Clinical Oncology, 2008, 26, 4714-4719.	0.8	615
500	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 253-261.	1.9	84
501	Identification of BRAF Inhibitors through In Silico Screening. Journal of Medicinal Chemistry, 2008, 51, 6121-6127.	2.9	45
502	Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors. Oncologist, 2008, 13, 845-858.	1.9	99
503	3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases. Journal of Medicinal Chemistry, 2008, 51, 1231-1241.	2.9	32
504	Phosphorylated Heat Shock Protein 27 Represses Growth of Hepatocellular Carcinoma via Inhibition of Extracellular Signal-regulated Kinase. Journal of Biological Chemistry, 2008, 283, 18852-18860.	1.6	40
505	Targeted therapies for pancreatic cancer. British Medical Bulletin, 2008, 87, 97-130.	2.7	26
506	A Small Molecule Disruptor of Rb/Raf-1 Interaction Inhibits Cell Proliferation, Angiogenesis, and Growth of Human Tumor Xenografts in Nude Mice. Cancer Research, 2008, 68, 3810-3818.	0.4	46
507	Treatment of Melanoma and Nonmelanoma Skin Cancer. Advances in Experimental Medicine and Biology, 2008, 624, 296-318.	0.8	12
509	Target specificity and off-target effects as determinants of cancer drug efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 273-280.	1.5	28

#	Article	IF	Citations
510	Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity. Journal of Clinical Oncology, 2008, 26, 3709-3714.	0.8	327
511	Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 5204-5212.	0.8	581
512	Expanding the Treatment Options for Hepatocellular Carcinoma. JAMA - Journal of the American Medical Association, 2008, 299, 1716.	3.8	15
513	Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor. Archives of Dermatology, 2008, 144, 886-92.	1.7	204
514	Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group. Journal of Clinical Oncology, 2008, 26, 2178-2185.	0.8	238
515	Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Molecular Cancer Therapeutics, 2008, 7, 890-896.	1.9	70
516	Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biology and Therapy, 2008, 7, 810-813.	1.5	12
517	Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy. American Journal of Roentgenology, 2008, 191, 133-139.	1.0	67
518	Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiological Genomics, 2008, 33, 278-291.	1.0	100
519	Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opinion on Therapeutic Targets, 2008, 12, 1389-1401.	1.5	16
520	Prospective Comparison of Sorafenib and Sunitinib for Second-Line Treatment of Cytokine-Refractory Kidney Cancer Patients. Oncology, 2008, 74, 216-222.	0.9	16
521	Biologic therapies for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2008, 8, 1331-1338.	1.1	6
522	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics, 2008, 7, 3129-3140.	1.9	1,237
523	Urological Oncology. , 2008, , .		3
524	Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Review of Anticancer Therapy, 2008, 8, 1743-1749.	1.1	76
525	Angiosarcoma of the breast following surgery and radiotherapy for breast cancer. Nature Clinical Practice Oncology, 2008, 5, 727-736.	4.3	51
526	Delphinidin Attenuates Neoplastic Transformation in JB6 Cl41 Mouse Epidermal Cells by Blocking Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signaling. Cancer Prevention Research, 2008, 1, 522-531.	0.7	48
527	Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor. Clinical Cancer Research, 2008, 14, 2833-2840.	3.2	13

#	Article	IF	Citations
528	Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy. Clinical Cancer Research, 2008, 14, 270-280.	3.2	83
529	Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. Oncologist, 2008, 13, 1084-1096.	1.9	198
530	Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Molecular Cancer Therapeutics, 2008, 7, 3519-3526.	1.9	87
531	Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Molecular Cancer Therapeutics, 2008, 7, 3509-3518.	1.9	44
532	Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial. Journal of the National Cancer Institute, 2008, 100, 1454-1463.	3.0	131
533	Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer. Cancer Research, 2008, 68, 6109-6117.	0.4	167
534	Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors. Current Cancer Drug Targets, 2008, 8, 76-85.	0.8	18
536	Stat3 mediates myeloid cellâ€“dependent tumor angiogenesis in mice. Journal of Clinical Investigation, 2008, 118, 3367-3377.	3.9	473
537	Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement. Clinical Cancer Research, 2008, 14, 4908-4914.	3.2	44
538	Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. American Journal of Health-System Pharmacy, 2008, 65, 123-131.	0.5	54
539	Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer. Current Molecular Medicine, 2008, 8, 138-147.	0.6	166
540	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics, 2008, 7, 3670-3684.	1.9	311
541	Innovative Leukemia and Lymphoma Therapy. , 0, , .		0
543	Pharmacodynamic Monitoring of Molecular-Targeted Agents in the Peripheral Blood of Leukemia Patients Using Flow Cytometry. Toxicologic Pathology, 2008, 36, 133-139.	0.9	17
544	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. Circulation, 2008, 118, 2081-2090.	1.6	139
545	A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clinical Cancer Research, 2008, 14, 4836-4842.	3.2	136
546	Sorafenib in Hepatocellular Carcinoma: Separating the Hype From the Hope. Journal of Clinical Oncology, 2008, 26, 5845-5848.	0.8	28
547	Newer opportunities in systemic therapy of lung cancer. Annals of Oncology, 2008, 19, vii31-vii37.	0.6	5

#	Article	IF	Citations
548	Chapter 6 Mouse Models to Investigate Anti-Cancer Effects of VEGF Inhibitors. Methods in Enzymology, 2008, 445, 125-139.	0.4	2
549	Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumorâ€"Associated PDGFRAD842V Mutation. Clinical Cancer Research, 2008, 14, 5749-5758.	3.2	116
550	Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Molecular Cancer Therapeutics, 2008, 7, 648-658.	1.9	35
551	Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2008, 8, 392-403.	0.8	10
552	Targeting Angiogenesis in Renal Cell Carcinoma. Current Cancer Drug Targets, 2008, 8, 349-358.	0.8	45
553	Novel anti-myeloma agents and angiogenesis. Leukemia and Lymphoma, 2008, 49, 677-689.	0.6	38
555	Molecular Targets and Targeted Therapies for Malignant Mesothelioma. Current Medicinal Chemistry, 2008, 15, 855-867.	1.2	33
557	Artemisinin Inhibits Tumor Lymphangiogenesis by Suppression of Vascular Endothelial Growth Factor C. Pharmacology, 2008, 82, 148-155.	0.9	44
558	Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biology and Therapy, 2008, 7, 496-501.	1.5	182
559	Current concepts of metastasis in melanoma. Expert Review of Dermatology, 2008, 3, 569-585.	0.3	196
560	Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia. Journal of the National Cancer Institute, 2008, 100, 184-198.	3.0	334
561	Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leukemia and Lymphoma, 2008, 49, 852-863.	0.6	44
562	Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood, 2008, 111, 5610-5620.	0.6	258
563	Sorafenib in Lung Cancer: Clinical Developments and Future Directions. Journal of Thoracic Oncology, 2008, 3, S124-S127.	0.5	29
564	K-ras as a Target for Lung Cancer Therapy. Journal of Thoracic Oncology, 2008, 3, S160-S163.	0.5	39
565	The MAPK pathway in melanoma. Current Opinion in Oncology, 2008, 20, 183-189.	1.1	215
566	Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments. Current Clinical Pharmacology, 2008, 3, 85-98.	0.2	23
567	Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond. Current Pharmaceutical Design, 2008, 14, 2229-2251.	0.9	14

#	Article	IF	Citations
568	The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway. Current Clinical Pharmacology, 2008, 3, 132-143.	0.2	175
569	Wnt Signaling in Renal Cancer. Current Drug Targets, 2008, 9, 591-600.	1.0	34
570	Therapeutic Potential of Directed Tyrosine Kinase Inhibitor Therapy in Sarcomas. Cancer Control, 2008, 15, 47-54.	0.7	26
571	Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. Biomedical Research, 2008, 29, 271-278.	0.3	18
572	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Current Opinion in Oncology, 2008, 20, 444-453.	1.1	60
573	The Role of Angiogenesis Inhibitors in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 20-25.	1.0	31
574	Antiangiogenic therapy in nonsmall cell lung cancer. Current Opinion in Oncology, 2008, 20, 176-182.	1.1	22
575	Sorafenib for Metastatic Renal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 182-187.	0.6	49
578	Towards a Treatment for RAS-MAPK Pathway Disorders. Monographs in Human Genetics, 2008, , 151-164.	0.5	0
579	Evolving therapies in the treatment of hepatocellular carcinoma. Biologics: Targets and Therapy, 2008, Volume 2, 453-462.	3.0	17
580	Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics: Targets and Therapy, 2008, 2, 779.	3.0	34
581	A New Generation of Drugs in Cancer Treatment: Molecularly Targeted Therapies. , 0, , 193-221.		0
582	Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 707.	3.0	17
583	Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. OncoTargets and Therapy, 2008, 1, 67.	1.0	21
584	The biology and oncology of RAFâ€“ERK signaling. , 2008, , 382-402.		0
585	New insights in drug development for the non-small cell lung cancer therapy. Frontiers in Bioscience - Landmark, 2008, Volume, 5108.	3.0	4
586	Target-Directed Drug Discovery. , 0, , 223-243.		3
587	Molecularly targeted therapy for hepatocellular carcinoma. Acta Hepatologica Japonica, 2008, 49, 133-144.	0.0	0

#	Article	IF	Citations
588	Sorafenib, a systemic therapy for hepatocellular carcinoma. Annals of Hepatology, 2008, 7, 46-51.	0.6	28
590	Systemic therapies for advanced hepatocellular carcinoma. , 0, , 97-121.		0
591	Targeted therapy in melanoma. Biologics: Targets and Therapy, 0, , 475.	3.0	6
592	Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Frontiers in Bioscience - Landmark, 2009, Volume, 2248.	3.0	28
593	Sorafenib in the Management of Metastatic Renal Cell Carcinoma. Current Oncology, 2009, 16, 27-32.	0.9	16
595	Molecularly Targeted Therapies for Thyroid Cancers. Endocrine Practice, 2009, 15, 605-611.	1.1	11
596	New Treatments for Renal Cell Carcinoma: Targeted Therapies. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 645-656.	2.3	16
597	Sorafenib in Hepatocellular Carcinoma. Clinical Medicine Therapeutics, 2009, 1, CMT.S2314.	0.1	1
599	Targeted molecular therapies in thyroid carcinoma. Arquivos Brasileiros De Endocrinologia E Metabologia, 2009, 53, 1061-1073.	1.3	11
600	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Journal of Clinical Oncology, 2009, 27, 3027-3035.	0.8	467
601	Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Molecular Cancer Therapeutics, 2009, 8, 152-159.	1.9	50
602	Emerging drugs in the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2009, 14, 311-328.	1.0	13
603	The future of targeted therapy approaches in melanoma. Expert Opinion on Drug Discovery, 2009, 4, 445-456.	2.5	1
604	Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy: Figure 1.. Cancer Research, 2009, 69, 3241-3244.	0.4	78
605	Identification of Novel in Vivo Phosphorylation Sites of the Human Proapoptotic Protein BAD. Journal of Biological Chemistry, 2009, 284, 28004-28020.	1.6	48
606	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. Journal of Clinical Oncology, 2009, 27, 2823-2830.	0.8	517
607	Melanoma: targeting signaling pathways and RaLP. Expert Opinion on Therapeutic Targets, 2009, 13, 93-104.	1.5	8
608	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology, 2009, 27, 3312-3318.	0.8	1,007

#	Article	IF	Citations
609	C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas. Clinical Cancer Research, 2009, 15, 5704-5713.	3.2	37
610	rNAPc2 Inhibits Colorectal Cancer in Mice through Tissue Factor. Clinical Cancer Research, 2009, 15, 208-216.	3.2	48
611	Protein Kinase CÎ´ Supports Survival of MDA-MB-231 Breast Cancer Cells by Suppressing the ERK1/2 Pathway. Journal of Biological Chemistry, 2009, 284, 33456-33465.	1.6	45
612	Targeting angiogenesis in melanoma. Expert Review of Dermatology, 2009, 4, 237-248.	0.3	0
613	Metastatic renal cell carcinoma: A guide to therapy based on current evidence. Urology Annals, 2009, 1, 9.	0.3	1
614	Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 4274-4280.	0.8	191
615	Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT. PLoS ONE, 2009, 4, e7258.	1.1	346
616	Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Molecular Cancer Therapeutics, 2009, 8, 2546-2558.	1.9	40
618	AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Molecular Cancer Therapeutics, 2009, 8, 2537-2545.	1.9	30
619	Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 5040-5048.	3.2	26
620	Matrix Metalloproteinaseâ€“Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis. Molecular Cancer Research, 2009, 7, 452-461.	1.5	19
621	Commentary: Sorafenib Use in Patients with Advanced Hepatocellular Carcinoma and Underlying Childâ€Pugh B Cirrhosisâ€”Evidence and Controversy. Oncologist, 2009, 14, 67-69.	1.9	28
622	Combination Systemic Therapy for Advanced Renal Cell Carcinoma. Oncologist, 2009, 14, 1218-1224.	1.9	17
623	Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 95-107.	1.4	10
624	Treatment of Hepatocellular Carcinoma. Oncology, 2009, 77, 43-49.	0.9	6
625	Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer. Oncology, 2009, 77, 122-131.	0.9	6
626	Targeting Vascular Endothelial Growth Factor in Renal Cell Carcinoma. Tumor Biology, 2009, 30, 292-299.	0.8	13
627	Systemic Therapies in Hepatocellular Carcinoma. Digestive Diseases, 2009, 27, 175-188.	0.8	58

#	Article	IF	Citations
628	Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biology and Therapy, 2009, 8, 1729-1736.	1.5	45
629	Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries. International Journal of Oncology, 2009, 35, 973-6.	1.4	10
630	Development of Extracellular Signal-Regulated Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2009, 9, 678-689.	1.0	30
631	Mode of action and clinical impact of VEGF signaling inhibitors. Expert Review of Anticancer Therapy, 2009, 9, 649-662.	1.1	25
632	Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. Journal of Neurosurgery, 2009, 111, 497-503.	0.9	19
633	Strategies to improve drug delivery in bladder cancer therapy. Expert Opinion on Drug Delivery, 2009, 6, 727-744.	2.4	19
634	Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biology and Therapy, 2009, 8, 856-865.	1.5	66
635	Angiogenesis in the Treatment of Non-Small Cell Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 206-217.	3.5	31
636	Early development of sunitinib in hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2009, 9, 143-150.	1.1	28
637	Update on novel agents in renal cell carcinoma. Expert Review of Anticancer Therapy, 2009, 9, 1817-1827.	1.1	16
638	Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer. Current Medicinal Chemistry, 2009, 16, 3919-3930.	1.2	12
639	New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 115-124.	1.1	9
640	Does Arterial Spin-labeling MR Imagingâ€“measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?. Radiology, 2009, 251, 731-742.	3.6	111
641	Emerging Raf inhibitors. Expert Opinion on Emerging Drugs, 2009, 14, 633-648.	1.0	33
642	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. Future Oncology, 2009, 5, 871-888.	1.1	6
643	Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncology, 2009, 5, 775-778.	1.1	18
644	Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biology and Therapy, 2009, 8, 1904-1913.	1.5	61
647	Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2009, 1, 15-27.	1.4	8

#	Article	IF	Citations
648	Novel therapeutics for the treatment of metastatic melanoma. Future Oncology, 2009, 5, 543-557.	1.1	20
649	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research, 2009, 15, 5820-5828.	3.2	35
650	Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib. British Journal of Ophthalmology, 2009, 93, 958-963.	2.1	13
651	Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2009, 9, 1793-1805.	1.1	20
652	Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species. Xenobiotica, 2009, 39, 700-709.	0.5	8
653	Sorafenib Inhibits Nonâ€“Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells. Cancer Research, 2009, 69, 6515-6521.	0.4	84
654	Identifying Drug Effects via Pathway Alterations using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data. PLoS Computational Biology, 2009, 5, e1000591.	1.5	112
655	Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research, 2009, 15, 1076-1085.	3.2	38
656	Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 360-367.	1.3	50
657	Angiogenesis: An update and potential drug approaches (Review). International Journal of Oncology, 2009, 36, .	1.4	5
658	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression. Cancer Research, 2009, 69, 3042-3051.	0.4	164
659	Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. Journal of Clinical Oncology, 2009, 27, 4469-4474.	0.8	131
660	Targeted therapy in biliary tract cancer: 2009 update. Future Oncology, 2009, 5, 1675-1684.	1.1	8
661	Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 1280-1289.	0.8	463
662	Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. European Journal of Endocrinology, 2009, 160, 331-336.	1.9	70
663	Review: Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 183-205.	1.4	16
664	Menadione Reduction by Pharmacological Doses of Ascorbate Induces an Oxidative Stress That Kills Breast Cancer Cells. International Journal of Toxicology, 2009, 28, 33-42.	0.6	27
665	Target-based therapies in breast cancer: current status and future perspectives. Endocrine-Related Cancer, 2009, 16, 675-702.	1.6	62

#	Article	IF	Citations
666	Effective Incorporation of Biomarkers into Phase II Trials. Clinical Cancer Research, 2009, 15, 1898-1905.	3.2	82
667	Melanoma: Molecular pathogenesis and emerging target therapies (Review). International Journal of Oncology, 2009, 34, 1481-9.	1.4	64
668	Antitumor Efficacy of Recombinant Human Interleukin-2 Combined with Sorafenib Against Mouse Renal Cell Carcinoma. Japanese Journal of Clinical Oncology, 2009, 39, 303-309.	0.6	8
669	Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301. Journal of Clinical Oncology, 2009, 27, 1800-1805.	0.8	195
670	Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1493-1499.	1.8	101
671	New targets and therapeutic approaches for endocrine malignanciesâˆ†. , 2009, 123, 117-141.		97
672	Fumagillin inhibits colorectal cancer growth and metastasis in mice: In vivo and in vitro study of antiâ€angiogenesis. Pathology International, 2009, 59, 448-461.	0.6	19
673	Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer, 2009, 9, 208.	1.1	71
674	Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study. BMC Cancer, 2009, 9, 249.	1.1	46
675	Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer, 2009, 9, 297.	1.1	42
676	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer, 2009, 9, 387.	1.1	24
677	Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy. BMC Medicine, 2009, 7, 41.	2.3	127
678	Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?. BMC Medicine, 2009, 7, 42.	2.3	13
679	Novel Agents on the Horizon for Cancer Therapy. Ca-A Cancer Journal for Clinicians, 2009, 59, 111-137.	157.7	275
680	Second-Line Therapy for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2009, 10, 91-98.	1.1	5
681	Emerging Data with Antiangiogenic Therapies in Early and Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2009, 10, S7-S16.	1.1	15
682	Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines. Experimental Cell Research, 2009, 315, 3259-3266.	1.2	5
683	RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1371-1380.	1.6	128

#	Article	IF	Citations
684	Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 2673-2683.	1.6	118
685	VE-Cadherin-Mediated Cell-Cell Interaction Suppresses Sprouting via Signaling to MLC2 Phosphorylation. Current Biology, 2009, 19, 668-674.	1.8	138
686	Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis. European Urology, 2009, 55, 1430-1439.	0.9	87
687	Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. European Urology, 2009, 56, 959-971.	0.9	58
688	Molecularly targeted therapies for glioma. Annals of Neurology, 2009, 66, 717-729.	2.8	22
689	Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology, 2009, 49, 1245-1256.	3.6	272
690	Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. International Journal of Cancer, 2010, 126, 1327-1338.	2.3	53
691	Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer, 2009, 115, 61-67.	2.0	163
692	Phase 2 openâ€label study of singleâ€agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis Bâ€“endemic Asian population. Cancer, 2009, 115, 428-436.	2.0	136
693	Vascular endothelial growth factorâ€targeted therapy in metastatic renal cell carcinoma. Cancer, 2009, 115, 2306-2312.	2.0	84
694	Analysis of PTEN and HIFâ€1Î± and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferonâ€Î±. Cancer, 2009, 115, 3651-3660.	2.0	87
695	Role of RAF/MEK/ERK pathway, pâ€STATâ€3 and Mclâ€1 in sorafenib activity in human pancreatic cancer cell lines. Journal of Cellular Physiology, 2009, 220, 214-221.	2.0	69
696	Using cells devoid of RAS proteins as tools for drug discovery. Molecular Carcinogenesis, 2009, 48, 1038-1047.	1.3	7
697	Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient. International Journal of Clinical Oncology, 2009, 14, 465-467.	1.0	8
698	A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. Angiogenesis, 2009, 12, 287-296.	3.7	10
699	Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. Journal of Molecular Graphics and Modelling, 2009, 28, 336-346.	1.3	91
700	New therapeutic developments in renal cell cancer. Critical Reviews in Oncology/Hematology, 2009, 69, 56-63.	2.0	5
701	Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. Journal of Neuro-Oncology, 2009, 91, 47-50.	1.4	35

#	Article	IF	Citations
702	Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Research and Treatment, 2009, 116, 31-38.	1.1	18
703	Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. Purinergic Signalling, 2009, 5, 117-125.	1.1	25
704	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 2009, 3, 79-87.	0.8	3
705	Targeting angiogenesis in bladder cancer. Current Oncology Reports, 2009, 11, 244-249.	1.8	31
706	Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. Current Oncology Reports, 2009, 11, 405-411.	1.8	9
707	Targeted therapies in thyroid cancer. Targeted Oncology, 2009, 4, 275-285.	1.7	2
708	Therapeutic Protein Kinase Inhibitors. Cellular and Molecular Life Sciences, 2009, 66, 1163-1177.	2.4	177
709	Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacology, 2009, 9, 8.	0.4	63
710	Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science, 2009, 100, 1-8.	1.7	98
711	Mechanism of inhibition of tumor angiogenesis by Î²â€hydroxyisovalerylshikonin. Cancer Science, 2009, 100, 269-277.	1.7	45
712	Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. British Journal of Dermatology, 2009, 161, 1045-1051.	1.4	218
713	Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide. Journal of Investigative Dermatology, 2009, 129, 1500-1515.	0.3	116
714	Tumour cell survival signalling by the ERK1/2 pathway. Cell Death and Differentiation, 2009, 16, 368-377.	5.0	410
715	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene, 2009, 28, 85-94.	2.6	195
716	Molecular therapy for the treatment of hepatocellular carcinoma. British Journal of Cancer, 2009, 100, 19-23.	2.9	69
717	Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Experimental Dermatology, 2009, 18, 337-349.	1.4	11
718	Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. International Journal of Urology, 2009, 16, 444-448.	0.5	9
719	Targeted therapies in metastatic renal cancer in 2009. BJU International, 2009, 103, 1334-1342.	1.3	19

#	Article	IF	Citations
720	Phosphorylation of p70S6 kinase predicts overall survival in patients with clear marginâ€resected hepatocellular carcinoma. Liver International, 2009, 29, 399-405.	1.9	44
721	Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver International, 2009, 29, 10-17.	1.9	65
722	New drugs for the treatment of hepatocellular carcinoma. Liver International, 2009, 29, 148-158.	1.9	22
723	Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 959-960.	1.3	9
724	Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5452-5457.	1.0	23
725	Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 1109-1114.	1.4	107
726	Identification and functional validation of therapeutic targets for malignant melanoma. Critical Reviews in Oncology/Hematology, 2009, 72, 194-214.	2.0	10
727	Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. Bioorganic and Medicinal Chemistry, 2009, 17, 731-740.	1.4	34
728	Discovery of highly potent and selective type I B-Raf kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6571-6574.	1.0	23
729	Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6538-6543.	1.0	47
730	Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient. Journal of Clinical Oncology, 2009, 27, 3225-3234.	0.8	105
731	Protein kinase inhibitors: contributions from structure to clinical compounds. Quarterly Reviews of Biophysics, 2009, 42, 1-40.	2.4	228
732	A Review of Kinases Implicated in Pancreatic Cancer. Pancreatology, 2009, 9, 738-754.	0.5	35
733	The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF Kinase. Biochemistry, 2009, 48, 5187-5198.	1.2	72
734	Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treatment Reviews, 2009, 35, 297-307.	3.4	46
735	Mechanisms of resistance to FLT3 inhibitors. Drug Resistance Updates, 2009, 12, 8-16.	6.5	51
736	The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates, 2009, 12, 95-102.	6.5	56
737	Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial. European Journal of Cancer, 2009, 45, 579-587.	1.3	78

#	Article	IF	Citations
738	Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer, 2009, 45, 2473-2487.	1.3	68
739	NF-Î²B inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Letters, 2009, 278, 145-155.	3.2	67
740	Targeting the RAFâ€“MEKâ€“ERK pathway in cancer therapy. Cancer Letters, 2009, 283, 125-134.	3.2	411
741	Chemotherapy and biologic therapies for melanoma: do they work?. Clinics in Dermatology, 2009, 27, 614-625.	0.8	83
742	Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochemical and Biophysical Research Communications, 2009, 387, 239-244.	1.0	30
744	Dermatologic symptoms associated with the multikinase inhibitor sorafenib. Journal of the American Academy of Dermatology, 2009, 60, 299-305.	0.6	142
746	A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling and the extracellular environment. Journal of Hepatology, 2009, 50, 1122-1131.	1.8	18
747	Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Journal of Hepatology, 2009, 51, 315-321.	1.8	84
748	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. Journal of Hepatology, 2009, 51, 865-873.	1.8	95
749	C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E. Molecular Cell, 2009, 36, 477-486.	4.5	61
750	The pathogenesis of cancer metastasis: relevance to therapy. , 2009, , 17-40.		3
751	Tyrosine kinase inhibitors and the thyroid. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 713-722.	2.2	40
752	Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2009, 22, 395-407.	0.7	20
754	Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Review of Anticancer Therapy, 2009, 9, 1583-1598.	1.1	26
755	Sorafenib. Drugs, 2009, 69, 223-240.	4.9	430
756	Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib. Clinical Genitourinary Cancer, 2009, 7, 20-23.	0.9	103
757	Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure. Clinical Lymphoma and Myeloma, 2009, 9, S272-S279.	1.4	8
758	Standard Management of Patients With Chronic Myeloid Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S382-S390.	1.4	4

#	Article	IF	Citations
759	Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Molecular Cancer, 2009, 8, 27.	7.9	45
760	The Molecular Basis of Cancer and the Development of Targeted Therapy. Surgical Clinics of North America, 2009, 89, 1-15.	0.5	13
761	Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study. Molecular Pharmaceutics, 2009, 6, 144-157.	2.3	15
762	Adverse effects of anticancer agents that target the VEGF pathway. Nature Reviews Clinical Oncology, 2009, 6, 465-477.	12.5	492
763	Multitarget drugs: the present and the future of cancer therapy. Expert Opinion on Pharmacotherapy, 2009, 10, 589-600.	0.9	66
764	Chapter 1 Ras Signaling and Therapies. Advances in Cancer Research, 2009, 102, 1-17.	1.9	182
765	Current status and future prospects for anti-angiogenic therapies in cancer. Expert Opinion on Drug Discovery, 2009, 4, 961-979.	2.5	24
766	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Review of Clinical Pharmacology, 2009, 2, 129-136.	1.3	11
767	Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation?. Expert Review of Gastroenterology and Hepatology, 2009, 3, 211-213.	1.4	2
768	PDGFRÎ±: a new therapeutic target in the treatment of hepatocellular carcinoma?. Expert Opinion on Therapeutic Targets, 2009, 13, 443-454.	1.5	42
769	Novel therapeutics for melanoma. Expert Review of Anticancer Therapy, 2009, 9, 839-849.	1.1	19
770	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Review of Neurotherapeutics, 2009, 9, 1815-1836.	1.4	39
771	Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma. Cancer Investigation, 2009, 27, 851-856.	0.6	17
772	Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 4462-4468.	0.8	323
773	Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Expert Review of Anticancer Therapy, 2009, 9, 1295-1304.	1.1	9
774	Anti-angiogenesis approach to genitourinary cancer treatment. Update on Cancer Therapeutics, 2009, 3, 182-188.	0.9	22
775	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Molecular Cancer, 2009, 8, 118.	7.9	159
776	Anticancer strategies involving the vasculature. Nature Reviews Clinical Oncology, 2009, 6, 395-404.	12.5	234

#	Article	IF	Citations
777	Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncology, The, 2009, 10, 992-1000.	5.1	496
778	Renal cell carcinoma. Lancet, The, 2009, 373, 1119-1132.	6.3	1,363
779	Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Review of Anticancer Therapy, 2009, 9, 739-745.	1.1	116
780	How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer: Table 1. Journal of Clinical Pathology, 2009, 62, 414-421.	1.0	25
781	An overview of small-molecule inhibitors of VEGFR signaling. Nature Reviews Clinical Oncology, 2009, 6, 569-579.	12.5	305
782	Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Review of Anticancer Therapy, 2009, 9, 373-379.	1.1	29
783	Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma. Journal of Urology, 2009, 182, 29-34.	0.2	153
784	Drug Targeting of Oncogenic Pathways in Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 599-618.	0.9	6
785	Indications for Neoadjuvant, Adjuvant, and Palliative Chemotherapy in the Treatment of Biliary Tract Cancers. Surgical Oncology Clinics of North America, 2009, 18, 361-379.	0.6	5
786	BRAF Signaling and Targeted Therapies in Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 529-545.	0.9	159
787	Liver transplantation: an update 2009. Current Opinion in Gastroenterology, 2009, 25, 202-208.	1.0	10
788	Biomarker-Driven Early Clinical Trials in Oncology. Cancer Journal (Sudbury, Mass), 2009, 15, 406-420.	1.0	149
789	Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 111-124.	0.2	0
790	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs, 2009, 20, 616-624.	0.7	102
791	VEGF Inhibitors and Prostate Cancer Therapy. Current Molecular Pharmacology, 2009, 2, 161-168.	0.7	59
792	Activation of Cytosolic Phospholipase A2Î± by Epidermal Growth Factor (EGF) and Phorbol Ester in HeLa Cells: Different Effects of Inhibitors for EGF Receptor, Protein Kinase C, Src, and C-Raf. Journal of Pharmacological Sciences, 2009, 111, 182-192.	1.1	14
793	Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 618-630.	2.3	249
794	BRAF^{V600E}mutation in papillary thyroid carcinoma: a potential target for therapy?. Expert Review of Endocrinology and Metabolism, 2009, 4, 467-480.	1.2	0

#	Article	IF	Citations
795	The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression. Current Drug Targets, 2009, 10, 455-464.	1.0	10
796	PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis. Current Pharmaceutical Design, 2009, 15, 380-388.	0.9	18
797	Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 146-156.	0.8	7
798	Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis. Journal of Clinical Gastroenterology, 2009, 43, 489-495.	1.1	146
799	Sorafenib tosylate in advanced kidney cancer: past, present and future. Anti-Cancer Drugs, 2009, 20, 409-415.	0.7	19
800	Vascular endothelial growth factor pathway. Pharmacogenetics and Genomics, 2010, 20, 346-349.	0.7	18
801	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2010, 22, 391-398.	0.8	60
802	Vascular Endothelial Growth Factor Receptor as Target for Advanced Non-Small Cell Lung Cancer Therapy. Current Drug Targets, 2010, 11, 865-874.	1.0	3
803	Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis. Current Pharmaceutical Design, 2010, 16, 1396-1409.	0.9	11
804	Strategies for Overcoming Chemotherapy Resistance in Enterohepatic Tumours. Current Molecular Medicine, 2010, 10, 467-485.	0.6	15
805	Expression and Mutational Status of c-kit in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2010, 5, 1447-1453.	0.5	61
806	Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anti-Cancer Drugs, 2010, 21, 326-332.	0.7	48
807	Novel Targeted therapy for advanced renal carcinoma: trials in progress. Current Opinion in Urology, 2010, 20, 382-387.	0.9	8
808	Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anti-Cancer Drugs, 2010, 21, 514-522.	0.7	22
809	Mutation-driven drug development in melanoma. Current Opinion in Oncology, 2010, 22, 178-183.	1.1	94
810	Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review. Journal of Thoracic Oncology, 2010, 5, 129-139.	0.5	13
811	Recent Development of Molecular-Targeted Drugs in Lung Cancer. Internal Medicine, 2010, 49, 1923-1934.	0.3	6
813	Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer, 2010, 20, 787-793.	1.2	53

#	Article	IF	Citations
814	A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. Journal of Thoracic Oncology, 2010, 5, 1655-1661.	0.5	115
815	Sorafenib in hepatocellular carcinoma. British Journal of Hospital Medicine (London, England: 2005), 2010, 71, 451-456.	0.2	14
816	Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media. Experimental and Therapeutic Medicine, 2010, 1, 863-866.	0.8	13
817	Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma. Annals of Internal Medicine, 2010, 153, 587.	2.0	34
818	Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. International Journal of Oncology, 2010, 37, 15-20.	1.4	56
819	Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. International Journal of Oncology, 2010, 36, 1521-31.	1.4	6
820	Sensitivity of doxorubicin-resistant cells to sorafenib: Possible role for inhibition of eukaryotic initiation factor-2Î± phosphorylation. International Journal of Oncology, 2010, 37, 509-17.	1.4	1
821	Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial. Journal of Thoracic Oncology, 2010, 5, 1835-1840.	0.5	56
822	Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochemical Journal, 2010, 430, 405-413.	1.7	355
823	A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome. Internal Medicine, 2010, 49, 991-994.	0.3	29
824	Novel Synthesis of Ureas: Application of t-Butylureas. Chemical and Pharmaceutical Bulletin, 2010, 58, 82-86.	0.6	4
825	Hepatocellular Carcinomas in Cirrhotic and Noncirrhotic Human Livers Share Angiogenic Characteristics. Annals of Surgical Oncology, 2010, 17, 1564-1571.	0.7	18
826	Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?. Annals of Surgical Oncology, 2010, 17, 1247-1256.	0.7	52
827	Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opinion on Therapeutic Patents, 2010, 20, 885-897.	2.4	31
828	Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRÎ²/B-RAF. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4299-4304.	3.3	55
829	Acetoacetanilides as Masked Isocyanates: Facile and Efficient Synthesis of Unsymmetrically Substituted Ureas. Organic Letters, 2010, 12, 4220-4223.	2.4	45
830	Selectively Nonselective Kinase Inhibition: Striking the Right Balance. Journal of Medicinal Chemistry, 2010, 53, 1413-1437.	2.9	280
831	Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies. Science Translational Medicine, 2010, 2, 35ra41.	5.8	142

#	Article	IF	Citations
832	Novel Potent Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitors: Synthesis, Structureâ"Activity Relationships, and Antitumor Activities of 2-Indolinone Derivatives. Journal of Medicinal Chemistry, 2010, 53, 8140-8149.	2.9	47
833	Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 935-943.	1.1	17
834	Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 203-207.	1.1	55
835	Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents1. Bioorganic and Medicinal Chemistry, 2010, 18, 5261-5273.	1.4	19
836	The role of evolutionarily conserved signalling systems in Echinococcus multilocularis development and hostâ€"parasite interaction. Medical Microbiology and Immunology, 2010, 199, 247-259.	2.6	58
837	Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1633-1640.	1.2	26
838	Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. Journal of Gastroenterology, 2010, 45, 443-450.	2.3	33
839	Examining the safety profile of angiogenesis inhibitors: implications for clinical practice. Targeted Oncology, 2010, 5, 257-267.	1.7	3
840	Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib. Cardiovascular Toxicology, 2010, 10, 1-8.	1.1	41
841	Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Medical Oncology, 2010, 27, 899-906.	1.2	29
842	Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Medical Oncology, 2010, 27, 1436-1437.	1.2	26
843	Molecular basis for the treatment of renal cell carcinoma. Clinical and Translational Oncology, 2010, 12, 15-21.	1.2	17
844	Management Strategies for Patients with KRAS Mutations. Current Colorectal Cancer Reports, 2010, 6, 199-205.	1.0	0
845	Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment, 2010, 124, 79-88.	1.1	35
846	Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced nonâ€"small cell lung cancer. Investigational New Drugs, 2010, 28, 844-853.	1.2	42
847	Effect of sorafenib on experimental choroidal neovascularization in the rat. Clinical and Experimental Ophthalmology, 2010, 38, 718-726.	1.3	10
848	Angiogenesis Inhibitors: Current Strategies and Future Prospects. Ca-A Cancer Journal for Clinicians, 2010, 60, 222-243.	157.7	413
849	Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 311-319.	1.1	17

#	Article	IF	Citations
850	The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer, 2010, 10, 560.	1.1	39
851	Validating cancer drug targets through chemical genetics. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 251-257.	3.3	6
852	BRAF as therapeutic target in melanoma. Biochemical Pharmacology, 2010, 80, 561-567.	2.0	151
853	Molecularly targeted therapy in hepatocellular carcinoma. Biochemical Pharmacology, 2010, 80, 550-560.	2.0	110
854	Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochemical Pharmacology, 2010, 80, 638-646.	2.0	16
855	Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanoma. Biochemical Pharmacology, 2010, 80, 755-761.	2.0	33
856	Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochemical Pharmacology, 2010, 80, 624-637.	2.0	174
857	Targeted therapy of thyroid cancer. Biochemical Pharmacology, 2010, 80, 592-601.	2.0	70
858	Molecular characterisation of MEK1/2- and MKK3/6-like mitogen-activated protein kinase kinases (MAPKK) from the fox tapeworm Echinococcus multilocularis. International Journal for Parasitology, 2010, 40, 555-567.	1.3	42
859	Promising novel therapies for the treatment of endometrial cancer. Gynecologic Oncology, 2010, 116, 187-194.	0.6	42
860	Oncologistâ€™s/haematologistâ€™s view on the roles of pathologists for molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine, 2010, 14, 805-817.	1.6	3
861	Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, 2010, 116, 1272-1280.	2.0	240
862	Early alphaâ€fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer, 2010, 116, 4590-4596.	2.0	154
863	BRAF, a target in melanoma. Cancer, 2010, 116, 4902-4913.	2.0	106
864	Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the firstâ€line treatment of patients with glioblastoma multiforme. Cancer, 2010, 116, 3663-3669.	2.0	119
865	A frontâ€line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer. Cancer, 2010, 116, 5686-5693.	2.0	34
866	Vitamin K enhancement of sorafenibâ€mediated HCC cell growth inhibition in vitro and in vivo. International Journal of Cancer, 2010, 127, 2949-2958.	2.3	47
867	Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. Journal of Surgical Oncology, 2010, 102, 821-826.	0.8	22

#	Article	IF	Citations
868	Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and câ€jun NH2â€terminal kinase pathways. Journal of Cellular Physiology, 2010, 224, 112-119.	2.0	27
869	Involvement of receptor tyrosine phosphatase DEPâ€1 mediated PI3Kâ€cofilin signaling pathway in Sorafenibâ€induced cytoskeletal rearrangement in hepatoma cells. Journal of Cellular Physiology, 2010, 224, 559-565.	2.0	21
870	Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 23-66.	5.0	42
871	Endoglin (CD105) expression and angiogenesis status in small cell lung cancer. Pathology Research and Practice, 2010, 206, 725-730.	1.0	15
872	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research, 2010, 34, 379-386.	0.4	26
873	Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report. Leukemia Research, 2010, 34, e270-e272.	0.4	29
874	Selection and characterisation of affibody molecules inhibiting the interaction between Ras and Raf in vitro. New Biotechnology, 2010, 27, 766-773.	2.4	13
875	Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 413-417.	1.0	31
876	1,4-Dihydropyrazolo[4,3-d]imidazole phenyl derivatives: A novel type II Raf kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3805-3808.	1.0	30
877	Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 292-304.	1.4	47
878	Current Problems with Systemic Treatment of Advanced Hepatocellular Cancer. Current Problems in Cancer, 2010, 34, 131-149.	1.0	3
879	Sorafenib and Radiation: A Promising Combination in Colorectal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 213-220.	0.4	31
880	Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. Journal of Molecular Signaling, 2010, 5, 2.	0.5	34
881	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1126-1133.	0.8	51
882	Stimulatory effects of the multiâ€kinase inhibitor sorafenib on human bladder cancer cells. British Journal of Pharmacology, 2010, 160, 1690-1698.	2.7	27
883	E7050: A dual câ€Met and VEGFRâ€2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Science, 2010, 101, 210-215.	1.7	90
884	Contribution of BCRâ€“ABLâ€independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Science, 2010, 101, 137-142.	1.7	27
885	Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesisâ€related endothelial cell functions and angiogenesis in vivo. Cancer Science, 2010, 101, 2462-2469.	1.7	49

#	Article	IF	Citations
886	Intraâ€arterial therapy with cisplatin suspension in lipiodol and 5â€fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Alimentary Pharmacology and Therapeutics, 2010, 32, 543-550.	1.9	37
887	Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. British Journal of Dermatology, 2010, 162, 697-699.	1.4	20
888	Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene, 2010, 29, 1190-1202.	2.6	84
889	The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29, 4989-5005.	2.6	754
890	Multiple receptor tyrosine kinases regulate HIF-1Î± and HIF-2Î± in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene, 2010, 29, 2938-2949.	2.6	69
891	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. British Journal of Cancer, 2010, 102, 68-72.	2.9	197
892	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2010, 102, 981-986.	2.9	127
893	Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British Journal of Cancer, 2010, 102, 1219-1223.	2.9	120
894	A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension. Clinical Pharmacology and Therapeutics, 2010, 87, 303-310.	2.3	89
895	KIT as a Therapeutic Target in Melanoma. Journal of Investigative Dermatology, 2010, 130, 20-27.	0.3	99
896	A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia, 2010, 24, 1437-1444.	3.3	95
897	Envisioning the future of early anticancer drug development. Nature Reviews Cancer, 2010, 10, 514-523.	12.8	262
898	Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery, 2010, 9, 956-970.	21.5	118
899	Role of targeted therapy in the treatment of advanced prostate cancer. BJU International, 2010, 105, 748-767.	1.3	26
900	Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: A case report. International Journal of Urology, 2010, 17, 286-288.	0.5	3
902	New targeted therapies in the treatment of patients with metastatic melanoma. Wspolczesna Onkologia, 2010, 1, 15-22.	0.7	6
904	Anti-angiogenesis therapies: their potential in cancer management. OncoTargets and Therapy, 2010, 3, 69.	1.0	39
905	Consequences and Utility of the Zinc-Dependent Metalloprotease Activity of Anthrax Lethal Toxin. Toxins, 2010, 2, 1038-1053.	1.5	17

#	Article	IF	Citations
906	Thyroid Cancer: Current Molecular Perspectives. Journal of Oncology, 2010, 2010, 1-17.	0.6	23
907	Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises. Journal of Oncology, 2010, 2010, 1-7.	0.6	27
908	New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. OncoTargets and Therapy, 2010, 3, 147.	1.0	14
909	A Comprehensive Molecular Interaction Map for Rheumatoid Arthritis. PLoS ONE, 2010, 5, e10137.	1.1	51
910	r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction. PLoS ONE, 2010, 5, e12031.	1.1	38
911	A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates. PLoS ONE, 2010, 5, e15588.	1.1	90
912	Sustained Remission with the Kinase Inhibitor Sorafenib in Stage IV Metastatic Adrenocortical Carcinoma. Endocrine Practice, 2010, 16, 441-445.	1.1	19
913	Long-lasting Response with Metronomic Capecitabine in Advanced Hepatocellular Carcinoma. Tumori, 2010, 96, 768-770.	0.6	11
914	Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncology Letters, 2010, 1, 729-732.	0.8	15
915	Targeting Ras for Anticancer Drug Discovery. , 2010, , 2837-2857.		0
916	The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer. Current Drug Targets, 2010, 11, 2-11.	1.0	6
917	Comparison of the efficiencies of two TR-FRET methods to detect in vitro natural and synthesized inhibitors of the Raf/MEK/ERK signaling pathway. International Journal of High Throughput Screening, 2010, , 81.	0.5	2
918	Induction of DNA Damage-Inducible Gene GADD45Î² Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2010, 70, 9309-9318.	0.4	76
919	Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies. Oncologist, 2010, 15, 1135-1146.	1.9	27
920	Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Annals of Oncology, 2010, 21, 1027-1031.	0.6	94
921	Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy. Molecular Cancer Therapeutics, 2010, 9, 2090-2101.	1.9	45
922	Synthesis of N-[3,4-Dihydro-4-(acetoxymethyl)-2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]-Nâ€²-(4-nitrophenyl)thiourea and N-[3,4-dihydro-4-(hydroxymethyl)-2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]-Nâ€²-(4-nitrophenyl)thiourea, a Major Metabolite of N-(3,4-Dihydro-2,2,4,4-tetramethyl-2H-1-benzothiopyran-6-YL)-Nâ€²-(4-nitrophenyl)thiourea. Phosphorus, Su	0.8	5
923	Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study. Oncologist, 2010, 15, 1198-1204.	1.9	87

#	Article	IF	Citations
924	Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. Oncologist, 2010, 15, 85-92.	1.9	162
925	BRAF Inactivation Drives Aneuploidy by Deregulating CRAF. Cancer Research, 2010, 70, 8475-8486.	0.4	40
926	New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways. Clinical Cancer Research, 2010, 16, 3811-3818.	3.2	41
927	Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinaseâ€“Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma. Molecular Cancer Therapeutics, 2010, 9, 190-201.	1.9	28
928	Tyrosine Kinase Inhibitors. Current Cancer Drug Targets, 2010, 10, 462-483.	0.8	37
929	New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2010, 16, 2921-2926.	3.2	70
930	Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics, 2010, 9, 2411-2422.	1.9	76
931	Combination Therapy of Interleukin-2 and Sorafenib Improves Survival Benefits and Prevents Spontaneous Pulmonary Metastasis in Murine Renal Cell Carcinoma Models. Japanese Journal of Clinical Oncology, 2010, 40, 503-507.	0.6	6
932	A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF. Cancer Research, 2010, 70, 8036-8044.	0.4	25
933	Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 1835-1842.	0.8	421
934	Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response. Clinical Cancer Research, 2010, 16, 3329-3334.	3.2	160
935	Presurgical Targeted Therapy with Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma: Clinical Results and Histopathological Therapeutic Effects. Japanese Journal of Clinical Oncology, 2010, 40, 1173-1179.	0.6	34
936	A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-NaÃ¯ve Patients with Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 3078-3087.	3.2	82
937	Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 742-750.	1.9	93
938	Review: Hepatocellular carcinoma: the place of new medical therapies. Therapeutic Advances in Gastroenterology, 2010, 3, 259-267.	1.4	9
939	Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells. Chemotherapy, 2010, 56, 303-312.	0.8	21
940	Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development. Pharmaceuticals, 2010, 3, 2821-2837.	1.7	4
941	Recent Developments in the Molecular Biology of the Thyroid. , 2010, , 237-260.		2

#	Article	IF	Citations
942	Misdiagnosis of tuberous sclerosis in a Nigerian girl: A case report and review of literature. Annals of African Medicine, 2010, 9, 95.	0.2	8
943	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma. JAMA - Journal of the American Medical Association, 2010, 304, 2154.	3.8	412
944	Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. Journal of Clinical Oncology, 2010, 28, 780-787.	0.8	498
945	Feasibility and Activity of Sorafenib and Sunitinib in Advanced Penile Cancer: A Preliminary Report. Urologia Internationalis, 2010, 85, 334-340.	0.6	40
946	Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort. Molecular Cancer Therapeutics, 2010, 9, 751-760.	1.9	20
947	Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 233-247.	0.9	34
948	Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Research, 2010, 70, 3677-3686.	0.4	112
949	Setting up a Kinase Discovery and Development Project. Current Topics in Microbiology and Immunology, 2010, 355, 3-18.	0.7	6
951	Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert Review of Anticancer Therapy, 2010, 10, 1545-1557.	1.1	13
952	PLX4032: does it keep its promise for metastatic melanoma treatment?. Expert Opinion on Investigational Drugs, 2010, 19, 1439-1449.	1.9	24
953	Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 529-540.	1.1	37
954	Emerging drugs for ovarian cancer. Expert Opinion on Emerging Drugs, 2010, 15, 635-652.	1.0	4
955	Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics. Cancer Research, 2010, 70, 5004-5013.	0.4	196
956	Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clinical Cancer Research, 2010, 16, 4853-4863.	3.2	166
957	The Evolving Role of Histology in the Management of Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5311-5320.	0.8	247
958	Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420. Journal of Clinical Oncology, 2010, 28, 3330-3335.	0.8	112
959	(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor. Oncologist, 2010, 15, 539-547.	1.9	132
960	Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review. Oncologist, 2010, 15, 216-235.	1.9	47

#	Article	IF	Citations
961	Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Expert Review of Molecular Diagnostics, 2010, 10, 75-87.	1.5	18
963	Phase II clinical trials in oncology: are we hitting the target?. Expert Review of Anticancer Therapy, 2010, 10, 427-438.	1.1	7
964	Targeting Oncogenic BRAF in Human Cancer. Current Topics in Microbiology and Immunology, 2010, 355, 83-98.	0.7	42
965	Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3. Molecular Cancer Therapeutics, 2010, 9, 953-962.	1.9	110
966	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1856-1862.	0.8	347
967	Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells. Clinical Cancer Research, 2010, 16, 4990-5001.	3.2	79
968	Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203. Journal of Clinical Oncology, 2010, 28, 2947-2951.	0.8	199
969	Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the Clinic: How Can Outcomes Be Improved?. Oncologist, 2010, 15, 42-52.	1.9	133
970	Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. American Journal of Physiology - Renal Physiology, 2010, 299, F944-F951.	1.3	65
971	Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. British Journal of Ophthalmology, 2010, 94, 1533-1539.	2.1	29
972	Toxicity of sorafenib: clinical and molecular aspects. Expert Opinion on Drug Safety, 2010, 9, 275-287.	1.0	53
973	Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma. Oncology, 2010, 78, 148-153.	0.9	87
974	Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan. Oncology, 2010, 78, 154-166.	0.9	89
975	Positioning and Indication of Sorafenib in the Treatment Algorithm and Real Practice Setting: Western and Eastern Approach â€“ Asian Perspective. Oncology, 2010, 78, 167-171.	0.9	12
976	Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology, 2010, 78, 340-347.	0.9	44
977	Platelet count less than SHARP: what does a case series reveal?. Expert Opinion on Drug Safety, 2010, 9, 1-8.	1.0	5
978	Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter Proteins. Current Drug Metabolism, 2010, 11, 618-628.	0.7	40
979	Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacologica Sinica, 2010, 31, 1643-1648.	2.8	40

#	Article	IF	Citations
980	Sunitinib for metastatic renal cell carcinoma. Future Oncology, 2010, 6, 1377-1385.	1.1	4
981	A case of variant angina in a patient under chronic treatment with sorafenib. Nature Reviews Clinical Oncology, 2010, 7, 476-480.	12.5	26
983	Progress in the Management of Advanced Renal Cell Carcinoma (RCC). Aktuelle Urologie, 2010, 41, S57-S60.	0.3	0
984	Recent Advances in the Research and Development of B-Raf Inhibitors. Current Medicinal Chemistry, 2010, 17, 1618-1634.	1.2	26
985	Hormone-Biological Therapy in Breast Cancer: Preclinical Evidence,Clinical Studies and Future Directions. Current Cancer Drug Targets, 2010, 10, 3-18.	0.8	3
986	Macrocyclic Inhibitors of Hsp90. Current Topics in Medicinal Chemistry, 2010, 10, 1380-1402.	1.0	39
987	Current Review of Small Molecule Ret Kinase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2010, 10, 138-146.	1.1	6
988	Safety profile of new anticancer drugs. Expert Opinion on Drug Safety, 2010, 9, 301-317.	1.0	21
989	RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Research, 2010, 70, 5518-5527.	0.4	375
991	Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas. Current Cancer Drug Targets, 2010, 10, 840-848.	0.8	82
992	Non-ATP Competitive Protein Kinase Inhibitors. Current Medicinal Chemistry, 2010, 17, 2804-2821.	1.2	108
993	Novel Agents in the Management of Lung Cancer. Current Medicinal Chemistry, 2010, 17, 4291-4325.	1.2	21
994	The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases. Molecular Cancer Therapeutics, 2010, 9, 369-378.	1.9	72
995	In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells. Current Cancer Drug Targets, 2010, 10, 600-610.	0.8	13
996	New therapies in soft tissue sarcoma. Expert Opinion on Emerging Drugs, 2010, 15, 237-248.	1.0	29
997	Translational therapies for malignant pleural mesothelioma. Expert Review of Respiratory Medicine, 2010, 4, 249-260.	1.0	7
998	Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. Growth Factors, 2010, 28, 211-220.	0.5	23
999	Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells. Current Cancer Drug Targets, 2010, 10, 422-431.	0.8	19

#	Article	IF	Citations
1000	Targeting B-Raf as a treatment strategy for polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2010, 299, F942-F943.	1.3	2
1002	Mechanism of Synergistic Antitumor Effect of Sorafenib and Interferon-Î± on Treatment of Renal Cell Carcinoma. Journal of Urology, 2010, 184, 2549-2556.	0.2	15
1003	Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opinion on Pharmacotherapy, 2010, 11, 2187-2198.	0.9	12
1004	Tyrosine kinase inhibitors to treat liver cancer. Expert Opinion on Emerging Drugs, 2010, 15, 13-26.	1.0	20
1005	Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer, 2010, 70, 233-246.	0.9	15
1006	Management of breast cancer with targeted agents: importance of heterogenicity. Nature Reviews Clinical Oncology, 2010, 7, 139-147.	12.5	143
1007	Curcuma wenyujin Extract Induces Apoptosis and Inhibits Proliferation of Human Cervical Cancer Cells In Vitro and In Vivo. Integrative Cancer Therapies, 2010, 9, 36-49.	0.8	47
1008	Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. Journal of Translational Medicine, 2010, 8, 14.	1.8	39
1009	Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma. Clinical Drug Investigation, 2010, 30, 799-804.	1.1	13
1010	Clinical overview of sorafenib in breast cancer. Future Oncology, 2010, 6, 655-663.	1.1	26
1011	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 809-819.	13.9	3,288
1012	Role of the Serrated Pathway in Colorectal Cancer Pathogenesis. Gastroenterology, 2010, 138, 2088-2100.	0.6	844
1013	Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology, 2010, 28, 2323-2330.	0.8	355
1014	Improving Inferior Vena Cava Filter Retrieval Rates: Impact of a Dedicated Inferior Vena Cava Filter Clinic. Journal of Vascular and Interventional Radiology, 2010, 21, 1847-1851.	0.2	172
1015	Comprehensive Structural and Functional Characterization of the Human Kinome by Protein Structure Modeling and Ligand Virtual Screening. Journal of Chemical Information and Modeling, 2010, 50, 1839-1854.	2.5	37
1016	Ras history. Small GTPases, 2010, 1, 2-27.	0.7	586
1017	Sorafenib exerts anti-glioma activity in vitro and in vivo. Neuroscience Letters, 2010, 478, 165-170.	1.0	77
1018	The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages. International Immunopharmacology, 2010, 10, 1220-1228.	1.7	80

#	Article	IF	Citations
1019	AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). Journal of Hepatology, 2010, 52, 79-87.	1.8	88
1020	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Journal of Hepatology, 2010, 52, 88-95.	1.8	64
1021	Molecular therapeutic approaches to melanoma. Molecular Aspects of Medicine, 2010, 31, 194-204.	2.7	28
1022	Emerging molecular therapies of advanced thyroid cancer. Molecular Aspects of Medicine, 2010, 31, 215-226.	2.7	38
1023	Signal transduction therapy of cancer. Molecular Aspects of Medicine, 2010, 31, 287-329.	2.7	74
1024	Will newer tyrosine kinase inhibitors have an impact inÂAML?. Best Practice and Research in Clinical Haematology, 2010, 23, 489-494.	0.7	9
1025	Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Letters, 2010, 288, 57-67.	3.2	34
1026	Suppression of hypoxia-induced HIF-1Î± accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633. Cancer Letters, 2010, 296, 17-26.	3.2	26
1027	Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters, 2010, 299, 1-10.	3.2	52
1028	Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews, 2010, 36, 416-424.	3.4	89
1029	Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. European Journal of Cancer, 2010, 46, 2432-2440.	1.3	84
1030	The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochemical and Biophysical Research Communications, 2010, 398, 74-78.	1.0	105
1031	Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell, 2010, 140, 209-221.	13.5	1,318
1032	Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 21-27.	0.8	33
1033	A survey of therapy for advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 121-133.	0.8	26
1034	The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Research in Veterinary Science, 2010, 88, 94-100.	0.9	20
1035	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of Hepatology, 2010, 53, 126-131.	1.8	124
1036	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treatment Reviews, 2010, 36, S1-S5.	3.4	37

#	Article	IF	Citations
1037	The therapy of kidney cancer with biomolecular drugs. Cancer Treatment Reviews, 2010, 36, S16-S20.	3.4	33
1038	The Pulmonary Toxicity of Anticancer Agents. , 2010, , 477-510.		6
1039	Novel inhibitors in development for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2010, 19, 615-629.	1.9	30
1040	Molecularly Targeted Therapies for Astrocytomas. , 2010, , 231-265.		1
1043	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. Journal of Experimental and Clinical Cancer Research, 2010, 29, 95.	3.5	94
1044	Membrane Receptors, Channels and Transporters in Pulmonary Circulation. Advances in Experimental Medicine and Biology, 2010, , .	0.8	4
1045	Sorafenib: Rays of Hope in Thyroid Cancer. Thyroid, 2010, 20, 1351-1358.	2.4	19
1046	Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 585-596.	1.1	20
1047	A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia and Lymphoma, 2010, 51, 252-260.	0.6	85
1048	The genetic basis of kidney cancer: a metabolic disease. Nature Reviews Urology, 2010, 7, 277-285.	1.9	634
1049	Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncology, 2010, 6, 1085-1094.	1.1	66
1050	Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration. BioDrugs, 2010, 24, 183-194.	2.2	50
1051	Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly â€“ A Mini-Review. Gerontology, 2010, 56, 303-309.	1.4	61
1052	Advances in targeted therapeutic agents. Expert Opinion on Drug Discovery, 2010, 5, 1123-1140.	2.5	23
1053	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Review of Anticancer Therapy, 2010, 10, 825-835.	1.1	17
1054	Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2010, 19, 663-672.	1.9	23
1055	Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1383-1394.	1.5	7
1056	Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy, 2011, 7, 1159-1172.	4.3	287

#	Article	IF	Citations
1057	New targeted therapies for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2011, 20, 933-945.	1.9	3
1058	An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Expert Opinion on Investigational Drugs, 2011, 20, 1039-1045.	1.9	9
1059	Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial. Oncology Reports, 2011, 26, 1547-53.	1.2	41
1060	Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial. Journal of Clinical Pharmacology, 2011, 51, 1674-1684.	1.0	19
1061	Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 2582-2589.	0.8	150
1062	The Ras Signaling Inhibitor LOX-PP Interacts with Hsp70 and c-Raf To Reduce Erk Activation and Transformed Phenotype of Breast Cancer Cells. Molecular and Cellular Biology, 2011, 31, 2683-2695.	1.1	35
1063	Biochemical Characterization of TAK-593, a Novel VEGFR/PDGFR Inhibitor with a Two-Step Slow Binding Mechanism. Biochemistry, 2011, 50, 738-751.	1.2	35
1064	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Annals of Oncology, 2011, 22, 1528-1534.	0.6	52
1065	Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation, 2011, 29, 325-337.	0.6	66
1066	Response to Sorafenib at a Low Dose in Patients with Radioiodine-Refractory Pulmonary Metastases from Papillary Thyroid Carcinoma. Thyroid, 2011, 21, 119-124.	2.4	51
1067	Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 361-366.	0.2	30
1068	Analogues and Derivatives of Oncrasin-1, a Novel Inhibitor of the C-Terminal Domain of RNA Polymerase II and Their Antitumor Activities. Journal of Medicinal Chemistry, 2011, 54, 2668-2679.	2.9	49
1069	Induction Chemotherapy for Hepatocellular Carcinoma. , 2011, , 237-250.		0
1070	Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?. Expert Opinion on Investigational Drugs, 2011, 20, 1413-1434.	1.9	13
1071	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2011, 20, 61-74.	1.9	9
1072	Systemic Therapy for Metastatic Nonâ€“Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions. Hematology/Oncology Clinics of North America, 2011, 25, 853-869.	0.9	24
1073	Inhibition of Ras for cancer treatment: the search continues. Future Medicinal Chemistry, 2011, 3, 1787-1808.	1.1	349
1074	Update on new drugs in small cell lung cancer. Expert Opinion on Investigational Drugs, 2011, 20, 441-455.	1.9	14

#	Article	IF	Citations
1075	Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia, 2011, 25, 838-847.	3.3	60
1076	The Feasibility of BCG and Sunitinib Combination Therapy for Transitional Cell Carcinoma. Urological Science, 2011, 22, 19-27.	0.2	3
1077	A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer, 2011, 71, 151-155.	0.9	12
1078	Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer, 2011, 74, 197-205.	0.9	22
1079	Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatology Research, 2011, 41, 296-302.	1.8	73
1080	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2011, 50, 551-603.	1.6	163
1081	Axitinib for the Management of Metastatic Renal Cell Carcinoma. Drugs in R and D, 2011, 11, 113-126.	1.1	130
1082	Trends in Kinase Selectivity: Insights for Target Class-Focused Library Screening. Journal of Medicinal Chemistry, 2011, 54, 54-66.	2.9	78
1083	Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluationin vitroandin vivo. Journal of Microencapsulation, 2011, 28, 528-536.	1.2	43
1084	Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib. Academic Radiology, 2011, 18, 89-96.	1.3	25
1085	Induction Chemotherapy. , 2011, , .		5
1086	Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts. Clinics in Dermatology, 2011, 29, 587-601.	0.8	19
1087	Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options. Cancer Treatment Reviews, 2011, 37, 169-177.	3.4	49
1088	Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treatment Reviews, 2011, 37, 344-352.	3.4	37
1089	Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer. Cancer Treatment Reviews, 2011, 37, 611-617.	3.4	26
1090	Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth. Cytokine, 2011, 53, 115-129.	1.4	17
1091	Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. European Journal of Cancer, 2011, 47, 277-286.	1.3	43
1092	Molecular classification of hepatocellular carcinoma anno 2011. European Journal of Cancer, 2011, 47, 1789-1797.	1.3	73

#	Article	IF	Citations
1093	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. European Journal of Cancer, 2011, 47, 2117-2127.	1.3	496
1094	Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. European Journal of Surgical Oncology, 2011, 37, 513-520.	0.5	55
1095	Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 1836-1846.	2.9	32
1096	Erythema marginatum hemorrhagicum: AÂunique cutaneous side effect of sorafenib. Journal of the American Academy of Dermatology, 2011, 64, 1194-1196.	0.6	7
1097	Sorafenib-induced eruption resembling pityriasis rubra pilaris. Journal of the American Academy of Dermatology, 2011, 65, 452-453.	0.6	23
1098	Treatment of shiitake dermatitis by balneo PUVA therapy. Journal of the American Academy of Dermatology, 2011, 65, 453-455.	0.6	10
1099	RET in breast cancer: functional and therapeutic implications. Trends in Molecular Medicine, 2011, 17, 149-157.	3.5	87
1100	Targeting STAT3 in hepatocellular carcinoma: Sorafenib againâ€¦. Journal of Hepatology, 2011, 55, 957-959.	1.8	19
1101	Management Of Tyrosine Kinase Inhibitorâ€“Induced Handâ€“Foot Skin Reaction: Viewpoints from the Medical Oncologist, Dermatologist, and Oncology Nurse. The Journal of Supportive Oncology, 2011, 9, 13-23.	2.3	36
1102	Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 4-11.	0.8	24
1103	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 756-763.	0.8	10
1104	Therapy for metastatic melanoma: an overview and update. Expert Review of Anticancer Therapy, 2011, 11, 725-737.	1.1	55
1105	Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress. Pigment Cell and Melanoma Research, 2011, 24, 107-109.	1.5	5
1106	Mandibular fracture in a patient treated with long-term antiangiogenic therapy and previous bisphosphonate exposure. Community Oncology, 2011, 8, 415-417.	0.2	1
1107	Targeted therapies for breast cancer. Journal of Clinical Investigation, 2011, 121, 3797-3803.	3.9	313
1108	Looking to the future: a new decade of pulmonary arterial hypertension therapy. European Respiratory Review, 2011, 20, 262-269.	3.0	55
1109	Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochemical Pharmacology, 2011, 82, 201-209.	2.0	162
1110	Sorafenib and the medical treatment of hepatocellular carcinoma. Journal of Solid Tumors, 2011, 1, .	0.1	1

#	Article	IF	Citations
1111	Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 560-575.	0.9	24
1112	Tyrosine kinase inhibitors: Multi-targeted or single-targeted?. World Journal of Clinical Oncology, 2011, 2, 80.	0.9	184
1113	Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Annals of Hepatology, 2011, 10, 21-27.	0.6	94
1114	The Lymphatics: On the Route to Cancer Metastasis. , 0, , 237-254.		0
1115	Pancreatic Endocrine Tumors: A Report on a Patient Treated with Sorafenib. Journal of Korean Medical Science, 2011, 26, 954.	1.1	4
1116	Molecular Biology of Thyroid Cancer. , 2011, , .		0
1117	Patterns of Presentation, Referral, and Treatment of Hepatocellular Carcinoma in a Pre-Sorafenib Era: Experience of a Canadian Provincial Cancer Agency. Current Oncology, 2011, 18, 297-303.	0.9	1
1118	New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. Therapeutics and Clinical Risk Management, 2011, 7, 429.	0.9	11
1119	Promising Experimental Therapies for Metastatic Melanoma. , 2011, , .		0
1120	Novel therapeutic Strategies for Targeting Liver Cancer Stem Cells. International Journal of Biological Sciences, 2011, 7, 517-535.	2.6	124
1121	Sorafenib (NexavarÂ®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema. Annals of Dermatology, 2011, 23, 119.	0.3	7
1122	Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?. Journal of Cancer, 2011, 2, 333-338.	1.2	39
1123	Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. OncoTargets and Therapy, 2011, 4, 43.	1.0	47
1124	Signal Transduction Pathways in Breast Cancer â€“ Drug Targets and Challenges. , 0, , .		0
1125	Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. PLoS ONE, 2011, 6, e28841.	1.1	40
1126	Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib. PLoS ONE, 2011, 6, e16978.	1.1	60
1127	Targeted therapies for advanced thyroid cancer. Current Opinion in Oncology, 2011, 23, 13-21.	1.1	21
1128	Types of Pancreatic Cancer in EUS-FNA and Chemotherapy. American Journal of Therapeutics, 2011, 18, 101-106.	0.5	3

#	Article	IF	Citations
1129	Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib. Journal of Clinical Gastroenterology, 2011, 45, 733-737.	1.1	5
1130	Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer. Anti-Cancer Drugs, 2011, 22, 384-391.	0.7	2
1131	Development of RET Kinase Inhibitors for Targeted Cancer Therapy. Current Medicinal Chemistry, 2011, 18, 162-175.	1.2	49
1132	Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma. Current Clinical Pharmacology, 2011, 6, 189-198.	0.2	12
1133	Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways. Current Topics in Medicinal Chemistry, 2011, 11, 1571-1590.	1.0	41
1134	Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. Oncology Letters, 2011, 2, 69-73.	0.8	6
1135	BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety. Clinical Investigation, 2011, 1, 1127-1139.	0.0	6
1136	Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood, 2011, 117, 882-889.	0.6	58
1137	Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib. Biological and Pharmaceutical Bulletin, 2011, 34, 433-435.	0.6	52
1138	Pazopanib in the treatment of renal cell carcinoma. Clinical Investigation, 2011, 1, 75-85.	0.0	3
1140	Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics. Drug Metabolism and Pharmacokinetics, 2011, 26, 612-620.	1.1	24
1141	Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 960-977.	2.3	90
1142	Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IXâ€specific chimeric monoclonal antibody cG250. BJU International, 2011, 107, 118-125.	1.3	20
1143	Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU International, 2011, 108, 1813-1819.	1.3	42
1144	MicroRNA, hypoxic stress and hepatocellular carcinoma: Future directions. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1586-1588.	1.4	3
1145	Sorafenibâ€induced premalignant and malignant skin lesions. International Journal of Dermatology, 2011, 50, 396-402.	0.5	34
1146	Sorafenibâ€associated handâ€“foot syndrome in Japanese patients. Journal of Dermatology, 2011, 38, 261-266.	0.6	22
1147	Multikinase inhibitor sorafenib exerts cytocidal efficacy against Nonâ€Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. British Journal of Haematology, 2011, 152, 401-412.	1.2	15

#	Article	IF	Citations
1148	BAY 43â€9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. British Journal of Haematology, 2011, 155, 398-402.	1.2	25
1149	Meta-analysis of dermatological toxicities associated with sorafenib. Clinical and Experimental Dermatology, 2011, 36, 344-350.	0.6	50
1150	Prognostic value of 18Fâ€FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver International, 2011, 31, 1144-1149.	1.9	56
1151	Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. International Journal of Clinical Practice, 2011, 65, 182-188.	0.8	23
1152	Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. British Journal of Cancer, 2011, 104, 1256-1261.	2.9	66
1153	PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. British Journal of Cancer, 2011, 104, 635-642.	2.9	154
1154	Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. British Journal of Cancer, 2011, 104, 941-947.	2.9	27
1155	Levels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. British Journal of Cancer, 2011, 104, 1144-1150.	2.9	55
1156	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Journal of Cellular and Molecular Medicine, 2011, 15, 316-326.	1.6	5
1157	The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies. Structure, 2011, 19, 1097-1107.	1.6	49
1158	t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: Report of a case treated with sorafenib and review of the literature. Leukemia Research, 2011, 35, e151-e153.	0.4	35
1159	Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. Seminars in Oncology, 2011, 38, S10-S19.	0.8	59
1160	Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study. Gynecologic Oncology, 2011, 123, 33-36.	0.6	47
1161	Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. International Journal of Pharmaceutics, 2011, 419, 339-346.	2.6	89
1162	VEGF targeted therapy in acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2011, 80, 241-256.	2.0	30
1163	New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies. European Journal of Medicinal Chemistry, 2011, 46, 5754-5762.	2.6	73
1164	Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma. Free Radical Biology and Medicine, 2011, 51, 2259-2271.	1.3	129
1165	Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6941-6944.	1.0	11

#	Article	IF	Citations
1166	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro-Oncology, 2011, 13, 1324-1330.	0.6	39
1167	Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges. Cancer Discovery, 2011, 1, 297-311.	7.7	47
1168	Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy, 2011, 11, 1817-1827.	1.1	7
1169	Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Medical Molecular Morphology, 2011, 44, 183-189.	0.4	29
1170	Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2011, 18, 3384-90.	0.7	21
1171	Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investigational New Drugs, 2011, 29, 481-488.	1.2	46
1172	A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs, 2011, 29, 1045-1049.	1.2	75
1173	Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Investigational New Drugs, 2011, 29, 1090-1093.	1.2	84
1174	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Investigational New Drugs, 2011, 29, 1511-1514.	1.2	37
1175	Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Research and Treatment, 2011, 125, 137-143.	1.1	36
1176	Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Research and Treatment, 2011, 130, 1063-1071.	1.1	48
1177	Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer and Metastasis Reviews, 2011, 30, 19-26.	2.7	41
1178	Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients. Pharmaceutical Research, 2011, 28, 3199-3207.	1.7	36
1179	Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. Wiener Klinische Wochenschrift, 2011, 123, 61-64.	1.0	9
1180	Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. Journal of Gastroenterology, 2011, 46, 779-789.	2.3	43
1181	Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Medical Molecular Morphology, 2011, 44, 117-124.	0.4	19
1183	Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. Cancer Immunology, Immunotherapy, 2011, 60, 793-808.	2.0	16
1184	A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 751-764.	1.1	67

#	Article	IF	Citations
1185	Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2011, 68, 53-61.	1.1	18
1186	Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 139-145.	1.1	2
1187	High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemotherapy and Pharmacology, 2011, 68, 239-245.	1.1	34
1188	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemotherapy and Pharmacology, 2011, 68, 1111-1118.	1.1	43
1189	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 539-545.	1.1	29
1190	The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cellular and Molecular Life Sciences, 2011, 68, 1079-1090.	2.4	33
1191	Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. Medical Oncology, 2011, 28, 1384-1388.	1.2	10
1192	Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatology International, 2011, 5, 850-856.	1.9	40
1193	Targeting angiogenesis for the treatment of advanced melanoma. Oncology Reviews, 2011, 5, 167-176.	0.8	2
1194	VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 799-806.	1.0	4
1195	The â€œSWOTâ€•of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?. Current Oncology Reports, 2011, 13, 479-487.	1.8	33
1196	Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell International, 2011, 11, 44.	1.8	24
1197	Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Molecular Cancer, 2011, 10, 90.	7.9	60
1198	High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. Journal of Translational Medicine, 2011, 9, 220.	1.8	24
1199	KRAS and BRAF: drug targets and predictive biomarkers. Journal of Pathology, 2011, 223, 220-230.	2.1	133
1200	A new era: melanoma genetics and therapeutics. Journal of Pathology, 2011, 223, 242-251.	2.1	107
1201	Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. Journal of Pathology, 2011, 225, 212-221.	2.1	35
1202	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transplantation, 2011, 17, S67-S71.	1.3	20

#	Article	IF	Citations
1203	Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology, 2011, 103, 574-586.	0.8	21
1204	Effect of sorafenib on murine liver regeneration. Hepatology, 2011, 53, 577-586.	3.6	31
1205	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology, 2011, 53, 483-492.	3.6	97
1206	Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology, 2011, 53, 493-503.	3.6	75
1207	Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities. Hepatology, 2011, 53, 695-704.	3.6	62
1208	Sorafenib inhibits transforming growth factor Î²1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes. Hepatology, 2011, 53, 1708-1718.	3.6	88
1209	Hypothyroidism in patients with renal cell carcinoma. Cancer, 2011, 117, 534-544.	2.0	178
1210	FLT3 inhibitors in the treatment of acute myeloid leukemia. Cancer, 2011, 117, 3293-3304.	2.0	52
1211	Regorafenib (BAY 73â€4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, 2011, 129, 245-255.	2.3	1,068
1212	Synthesis of 1Hâ€Pyrazoleâ€1â€carboxamide Derivatives and Their Antiproliferative Activity against Melanoma Cell Line. Archiv Der Pharmazie, 2011, 344, 197-204.	2.1	13
1213	Design, Synthesis, and Antiproliferative Activity of 3,4â€Diarylpyrazoleâ€1â€carboxamide Derivatives Against Melanoma Cell Line. Archiv Der Pharmazie, 2011, 344, 745-754.	2.1	11
1214	In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases. Chemistry and Biology, 2011, 18, 699-710.	6.2	292
1215	[11C]Sorafenib: Radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2220-2223.	1.0	48
1216	Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3286-3289.	1.0	19
1217	Is VEGF a predictive biomarker to anti-angiogenic therapy?. Critical Reviews in Oncology/Hematology, 2011, 79, 103-111.	2.0	31
1218	Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins. Molecular Cancer Therapeutics, 2011, 10, 1241-1251.	1.9	55
1219	Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncology, 2011, 7, 1247-1253.	1.1	28
1220	c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biology and Therapy, 2011, 12, 531-538.	1.5	24

#	Article	IF	Citations
1221	Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy. Molecular Therapy, 2011, 19, 1170-1179.	3.7	122
1222	Targeted therapies for thyroid tumors. Modern Pathology, 2011, 24, S44-S52.	2.9	75
1223	Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy, 2011, 3, 213-227.	1.0	53
1224	The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer. Current Medicinal Chemistry, 2011, 18, 5022-5032.	1.2	27
1225	Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents. Mini-Reviews in Medicinal Chemistry, 2011, 11, 18-31.	1.1	20
1226	Modulators of Protein-Protein Interactions â€“ Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules. Current Topics in Medicinal Chemistry, 2011, 11, 1305-1319.	1.0	19
1227	Acrolentiginous melanomas. Journal of the Egyptian Women's Dermatologic Society, 2011, 8, 55-62.	0.2	0
1228	A New Rapid and Sensitive LC-MS Assay for the Determination of Sorafenib in Plasma: Application to a Patient Undergoing Hemodialysis. Therapeutic Drug Monitoring, 2011, 33, 705-710.	1.0	13
1229	Sorafenib Inhibits the Hepatocyte Growth Factorâ€“Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2011, 10, 169-177.	1.9	109
1230	Current systemic management of metastatic renal cell carcinoma â€“ first line and second line therapy. Current Opinion in Supportive and Palliative Care, 2011, 5, 211-221.	0.5	6
1231	The BATTLE Trial: A Bold Step toward Improving the Efficiency of Biomarker-Based Drug Development. Cancer Discovery, 2011, 1, 17-20.	7.7	21
1232	Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opinion on Emerging Drugs, 2011, 16, 407-423.	1.0	6
1233	Clinical Presentation and Management of Handâ€“Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer. Oncologist, 2011, 16, 1508-1519.	1.9	58
1234	Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies. Clinical Cancer Research, 2011, 17, 7080-7092.	3.2	58
1235	Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo. Clinical Cancer Research, 2011, 17, 1373-1381.	3.2	34
1236	Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 1607-1618.	1.1	14
1238	Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination. Clinical Cancer Research, 2011, 17, 4541-4549.	3.2	28
1239	Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 155-161.	1.3	270

#	Article	IF	Citations
1240	Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Therapeutic Advances in Medical Oncology, 2011, 3, 95-100.	1.4	12
1241	ERK Crosstalks with 4EBP1 to Activate Cyclin D1 Translation during Quinol-Thioetherâ€“Induced Tuberous Sclerosis Renal Cell Carcinoma. Toxicological Sciences, 2011, 124, 75-87.	1.4	18
1242	Apoptotic Sphingolipid Ceramide in Cancer Therapy. Journal of Lipids, 2011, 2011, 1-15.	1.9	74
1243	Treatment of Advanced Hepatocellular Carcinoma: Sorafenib and Beyond. Clinical Medicine Reviews in Oncology, 2011, 3, 39-47.	0.0	0
1244	Acalculous Cholecystitis in a Patient with Hepatocellular Carcinoma on Sorafenib. ISRN Gastroenterology, 2011, 2011, 1-4.	1.5	12
1245	Targeted Treatment of Differentiated and Medullary Thyroid Cancer. Journal of Thyroid Research, 2011, 2011, 1-11.	0.5	6
1246	Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. Clinical Cancer Research, 2011, 17, 5257-5267.	3.2	75
1247	An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2â€“Dependent Angiogenesis without Affecting Ligand Binding. Molecular Cancer Therapeutics, 2011, 10, 770-783.	1.9	29
1248	New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects. Molecular Cancer Therapeutics, 2011, 10, 2215-2223.	1.9	98
1249	Ehrlichia chaffeensis Induces Monocyte Inflammatory Responses through MyD88, ERK, and NF-Î²B but Not through TRIF, Interleukin-1 Receptor 1 (IL-1R1)/IL-18R1, or Toll-Like Receptors. Infection and Immunity, 2011, 79, 4947-4956.	1.0	32
1250	Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. North American Journal of Medical Sciences, 2011, 3, 167-175.	1.7	27
1251	Changing Pathology with Changing Drugs: Skin Cancer. Pathobiology, 2011, 78, 61-75.	1.9	1
1252	Des-Î³-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma. Digestive Diseases, 2011, 29, 321-325.	0.8	49
1253	Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models. Oncology, 2011, 80, 167-174.	0.9	47
1254	AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature. Onkologie, 2011, 34, 538-542.	1.1	4
1255	Superselective Transarterial Chemoembolization for Hepatocellular Carcinoma: Recent Progression and Perspective. Oncology, 2011, 81, 105-110.	0.9	7
1256	Early Decrease in Î±-Fetoprotein, but Not Des-Î³-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2011, 81, 251-258.	0.9	78
1257	Targeted â€“ Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?. Reviews on Recent Clinical Trials, 2011, 6, 259-265.	0.4	18

#	Article	IF	Citations
1258	Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. Cancer Biology and Therapy, 2011, 11, 330-336.	1.5	14
1259	Raf Family Kinases: Old Dogs Have Learned New Tricks. Genes and Cancer, 2011, 2, 232-260.	0.6	322
1260	Impact of Renin-Angiotensin System in Hepatocellular Carcinoma. Current Cancer Drug Targets, 2011, 11, 431-441.	0.8	22
1261	Comparing the Efficacy of Sunitinib with Sorafenib in Xenograft Models of Human Hepatocellular Carcinoma: Mechanistic Explanation. Current Cancer Drug Targets, 2011, 11, 944-953.	0.8	18
1262	Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2011, 10, 1007-1017.	1.9	72
1263	Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics. Clinical Cancer Research, 2011, 17, 6914-6923.	3.2	81
1264	Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1â€²-Hydroxylation. Drug Metabolism and Disposition, 2011, 39, 757-762.	1.7	48
1265	Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research, 2011, 17, 1190-1199.	3.2	67
1267	Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. British Journal of Cancer, 2011, 105, 382-392.	2.9	50
1268	Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. Journal of Investigative Dermatology, 2011, 131, 2087-2095.	0.3	70
1270	Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine, 2011, 6, 1645-1654.	1.7	4
1271	Therapeutic Strategies for Targeting Ras Proteins. Genes and Cancer, 2011, 2, 359-372.	0.6	282
1272	Encountering unpredicted off-target effects of pharmacological inhibitors. Journal of Biochemistry, 2011, 150, 1-3.	0.9	14
1273	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 849-860.	3.2	58
1274	Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma. Gastroenterology Research and Practice, 2011, 2011, 1-3.	0.7	5
1275	DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo. Cancer Research, 2011, 71, 6073-6083.	0.4	212
1276	Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian Journal of Cancer, 2011, 48, 47.	0.2	22
1277	Bevacizumab in metastatic breast cancer: when may it be used?. Therapeutic Advances in Medical Oncology, 2011, 3, 85-93.	1.4	12

#	Article	IF	Citations
1278	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 2011, 20, 3933-3942.	1.4	120
1279	Brazilian Propolis Suppresses Angiogenesis by Inducing Apoptosis in Tube-Forming Endothelial Cells through Inactivation of Survival Signal ERK1/2. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-8.	0.5	33
1280	Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2012, 47, 809-819.	0.6	15
1281	Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study. OncoTargets and Therapy, 2012, 5, 457.	1.0	14
1282	Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7262.	0.6	4
1283	Gastrointestinal Stromal Tumors: A Review of Case Reports, Diagnosis, Treatment, and Future Directions. ISRN Gastroenterology, 2012, 2012, 1-16.	1.5	53
1284	Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	26
1285	Molecular Alterations Associated with Osteosarcoma Development. Sarcoma, 2012, 2012, 1-12.	0.7	23
1286	Predictors of Response to Targeted Therapy in Renal Cell Carcinoma. Archives of Pathology and Laboratory Medicine, 2012, 136, 490-495.	1.2	17
1287	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647.	3.5	110
1288	Erythema Multiforme Induced by Sorafenib for Metastatic Renal Cell Carcinoma. Japanese Journal of Clinical Oncology, 2012, 42, 820-824.	0.6	21
1289	Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. Bone Marrow Transplantation, 2012, 47, 872-873.	1.3	7
1290	BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of Oncology, 2012, 23, 2799-2805.	0.6	184
1291	Sorafenib in metastatic thyroid cancer. Endocrine-Related Cancer, 2012, 19, 209-216.	1.6	96
1292	Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs. Chemical Immunology and Allergy, 2012, 97, 191-202.	1.7	23
1293	Targeting Mutant BRAF in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 124-131.	1.0	70
1294	Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective. Japanese Journal of Clinical Oncology, 2012, 42, 247-255.	0.6	39
1295	CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity. Molecular Cancer Therapeutics, 2012, 11, 930-941.	1.9	42

#	Article	IF	Citations
1296	Pneumatosis Intestinalis and Bowel Perforation Associated With Molecular Targeted Therapy: An Emerging Problem and the Role of Radiologists in Its Management. American Journal of Roentgenology, 2012, 199, 1259-1265.	1.0	92
1297	Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocrine-Related Cancer, 2012, 19, 527-539.	1.6	63
1298	Therapeutic Kinase Inhibitors. Current Topics in Microbiology and Immunology, 2012, , .	0.7	1
1299	Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. Oncologist, 2012, 17, 359-366.	1.9	142
1300	RAS/RAF/MEK Inhibitors in Oncology. Current Medicinal Chemistry, 2012, 19, 1164-1176.	1.2	54
1301	Genitourinary Imaging: Part 2, Role of Imaging in Medical Management of Advanced Renal Cell Carcinoma. American Journal of Roentgenology, 2012, 199, W554-W564.	1.0	11
1302	Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity. Recent Patents on Anti-infective Drug Discovery, 2012, 7, 104-110.	0.5	20
1303	State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies. Current Medicinal Chemistry, 2012, 19, 4875-4884.	1.2	13
1304	A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia. Current Medicinal Chemistry, 2012, 19, 5294-5318.	1.2	22
1306	The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacologica Sinica, 2012, 33, 1311-1318.	2.8	33
1307	Combination of Local Transcatheter Arterial Chemoembolization and Systemic Anti-angiogenic Therapy for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2012, 1, 201-215.	4.2	22
1308	Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biology and Therapy, 2012, 13, 534-541.	1.5	25
1309	Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis, 2012, 33, 1782-1790.	1.3	27
1310	Targeted treatment for melanoma. Expert Review of Anticancer Therapy, 2012, 12, 1113-1115.	1.1	1
1311	Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non â€“ small Cell Lung Cancer. Current Cancer Drug Targets, 2012, 12, 107-123.	0.8	47
1312	Sorafenib inhibits p38Î± activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biology and Therapy, 2012, 13, 1471-1481.	1.5	22
1313	Phase I Trial of Sorafenib in Combination With 5â€Fluorouracil/Leucovorin in Advanced Solid Tumors. Journal of Clinical Pharmacology, 2012, 52, 656-669.	1.0	9
1314	Pancreatic Metastasis Arising from a BRAF^{V600E}-Positive Papillary Thyroid Cancer: The Role of Endoscopic Ultrasound-Guided Biopsy and Response to Sorafenib Therapy. Thyroid, 2012, 22, 536-541.	2.4	22

#	Article	IF	Citations
1315	Brain Metastasis from Follicular Thyroid Carcinoma: Treatment with Sorafenib. Thyroid, 2012, 22, 856-860.	2.4	28
1316	RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology, 2012, 30, 316-321.	0.8	366
1317	Sorafenib in locally advanced or metastatic breast cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1177-1191.	1.9	21
1319	Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3Î² and NF-Î²B to suppress tumor cell growth. Oncogene, 2012, 31, 4848-4858.	2.6	63
1320	A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. Cell Death and Disease, 2012, 3, e406-e406.	2.7	37
1321	The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. Oncogene, 2012, 31, 3913-3923.	2.6	41
1322	Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells. Oncogene, 2012, 31, 3845-3856.	2.6	38
1323	Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death and Disease, 2012, 3, e262-e262.	2.7	44
1324	Sorafenib in advanced melanoma: a critical role for pharmacokinetics?. British Journal of Cancer, 2012, 107, 455-461.	2.9	44
1325	New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment. Future Oncology, 2012, 8, 559-573.	1.1	8
1326	Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species ProductionIn VitroandIn Vivo. Molecular Cancer Therapeutics, 2012, 11, 2284-2293.	1.9	168
1327	Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma. Chemotherapy, 2012, 58, 468-474.	0.8	38
1328	Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. European Journal of Endocrinology, 2012, 166, 451-458.	1.9	132
1329	Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway. Archives of Dermatology, 2012, 148, 628-33.	1.7	89
1330	An overview of angiogenesis and renal cell carcinoma. International Journal of Nutrition, Pharmacology, Neurological Diseases, 2012, 2, 3.	0.6	7
1331	Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocrine-Related Cancer, 2012, 19, 305-319.	1.6	56
1332	Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review. Chemotherapy Research and Practice, 2012, 2012, 1-11.	1.6	14
1333	Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Annals of Oncology, 2012, 23, 2805-2811.	0.6	28

#	Article	IF	Citations
1334	1-(3-Fluorophenyl)-3-(4-nitrophenyl)urea. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o2030-o2030.	0.2	1
1335	Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances. Current Pharmaceutical Design, 2012, 18, 2867-2874.	0.9	7
1336	Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials. Current Pharmaceutical Design, 2012, 18, 2921-2935.	0.9	22
1337	Evaluation of the mRECIST and Î±-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib. Oncology, 2012, 83, 192-200.	0.9	66
1338	Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience. Digestive Diseases, 2012, 30, 609-616.	0.8	24
1339	Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib. Current Topics in Medicinal Chemistry, 2012, 12, 1649-1659.	1.0	25
1340	Quantifying the Structural Requirements for Designing Newer FLT3 Inhibitors. Medicinal Chemistry, 2012, 8, 913-927.	0.7	5
1341	Cancer Stem Cell as a Potential Therapeutic Target in Hepatocellular Carcinoma. Current Cancer Drug Targets, 2012, 12, 1081-1094.	0.8	34
1342	Inhibition of Corneal Neovascularization in Rats by Systemic Administration of Sorafenib. Cornea, 2012, 31, 907-912.	0.9	20
1343	Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 653-664.	1.0	19
1344	Targeted agents in second-line bladder cancer therapy. Anti-Cancer Drugs, 2012, 23, 1003-1015.	0.7	10
1345	Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. Anti-Cancer Drugs, 2012, 23, 525-533.	0.7	17
1346	Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation. International Journal of Nanomedicine, 2012, 7, 1329.	3.3	47
1347	A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43â€“9006) in Previously Treated Nonâ€“Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501. Journal of Thoracic Oncology, 2012, 7, 1574-1582.	0.5	48
1348	Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. International Journal of Oncology, 2012, 41, 1593-1600.	1.4	36
1349	5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncology Letters, 2012, 3, 1195-1202.	0.8	25
1350	Molecular targeted therapies for cancer: Sorafenib monoÃ¯Â¿Â½therapy and its combination with other therapies (Review). Oncology Reports, 2012, 27, 1303-11.	1.2	77
1351	Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. International Journal of Oncology, 2012, 41, 712-720.	1.4	26

#	Article	IF	Citations
1352	Design, Synthesis and Anticancer Activities of Diaryl Urea Derivatives Bearing <i>N</i>-Acylhydrazone Moiety. Chemical and Pharmaceutical Bulletin, 2012, 60, 1046-1054.	0.6	24
1353	Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 6089-6096.	1.4	28
1354	Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood, 2012, 119, 6089-6098.	0.6	98
1355	Targeting autophagy for the treatment of liver diseases. Pharmacological Research, 2012, 66, 463-474.	3.1	63
1356	Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 259-270.	1.5	24
1357	Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 458-466.	0.6	37
1358	Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2012, 106, 1997-2003.	2.9	96
1359	Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neuroscience Letters, 2012, 527, 62-70.	1.0	53
1360	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Review of Anticancer Therapy, 2012, 12, 1437-1448.	1.1	24
1361	A Phase I Doseâ€“Escalation Study of Regorafenib (BAY 73â€“4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 2658-2667.	3.2	293
1362	Sorafenib in liver cancer. Expert Opinion on Pharmacotherapy, 2012, 13, 1059-1067.	0.9	50
1363	Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo. Digestive Diseases and Sciences, 2013, 58, 257-64.	1.1	50
1364	Saturable absorption of sorafenib in patients with solid tumors: a population model. Investigational New Drugs, 2012, 30, 1991-2000.	1.2	42
1365	Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Investigational New Drugs, 2012, 30, 2001-2007.	1.2	3
1366	Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Investigational New Drugs, 2012, 30, 2377-2383.	1.2	104
1367	Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Investigational New Drugs, 2012, 30, 2384-2390.	1.2	61
1368	Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer. Breast Cancer Research, 2012, 14, R140.	2.2	6
1369	A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of V600EB-RAF inhibitors. Molecular Diversity, 2012, 16, 771-785.	2.1	6

#	Article	IF	Citations
1370	A Phase II Trial of Intrapatient Dose-Escalated Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2012, 10, 153-158.	0.9	36
1371	Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib. Clinical Genitourinary Cancer, 2012, 10, 225-231.	0.9	45
1372	Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertility and Sterility, 2012, 98, 1521-1530.e2.	0.5	67
1373	The effects of sorafenib on liver regeneration in a model of partial hepatectomy. Journal of Surgical Research, 2012, 178, 242-247.	0.8	11
1374	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA Journal, 2012, 3, 1.	3.3	18
1375	Complete clinical response of a patient with lymph node and pulmonary metastatic hepatocellular carcinoma to very low-dose sorafenib (NexavarÂ®) therapy. International Cancer Conference Journal, 2012, 1, 224-229.	0.2	1
1376	Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: A rationale for combination with radiation therapy. Radiotherapy and Oncology, 2012, 105, 64-71.	0.3	17
1377	Current Status of Targeted Therapy in Metastatic Transitional Cell Carcinoma of the Bladder. Seminars in Oncology, 2012, 39, 608-614.	0.8	4
1378	The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III. Neoplasia, 2012, 14, 509-518.	2.3	20
1379	Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. Pancreatology, 2012, 12, 219-226.	0.5	10
1381	Momordica Charantia Lectin, a Type II Ribosome Inactivating Protein, Exhibits Antitumor Activity toward Human Nasopharyngeal Carcinoma Cells In Vitro and In Vivo. Cancer Prevention Research, 2012, 5, 109-121.	0.7	88
1382	Sorafenib for the treatment of renal cancer. Expert Opinion on Pharmacotherapy, 2012, 13, 407-419.	0.9	25
1384	Sorafenib in melanoma. Expert Opinion on Investigational Drugs, 2012, 21, 557-568.	1.9	48
1385	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clinical and Experimental Metastasis, 2012, 29, 841-846.	1.7	14
1386	A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity. Annals of Surgical Oncology, 2012, 19, 3896-3905.	0.7	22
1387	Sorafenib-Induced Mitochondrial Complex I Inactivation and Cell Death in Human Neuroblastoma Cells. Journal of Proteome Research, 2012, 11, 1609-1620.	1.8	29
1388	Impact of restricting access to high-cost medications for hepatocellular carcinoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 465-473.	0.7	6
1389	Sorafenib in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1417-1426.	1.9	25

#	Article	IF	Citations
1390	Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1484-1491.	0.8	151
1391	Current and emerging medical treatments for nonâ€“small cell lung cancer: A primer for pulmonologists. Respiratory Medicine, 2012, 106, 473-492.	1.3	8
1392	Biologically Targeted Therapeutics in Pediatric Brain Tumors. Pediatric Neurology, 2012, 46, 203-211.	1.0	20
1393	Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. Hpb, 2012, 14, 500-505.	0.1	74
1394	Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in <scp>NMRI</scp>â€<scp>Foxn1^{nu}</scp> mice. Liver International, 2012, 32, 574-581.	1.9	13
1395	Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice. Clinical Cancer Research, 2012, 18, 3924-3933.	3.2	36
1396	Sorafenib Inhibits Hypoxia-Inducible Factor-1Î± Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma. Clinical Cancer Research, 2012, 18, 5662-5671.	3.2	104
1397	Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 595-601.	1.8	50
1398	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology, 2012, 56, 1080-1088.	1.8	109
1399	Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 1336-1342.	1.8	148
1400	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology, 2012, 57, 821-829.	1.8	736
1401	Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. Journal of Hepatology, 2012, 57, 1037-1043.	1.8	54
1402	Multiple Kinase Pathways Involved in the Different De Novo Sensitivity ofÂPancreatic Cancer Cell Lines to 17-AAG. Journal of Surgical Research, 2012, 176, 147-153.	0.8	2
1403	Targeting the RAS pathway in melanoma. Trends in Molecular Medicine, 2012, 18, 27-35.	3.5	70
1404	Revealing multi-binding sites for taspine to VEGFR-2 by cell membrane chromatography zonal elution. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 887-888, 67-72.	1.2	18
1405	The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts. Biochemical and Biophysical Research Communications, 2012, 417, 857-863.	1.0	9
1406	Combined anti-tumor effects of IFN-Î± and sorafenib on hepatocellular carcinoma in vitro and in vivo. Biochemical and Biophysical Research Communications, 2012, 422, 687-692.	1.0	25
1407	In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. International Journal of Biochemistry and Cell Biology, 2012, 44, 1351-1360.	1.2	28

#	Article	IF	Citations
1408	Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-Î¹B expression in vitro and in vivo. Biomedicine and Pharmacotherapy, 2012, 66, 12-20.	2.5	48
1409	Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 3746-3755.	1.4	22
1410	Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorganic and Medicinal Chemistry, 2012, 20, 4217-4225.	1.4	9
1411	Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Letters, 2012, 319, 98-108.	3.2	30
1412	Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Letters, 2012, 321, 101-109.	3.2	8
1413	Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152. Cancer Letters, 2012, 320, 215-224.	3.2	17
1414	Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. Cancer Letters, 2012, 322, 213-222.	3.2	15
1415	The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Letters, 2012, 324, 66-74.	3.2	92
1416	Design, synthesis and antiproliferative activities of diaryl urea derivatives bearing N-acylhydrazone moiety. Chinese Chemical Letters, 2012, 23, 915-918.	4.8	14
1417	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asiaâ€“Pacific trial. European Journal of Cancer, 2012, 48, 1452-1465.	1.3	240
1418	Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study. European Journal of Cancer, 2012, 48, 527-537.	1.3	70
1419	Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. European Journal of Cancer, 2012, 48, 465-474.	1.3	23
1420	Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3084-3092.	0.8	237
1421	Targeting oncogenic Ras signaling in hematologic malignancies. Blood, 2012, 120, 3397-3406.	0.6	171
1422	Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology, 2012, 56, 2363-2374.	3.6	56
1423	Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer, 2012, 12, 231.	1.1	44
1424	Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. World Journal of Surgical Oncology, 2012, 10, 60.	0.8	18
1425	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	1.8	563

#	Article	IF	Citations
1426	Simple Drugs Do Not Cure Complex Diseases: The Need for Multi-Targeted Drugs. RSC Drug Discovery Series, 2012, , 1-13.	0.2	5
1427	Discovery of Novel Vascular Endothelial Growth Factor Receptor 2 Inhibitors: A Virtual Screening Approach. Chemical Biology and Drug Design, 2012, 80, 893-901.	1.5	6
1428	The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats. European Journal of Clinical Investigation, 2012, 42, 1309-1316.	1.7	12
1429	Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology, 2012, 263, 590-599.	3.6	177
1430	Frontotemporal Lobar Degeneration. CNS Drugs, 2012, 26, 841-870.	2.7	108
1431	<scp>AL</scp>3810, a multiâ€tyrosine kinase inhibitor, exhibits potent antiâ€angiogenic and antiâ€tumour activity via targeting <scp>VEGFR</scp>,<scp> FGFR</scp> and <scp>PDGFR</scp>. Journal of Cellular and Molecular Medicine, 2012, 16, 2321-2330.	1.6	29
1432	Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Bioscience Reports, 2012, 32, 25-33.	1.1	17
1433	Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opinion on Investigational Drugs, 2012, 21, 451-472.	1.9	36
1434	Tivozanib: current status and future directions in the treatment of solid tumors. Expert Opinion on Investigational Drugs, 2012, 21, 1851-1859.	1.9	12
1435	Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives. Seminars in Oncology, 2012, 39, 493-502.	0.8	74
1436	MEK and RAF inhibitors for BRAF-mutated cancers. Expert Reviews in Molecular Medicine, 2012, 14, e17.	1.6	26
1437	Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase. Bioorganic and Medicinal Chemistry, 2012, 20, 6048-6058.	1.4	21
1438	Medullary thyroid cancer: advances in treatment and management of common adverse events associated with therapy. Community Oncology, 2012, 9, 188-197.	0.2	2
1439	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Critical Reviews in Oncology/Hematology, 2012, 83, 216-224.	2.0	42
1440	Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions. Critical Reviews in Oncology/Hematology, 2012, 84, 47-58.	2.0	37
1441	Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Critical Reviews in Oncology/Hematology, 2012, 84, 224-242.	2.0	8
1442	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Digestive and Liver Disease, 2012, 44, 432-437.	0.4	54
1443	Regorafenib for cancer. Expert Opinion on Investigational Drugs, 2012, 21, 879-889.	1.9	124

#	Article	IF	Citations
1444	Treatment selection in metastatic renal cell carcinoma: expert consensus. Nature Reviews Clinical Oncology, 2012, 9, 327-337.	12.5	121
1446	Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Medical Oncology, 2012, 29, 1896-1907.	1.2	23
1447	Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status. Medical Oncology, 2012, 29, 2276-2283.	1.2	1
1448	Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?. Medical Oncology, 2012, 29, 1908-1913.	1.2	15
1449	Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases. Clinical Journal of Gastroenterology, 2012, 5, 407-412.	0.4	16
1452	Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naÃ¯ve patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 293-303.	1.1	8
1453	Liver Cancer. , 2012, , 95-119.		0
1454	Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2012, 18, 2290-2300.	3.2	503
1455	From genes to drugs: targeted strategies for melanoma. Nature Reviews Cancer, 2012, 12, 349-361.	12.8	323
1457	Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews Drug Discovery, 2012, 11, 873-886.	21.5	667
1458	Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy. Liver Cancer, 2012, 1, 62-70.	4.2	103
1459	Clinical Trials of Small Molecule Inhibitors in High-Grade Glioma. Neurosurgery Clinics of North America, 2012, 23, 407-416.	0.8	11
1460	Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia, 2012, 26, 2176-2185.	3.3	118
1461	Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2012, 6, 391.	2.0	102
1462	Activation of PI3K/AKT and MAPK Pathway through a PDGFRÎ²-Dependent Feedback Loop Is Involved in Rapamycin Resistance in Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e33379.	1.1	47
1463	Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512. PLoS ONE, 2012, 7, e48787.	1.1	77
1464	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	0.8	279
1465	An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncology Reviews, 2012, 6, 8.	0.8	178

#	Article	IF	Citations
1466	Tumor Lymphangiogenesis as a Potential Therapeutic Target. Journal of Oncology, 2012, 2012, 1-23.	0.6	74
1467	Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatology Research and Practice, 2012, 2012, 1-9.	0.3	12
1468	The Role of Angiogenesis Inhibitors in the Management of Melanoma. Current Topics in Medicinal Chemistry, 2012, 12, 32-49.	1.0	19
1469	Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. International Journal of Nanomedicine, 2012, 7, 2901.	3.3	46
1470	Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1). Molecular Medicine, 2012, 18, 19-28.	1.9	40
1471	Safety and Efficacy of Sorafenib in Renal Cell Carcinoma. Cancer Growth and Metastasis, 2012, 5, CGM.S7526.	3.5	1
1472	Aberrant B-Raf Signaling in Human Cancer â˜’ 10 Years from Bench to Bedside. Critical Reviews in Oncogenesis, 2012, 17, 97-121.	0.2	56
1473	Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines. Canadian Urological Association Journal, 2012, 1, S34-40.	0.3	1
1474	Systemic Management of Advanced Hepatocellular Carcinoma Patients: The Role of Multi-Targeted Anti-Angiogenic Inhibitors. , 2012, , .		0
1475	Molecular Targeted Therapy for Growth Factors in Hepatocellular Carcinoma. , 2012, , .		0
1476	Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report. Journal of Cancer, 2012, 3, 158-165.	1.2	22
1477	Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study. Oncology Letters, 2012, 3, 935-939.	0.8	22
1478	Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomarkers, 2012, 10, 287-298.	0.8	10
1479	Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Experimental and Therapeutic Medicine, 2012, 4, 188-196.	0.8	6
1480	Targeted agents for the treatment of metastatic melanoma. OncoTargets and Therapy, 2012, 5, 31.	1.0	13
1481	Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Management and Research, 2012, 4, 243.	0.9	50
1482	Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Management and Research, 2012, 4, 423.	0.9	7
1483	The cell cycle and cancer. Journal of Pathology, 2012, 226, 352-364.	2.1	533

#	Article	IF	Citations
1484	Preclincial testing of Sorafenib and RAD001 in the Nf^{flox/flox};DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatric Blood and Cancer, 2012, 58, 173-180.	0.8	60
1485	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Annals of Oncology, 2012, 23, 508-516.	0.6	296
1486	Targeting the MAPKâ€“RASâ€“RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 103-119.	1.5	740
1487	Antiangiogenic agents in the management of non-small cell lung cancer. Cancer Biology and Therapy, 2012, 13, 247-263.	1.5	63
1488	Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biology and Therapy, 2012, 13, 349-357.	1.5	28
1489	Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatric Blood and Cancer, 2012, 58, 539-544.	0.8	71
1490	Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP. Pediatric Blood and Cancer, 2012, 59, 939-940.	0.8	20
1491	Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology, 2012, 56, 176-185.	3.6	130
1492	EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. International Journal of Cancer, 2012, 131, 2961-2969.	2.3	137
1493	Melanoma: from mutations to medicine. Genes and Development, 2012, 26, 1131-1155.	2.7	415
1494	Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature, 2012, 486, 80-84.	13.7	312
1495	Conformation-Specific Effects of Raf Kinase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7332-7341.	2.9	46
1496	Design and Synthesis of 2â€Iminothiazolidinâ€4â€one Moietyâ€Containing Compounds as Potent Antiproliferative Agents. Archiv Der Pharmazie, 2012, 345, 360-367.	2.1	14
1497	Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics, 2012, 11, 1770-1780.	1.9	67
1498	Management of Hepatocellular Carcinoma: Beyond Sorafenib. Current Oncology Reports, 2012, 14, 257-266.	1.8	27
1499	Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds. Journal of Medicinal Chemistry, 2012, 55, 3452-3478.	2.9	58
1500	The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance. Journal of Biological Chemistry, 2012, 287, 21796-21805.	1.6	72
1501	Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opinion on Therapeutic Targets, 2012, 16, 689-705.	1.5	34

#	Article	IF	Citations
1502	Small intestinal perforation caused by metastatic tumor necrosis after sorafenib (NexavarÂ®) therapy for advanced hepatocellular carcinoma. International Cancer Conference Journal, 2012, 1, 155-158.	0.2	2
1503	Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review. Digestive Diseases and Sciences, 2012, 57, 1122-1129.	1.1	106
1504	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Investigational New Drugs, 2012, 30, 1150-1157.	1.2	10
1505	Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model. Investigational New Drugs, 2012, 30, 936-949.	1.2	16
1506	Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Investigational New Drugs, 2012, 30, 1261-1269.	1.2	21
1507	The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investigational New Drugs, 2012, 30, 1773-1781.	1.2	50
1508	A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investigational New Drugs, 2012, 30, 1175-1183.	1.2	38
1509	Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Investigational New Drugs, 2012, 30, 1791-1801.	1.2	27
1510	Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 1540-1547.	1.2	14
1511	Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 1768-1772.	1.2	7
1512	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Investigational New Drugs, 2012, 30, 1646-1651.	1.2	135
1513	Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC). Investigational New Drugs, 2012, 30, 1802-1811.	1.2	12
1514	Sorafenib and Radiation Therapy for the Treatment of Advanced Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2012, 43, 344-348.	0.6	20
1515	Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics. Archives of Pharmacal Research, 2012, 35, 605-615.	2.7	30
1516	Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbeck's Archives of Surgery, 2012, 397, 569-578.	0.8	5
1517	Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. Journal of Cancer Research and Clinical Oncology, 2012, 138, 907-916.	1.2	10
1518	RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 377-387.	2.2	51
1519	Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with antiâ€angiogenic treatment. BJU International, 2012, 109, 200-206.	1.3	29

#	Article	IF	Citations
1520	Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transplant International, 2012, 25, 192-200.	0.8	11
1521	Multiple melanoma susceptibility factors function in an ultraviolet radiation response pathway in skin. British Journal of Dermatology, 2012, 166, 362-371.	1.4	10
1522	The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma â€“ a pilot study. Alimentary Pharmacology and Therapeutics, 2012, 35, 83-91.	1.9	83
1523	The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells. Cellular Signalling, 2012, 24, 1713-1721.	1.7	32
1524	Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer. Clinical Genitourinary Cancer, 2012, 10, 26-31.	0.9	19
1525	Safety Profile and Tolerability of Antiangiogenic Agents in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 96-106.	1.1	16
1526	Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Critical Reviews in Oncology/Hematology, 2012, 81, 136-150.	2.0	14
1527	Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2012, 82, 200-212.	2.0	12
1528	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review. Critical Reviews in Oncology/Hematology, 2012, 82, 323-337.	2.0	31
1529	Raf Inhibitors Target Ras Spatiotemporal Dynamics. Current Biology, 2012, 22, 945-955.	1.8	65
1530	Progress of molecular targeted therapies for prostate cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 140-152.	3.3	29
1531	Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochemical Pharmacology, 2012, 83, 1251-1260.	2.0	60
1532	In vitro inhibition of translation initiation by N,Nâ€²-diarylureasâ€”potential anti-cancer agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 402-409.	1.0	46
1533	Small molecule inhibitors of BRAF in clinical trials. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 789-792.	1.0	58
1534	Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 110-114.	1.0	21
1535	Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1678-1681.	1.0	17
1536	The Current State of Targeted Therapy in Melanoma: This Time It's Personal. Seminars in Oncology, 2012, 39, 204-214.	0.8	27
1537	Current advances and perspectives in the treatment of advanced melanoma. JDDG - Journal of the German Society of Dermatology, 2012, 10, 319-325.	0.4	15

#	Article	IF	Citations
1538	Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms. JDDG - Journal of the German Society of Dermatology, 2012, 10, 319-325.	0.4	13
1539	The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 164-171.	0.7	35
1540	Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatology Research, 2012, 42, 879-886.	1.8	86
1541	Xenograft models for preclinical drug testing: Implications for adrenocortical cancer. Molecular and Cellular Endocrinology, 2012, 351, 71-77.	1.6	20
1542	Phase <scp>II</scp> study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2012, 158, 108-119.	1.2	36
1543	Use of <scp>S</scp>orafenib as an effective treatment in an <scp>AML</scp> patient carrying a new point mutation affecting the <scp>J</scp>uxtamembrane domain of <scp>FLT</scp>3. British Journal of Haematology, 2012, 158, 555-558.	1.2	5
1544	Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 2012, 10, 23.	2.3	179
1545	Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus mâ€TOR inhibitors monotherapy?. Journal of Surgical Oncology, 2012, 105, 111-112.	0.8	9
1546	Aberrant signaling pathways in pancreatic cancer: A two compartment view. Molecular Carcinogenesis, 2012, 51, 25-39.	1.3	52
1547	Sorafenib, a multikinase inhibitor, is effective in vitro against nonâ€hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. American Journal of Hematology, 2012, 87, 277-283.	2.0	26
1548	A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer Chemotherapy and Pharmacology, 2012, 69, 137-144.	1.1	10
1549	Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 333-339.	1.1	10
1550	Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2012, 69, 773-780.	1.1	61
1551	Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Investigational New Drugs, 2012, 30, 376-381.	1.2	19
1552	Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 2012, 30, 382-386.	1.2	91
1553	Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Investigational New Drugs, 2012, 30, 144-156.	1.2	10
1554	A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. Investigational New Drugs, 2012, 30, 490-507.	1.2	11
1555	The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Investigational New Drugs, 2012, 30, 524-528.	1.2	20

#	Article	IF	Citations
1556	CLT1 targets angiogenic endothelium through CLIC1 and fibronectin. Angiogenesis, 2012, 15, 115-129.	3.7	20
1557	Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epsteinâ€“Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Head and Neck, 2013, 35, 579-591.	0.9	11
1558	Nutlinâ€3 enhances sorafenib efficacy in renal cell carcinoma. Molecular Carcinogenesis, 2013, 52, 39-48.	1.3	26
1559	Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 11-18.	1.3	78
1560	A phase II study of sorafenib (BAY 43â€“9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). Journal of Hematology and Oncology, 2013, 6, 46.	6.9	10
1561	Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Journal of Experimental and Clinical Cancer Research, 2013, 32, 12.	3.5	27
1562	Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?. Cellular and Molecular Life Sciences, 2013, 70, 4131-4140.	2.4	18
1563	Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2013, 69, 151-159.	0.8	30
1564	Expression of angiogenesisâ€related gene profiles and development of resistance to tyrosineâ€kinase inhibitor in advanced renal cell carcinoma: Characterization of sorafenibâ€resistant cells derived from a cutaneous metastasis. International Journal of Urology, 2013, 20, 923-930.	0.5	12
1565	Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2013, , .	0.1	8
1567	Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life, 2013, 65, 748-758.	1.5	53
1568	Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. British Journal of Cancer, 2013, 108, 334-341.	2.9	27
1569	Potential biofluid markers and treatment targets for renal cell carcinoma. Nature Reviews Urology, 2013, 10, 336-344.	1.9	23
1570	Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. International Journal of Nanomedicine, 2013, 8, 1517.	3.3	59
1571	Mechanisms of resistance to anti-angiogenesis therapies. Biochimie, 2013, 95, 1110-1119.	1.3	113
1572	Structureâ€“activity relationship study of intervenolin derivatives: synthesis, antitumor, and anti-Helicobacter pylori activities. Tetrahedron, 2013, 69, 7608-7617.	1.0	13
1573	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	0.8	1
1574	Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. Hematology/Oncology Clinics of North America, 2013, 27, 173-206.	0.9	86

#	Article	IF	Citations
1575	Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science. Journal of Vascular and Interventional Radiology, 2013, 24, 1123-1134.	0.2	33
1576	Sustained Complete Remission of Metastatic Hepatocellular Carcinoma with Single Agent Sorafenib. Journal of Gastrointestinal Cancer, 2013, 44, 98-101.	0.6	6
1577	Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. Clinical and Translational Oncology, 2013, 15, 425-433.	1.2	11
1578	Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asiaâ€“Pacific region. Journal of Gastroenterology, 2013, 48, 681-688.	2.3	47
1579	A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2013, 6, 255-257.	0.4	7
1580	Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. World Journal of Surgical Oncology, 2013, 11, 171.	0.8	32
1581	The Noncytotoxic Dose of Sorafenib Sensitizes Bel-7402/5-FU Cells to 5-FU by Down-Regulating 5-FU-Induced Nrf2 Expression. Digestive Diseases and Sciences, 2013, 58, 1615-1626.	1.1	17
1582	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1271-1277.	1.8	66
1583	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemotherapy and Pharmacology, 2013, 72, 1-12.	1.1	17
1584	Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemotherapy and Pharmacology, 2013, 71, 1231-1240.	1.1	29
1585	Design and synthesis of hydrazine and oxadiazole-containing derivatives of Sorafenib as antitumor agents. Chemical Research in Chinese Universities, 2013, 29, 454-459.	1.3	4
1586	Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer. Journal of Surgical Research, 2013, 185, 676-683.	0.8	11
1587	Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma. Neoplasia, 2013, 15, 1161-IN24.	2.3	57
1588	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (<scp>EPOIHCC</scp>). Liver International, 2013, 33, 327-337.	1.9	70
1589	Sorafenib Hepatobiliary Disposition: Mechanisms of Hepatic Uptake and Disposition of Generated Metabolites. Drug Metabolism and Disposition, 2013, 41, 1179-1186.	1.7	51
1590	Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Critical Reviews in Oncology/Hematology, 2013, 86, 161-175.	2.0	38
1591	A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. British Journal of Cancer, 2013, 109, 915-919.	2.9	102
1592	Individualising treatment choices in a crowded treatment algorithm. European Journal of Cancer, Supplement, 2013, 11, 160-168.	2.2	2

#	Article	IF	Citations
1593	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound. Journal of Hepatology, 2013, 59, 1014-1021.	1.8	75
1594	Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. Cancer Letters, 2013, 341, 111-126.	3.2	101
1595	New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: Synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies. European Journal of Medicinal Chemistry, 2013, 70, 10-21.	2.6	26
1596	Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood, 2013, 122, 1621-1633.	0.6	57
1597	Management of Hepatocellular Carcinoma. Surgical Clinics of North America, 2013, 93, 1423-1450.	0.5	34
1598	The VEGF pathway in lung cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 1169-1181.	1.1	85
1599	Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 731-747.	0.9	74
1600	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. Clinical Cancer Research, 2013, 19, 2117-2131.	3.2	96
1601	Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPKâ€“mTORC1 signaling. Breast Cancer Research and Treatment, 2013, 141, 67-78.	1.1	65
1602	Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. Journal of Translational Medicine, 2013, 11, 192.	1.8	28
1603	Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. International Journal of Clinical Oncology, 2013, 18, 743-749.	1.0	21
1604	Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. BMC Cancer, 2013, 13, 363.	1.1	19
1605	A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 140, 331-339.	1.1	22
1606	Tackling hepatitis B virus-associated hepatocellular carcinomaâ€”the future is now. Cancer and Metastasis Reviews, 2013, 32, 229-268.	2.7	19
1607	Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1. Investigational New Drugs, 2013, 31, 780-786.	1.2	2
1608	Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial. Journal of Clinical Oncology, 2013, 31, 3219-3225.	0.8	454
1609	Targeting MAPK pathway in melanoma therapy. Cancer and Metastasis Reviews, 2013, 32, 567-584.	2.7	72
1611	The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?. Lancet Oncology, The, 2013, 14, e283-e288.	5.1	40

#	Article	IF	Citations
1612	Design, synthesis, biological evaluation, and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors. Organic and Biomolecular Chemistry, 2013, 11, 7676.	1.5	25
1613	Regionale Therapie maligner Tumoren. , 2013, , .		1
1614	Synthesis and in vitro antitumor activity of novel diaryl urea derivatives. Chinese Chemical Letters, 2013, 24, 386-388.	4.8	9
1615	Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. Expert Opinion on Investigational Drugs, 2013, 22, 1-7.	1.9	13
1616	Evaluation of MAGEâ€Ð4 expression in hepatocellular carcinoma in Japanese patients. Journal of Surgical Oncology, 2013, 108, 557-562.	0.8	22
1617	Current and future systemic treatments for renal cell carcinoma. Seminars in Cancer Biology, 2013, 23, 38-45.	4.3	100
1618	Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. Gynecological Endocrinology, 2013, 29, 811-816.	0.7	10
1619	<scp>YL529</scp>, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models. British Journal of Pharmacology, 2013, 169, 1766-1780.	2.7	15
1620	Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 682-686.	1.0	19
1621	Investigational agents in development for the treatment of ovarian cancer. Investigational New Drugs, 2013, 31, 213-229.	1.2	25
1622	Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion. Advances in Experimental Medicine and Biology, 2013, 986, 143-170.	0.8	46
1623	Use of Acid Sphingomyelinase for Cancer Therapy. Advances in Cancer Research, 2013, 117, 91-115.	1.9	23
1624	BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications. Critical Reviews in Oncology/Hematology, 2013, 87, 55-68.	2.0	56
1625	Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Archives of Toxicology, 2013, 87, 227-247.	1.9	195
1626	Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 279-284.	1.0	16
1627	Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. Molecular and Cellular Biochemistry, 2013, 372, 65-74.	1.4	16
1628	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
1629	Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance. Clinical Cancer Research, 2013, 19, 2301-2309.	3.2	77

#	Article	IF	Citations
1630	Fluoroâ€Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery. Journal of Cellular Physiology, 2013, 228, 292-297.	2.0	66
1631	Targeting <scp>FLIP</scp> and Mclâ€1 using a combination of aspirin andÂsorafenib sensitizes colon cancer cells to <scp>TRAIL</scp>. Journal of Pathology, 2013, 229, 410-421.	2.1	28
1632	Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems. Neoplasia, 2013, 15, 939-IN27.	2.3	31
1633	Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma. Translational Oncology, 2013, 6, 511-519.	1.7	42
1634	Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Letters, 2013, 331, 250-261.	3.2	29
1635	Targeted Therapy for Cancer. Surgical Oncology Clinics of North America, 2013, 22, 805-821.	0.6	12
1636	Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiotherapy and Oncology, 2013, 109, 286-292.	0.3	37
1637	Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Letters, 2013, 329, 109-117.	3.2	63
1638	Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: Results of a pilot study. Digestive and Liver Disease, 2013, 45, 776-781.	0.4	30
1639	Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation. Experimental Cell Research, 2013, 319, 2166-2178.	1.2	20
1640	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics, 2013, 14, 1765-1777.	0.6	38
1641	The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 31-42.	1.8	80
1642	Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib. European Journal of Surgical Oncology, 2013, 39, 974-980.	0.5	31
1643	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Digestive and Liver Disease, 2013, 45, 408-413.	0.4	31
1644	Targeting tumor neovasculature in non-small-cell lung cancer. Critical Reviews in Oncology/Hematology, 2013, 86, 130-142.	2.0	31
1645	Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Letters, 2013, 329, 74-83.	3.2	154
1646	Sorafenib induces autophagy and suppresses activation of human macrophage. International Immunopharmacology, 2013, 15, 333-339.	1.7	39
1647	Targeted therapy in melanoma. Clinics in Dermatology, 2013, 31, 200-208.	0.8	23

#	Article	IF	Citations
1648	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecologic Oncology, 2013, 130, 25-30.	0.6	79
1649	The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin. Cardiovascular Toxicology, 2013, 13, 33-47.	1.1	21
1650	Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Medical Oncology, 2013, 30, 446.	1.2	30
1651	Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clinical and Translational Oncology, 2013, 15, 146-153.	1.2	14
1652	A New Target for an Old Drug: Identifying Mitoxantrone as a Nanomolar Inhibitor of PIM1 Kinase via Kinome-Wide Selectivity Modeling. Journal of Medicinal Chemistry, 2013, 56, 2619-2629.	2.9	53
1653	Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1989-1992.	1.0	34
1654	Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell and Melanoma Research, 2013, 26, 39-57.	1.5	94
1655	Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Molecular BioSystems, 2013, 9, 1127-1138.	2.9	29
1656	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2013, 39, 252-260.	3.4	68
1657	Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Recent Progression and Perspective. Oncology, 2013, 84, 28-33.	0.9	12
1658	An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clinical and Translational Oncology, 2013, 15, 343-357.	1.2	33
1659	Transarterial Sorafenib Chemoembolization: Preliminary Study of Technical Feasibility in a Rabbit Model. Journal of Vascular and Interventional Radiology, 2013, 24, 744-750.	0.2	14
1661	Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951). Future Oncology, 2013, 9, 13-20.	1.1	13
1662	Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators. Journal of Medicinal Chemistry, 2013, 56, 5219-5230.	2.9	104
1663	Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. AAPS Journal, 2013, 15, 78-84.	2.2	15
1664	Design, synthesis and antiproliferative activity studies of novel 1,2,3-triazoleâ€“dithiocarbamateâ€“urea hybrids. European Journal of Medicinal Chemistry, 2013, 64, 99-110.	2.6	96
1665	Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. International Journal of Oncology, 2013, 42, 101-108.	1.4	14
1666	Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle, 2013, 12, 491-500.	1.3	64

#	Article	IF	Citations
1667	Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 926, 83-91.	1.2	98
1668	Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). European Journal of Medicinal Chemistry, 2013, 63, 765-781.	2.6	46
1669	Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Investigational Drugs, 2013, 22, 765-773.	1.9	10
1670	Novel Antineoplastics Targeting Genetic Changes in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2013, 779, 1-34.	0.8	7
1671	Complete response to low-dose sorafenib in a patient with metastatic renal cell carcinoma: A case report. Canadian Urological Association Journal, 2013, 7, 351.	0.3	0
1672	Kinase Inhibitors of Marine Origin. Chemical Reviews, 2013, 113, 6761-6815.	23.0	112
1673	Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR. MedChemComm, 2013, 4, 979.	3.5	24
1674	Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2962-2967.	1.0	50
1675	Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma. Expert Opinion on Investigational Drugs, 2013, 22, 1023-1040.	1.9	32
1676	Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review. Critical Reviews in Oncology/Hematology, 2013, 88, 293-308.	2.0	35
1677	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology, 2013, 57, 1407-1415.	3.6	133
1679	Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. Drug Discovery Today, 2013, 18, 11-24.	3.2	10
1680	Current and Future Trials of Targeted Therapies in Cutaneous Melanoma. Advances in Experimental Medicine and Biology, 2013, 779, 223-255.	0.8	27
1681	Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. Organic and Biomolecular Chemistry, 2013, 11, 3706.	1.5	29
1682	Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. Journal of Human Hypertension, 2013, 27, 601-611.	1.0	50
1683	Monitoring Anti-Angiogenic Therapy in Colorectal Cancer Murine Model using Dynamic Contrast-Enhanced MRI â€" Comparing Pixel-by-Pixel with Region of Interest Analysis. Technology in Cancer Research and Treatment, 2013, 12, 71-78.	0.8	9
1684	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. Journal of Clinical Oncology, 2013, 31, 3791-3799.	0.8	388
1685	High-risk features in radiation-associated breast angiosarcomas. British Journal of Cancer, 2013, 109, 2340-2346.	2.9	60

#	Article	IF	Citations
1686	Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Investigational New Drugs, 2013, 31, 345-354.	1.2	17
1687	Crystal Structure of a Promoter Sequence in the B-raf Gene Reveals an Intertwined Dimer Quadruplex. Journal of the American Chemical Society, 2013, 135, 19319-19329.	6.6	45
1688	Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump. Molecular Cancer Therapeutics, 2013, 12, 2121-2134.	1.9	48
1689	Systemic therapies in hepatocellular carcinoma: present and future. Future Oncology, 2013, 9, 1533-1548.	1.1	42
1690	Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma. Current Oncology Reports, 2013, 15, 492-499.	1.8	5
1691	MEK Inhibition in the Treatment of Advanced Melanoma. Current Oncology Reports, 2013, 15, 473-482.	1.8	21
1692	Emerging BRAF inhibitors for melanoma. Expert Opinion on Emerging Drugs, 2013, 18, 431-443.	1.0	5
1693	Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 869-877.	1.1	14
1694	SCâ€1, a sorafenib derivative, shows antiâ€tumor effects in osteogenic sarcoma cells. Journal of Orthopaedic Research, 2013, 31, 335-342.	1.2	9
1695	RAFâ€targeted therapy for hepatocellular carcinoma in the regenerating liver. Journal of Surgical Oncology, 2013, 107, 393-401.	0.8	14
1696	A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1291-1293.	3.6	1
1697	Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines. Molecular and Clinical Oncology, 2013, 1, 29-34.	0.4	4
1698	Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Molecular and Clinical Oncology, 2013, 1, 241-248.	0.4	15
1699	Tivozanib for the treatment of metastatic renal cancer. Expert Review of Anticancer Therapy, 2013, 13, 649-660.	1.1	6
1700	MRI Assessment of Early Tumor Response in Metastatic Renal Cell Carcinoma Patients Treated With Sorafenib. American Journal of Roentgenology, 2013, 200, 120-126.	1.0	18
1701	Early Prediction of Treatment Response to Sorafenib with Elastosonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. Ultraschall in Der Medizin, 2013, 34, 541-549.	0.8	8
1702	Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. Current Pharmaceutical Design, 2013, 19, 927-939.	0.9	30
1703	A Two-Hybrid Approach to Identify Inhibitors of the RASâ€"RAF Interaction. The Enzymes, 2013, 33 Pt A, 213-248.	0.7	7

#	Article	IF	Citations
1704	Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. Clinical Science, 2013, 124, 457-466.	1.8	47
1705	Role of the Plasma Membrane Transporter of Organic Cations OCT1 and Its Genetic Variants in Modern Liver Pharmacology. BioMed Research International, 2013, 2013, 1-13.	0.9	46
1706	Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth. Molecular Cancer Therapeutics, 2013, 12, 598-609.	1.9	36
1707	Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncology, 2013, 9, 403-410.	1.1	22
1708	Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. Pharmaceuticals, 2013, 6, 988-1038.	1.7	16
1709	Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy. Endoscopy, 2013, 45, E179-E180.	1.0	4
1710	Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment. BioMed Research International, 2013, 2013, 1-9.	0.9	50
1711	Inhibition of Metastatic Potential in Breast CarcinomaIn VivoandIn Vitrothrough Targeting VEGFRs and FGFRs. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-13.	0.5	9
1712	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Therapeutic Drug Monitoring, 2013, 35, 562-587.	1.0	77
1713	A Systematic Review of Sorafenib in Child-Pugh A Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2013, 47, 871-880.	1.1	21
1714	Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient. Anti-Cancer Drugs, 2013, 24, 648-652.	0.7	2
1715	First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies. Clinical Cancer Research, 2013, 19, 909-919.	3.2	26
1716	Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Therapeutic Advances in Medical Oncology, 2013, 5, 324-333.	1.4	9
1717	An Update on Clinical Trials in the Treatment of Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2013, 47, S16-S19.	1.1	10
1718	HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas. Gut, 2013, 62, 440-451.	6.1	33
1719	Recent developments in the treatment of renal cell carcinoma. Therapeutic Advances in Urology, 2013, 5, 338-353.	0.9	64
1720	Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. Cancer Research, 2013, 73, 7043-7055.	0.4	102
1721	Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma. Molecular Cancer Therapeutics, 2013, 12, 1701-1714.	1.9	24

#	Article	IF	Citations
1722	Systemic Therapy and Synergies by Combination. Digestive Diseases, 2013, 31, 104-111.	0.8	11
1723	New treatment approaches in melanoma: current research and clinical prospects. Therapeutic Advances in Medical Oncology, 2013, 5, 73-80.	1.4	19
1724	Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Clinical Cancer Research, 2013, 19, 1557-1566.	3.2	65
1725	Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets. Advances in Experimental Medicine and Biology, 2013, 779, 291-308.	0.8	6
1726	BRAF in Melanoma: Current Strategies and Future Directions. Clinical Cancer Research, 2013, 19, 4326-4334.	3.2	76
1727	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anti-Cancer Drugs, 2013, 24, 431-440.	0.7	13
1728	Sorafenib in Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 319-324.	0.6	94
1729	Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2013, 19, 299-306.	1.0	9
1730	Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatology Research, 2013, 43, 147-154.	1.8	173
1731	Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S7633.	0.6	22
1732	Latest Approved Therapies for Metastatic Melanoma: What Comes Next?. Journal of Skin Cancer, 2013, 2013, 1-10.	0.5	26
1733	Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial. Clinical Cancer Research, 2013, 19, 6967-6975.	3.2	57
1734	New developments in management of gastrointestinal stromal tumors: regorafenib, the new player in the team. Gastrointestinal Cancer: Targets and Therapy, 2013, , 1.	5.5	3
1735	Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocrine-Related Cancer, 2013, 20, R233-R245.	1.6	39
1736	Antiâ€angiogenic and antiâ€tumor effects of <scp>TAK</scp>â€593, a potent and selective inhibitor of vascular endothelial growth factor and plateletâ€derived growth factor receptor tyrosine kinase. Cancer Science, 2013, 104, 486-494.	1.7	17
1737	Sorafenib for ovarian cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1049-1062.	1.9	18
1738	Antiproliferative Diarylpyrazole Derivatives as Dual Inhibitors of the <scp>ERK</scp> Pathway and <scp>COX</scp>â€2. Chemical Biology and Drug Design, 2013, 82, 336-347.	1.5	13
1739	Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. Journal of Cellular Physiology, 2013, 228, 1344-1350.	2.0	51

#	Article	IF	Citations
1740	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research, 2013, 19, 2541-2550.	3.2	72
1741	Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway. International Journal of Radiation Biology, 2013, 89, 724-731.	1.0	22
1742	Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective. Expert Review of Anticancer Therapy, 2013, 13, 1193-1206.	1.1	2
1743	A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leukemia and Lymphoma, 2013, 54, 760-766.	0.6	43
1744	Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. British Journal of Haematology, 2013, 161, 667-676.	1.2	20
1745	Chemotherapy-related cardiotoxicity. Therapeutic Advances in Cardiovascular Disease, 2013, 7, 87-98.	1.0	6
1746	The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. European Journal of Heart Failure, 2013, 15, 482-489.	2.9	61
1747	Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma. Dermatologic Surgery, 2013, 39, 981-987.	0.4	13
1748	Tyrosine Kinase Inhibitorâ€“Induced Thyroid Disorders: A Review and Hypothesis. Thyroid, 2013, 23, 151-159.	2.4	74
1749	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1081-1088.	1.9	28
1750	A Proposal Regarding Reporting of In Vitro Testing Results. Clinical Cancer Research, 2013, 19, 2828-2833.	3.2	59
1751	SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models. Cellular Physiology and Biochemistry, 2013, 32, 138-153.	1.1	6
1752	Regorafenib. Annals of Pharmacotherapy, 2013, 47, 1685-1696.	0.9	45
1753	Angiogenesis Inhibitors in the Treatment of Prostate Cancer. Chemical Immunology and Allergy, 2014, 99, 197-215.	1.7	7
1754	Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelialâ€“mesenchymal transition and fibroblast activation. Cell Death and Disease, 2013, 4, e665-e665.	2.7	81
1755	Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2013, 109, 2072-2078.	2.9	30
1756	Conformation-Specific Inhibitors of Raf Kinases. The Enzymes, 2013, 34 Pt. B, 41-66.	0.7	3
1757	The Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Model. Reproductive Sciences, 2013, 20, 26-32.	1.1	51

#	Article	IF	Citations
1758	Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biology and Therapy, 2013, 14, 703-710.	1.5	30
1759	Novel Quinolinylaminoisoquinoline Bioisosteres of Sorafenib as Selective RAF1 Kinase Inhibitors: Design, Synthesis, and Antiproliferative Activity against Melanoma Cell Line. Chemical and Pharmaceutical Bulletin, 2013, 61, 747-756.	0.6	8
1760	A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma. Internal Medicine, 2013, 52, 1589-1592.	0.3	12
1761	Inhibitory Effects of a New 1H-Pyrrolo[3,2-c]pyridine Derivative, KIST101029, on Activator Protein-1 Activity and Neoplastic Cell Transformation Induced by Insulin-Like Growth Factor-1. Biological and Pharmaceutical Bulletin, 2013, 36, 1466-1473.	0.6	2
1762	New Targeted Therapies in Melanoma. Cancer Control, 2013, 20, 282-288.	0.7	11
1763	Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC. Journal of Thoracic Oncology, 2013, 8, 301-308.	0.5	21
1764	Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model. Oncology Letters, 2013, 6, 667-672.	0.8	10
1765	Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S10594.	0.6	75
1766	Regorafenib: carving a niche in the crowded therapeutic landscape. Expert Review of Anticancer Therapy, 2013, 13, 385-393.	1.1	4
1767	Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells. International Journal of Oncology, 2013, 43, 1402-1412.	1.4	30
1768	Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway. Current Pharmaceutical Design, 2013, 19, 883-894.	0.9	47
1769	Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers. Current Pharmaceutical Design, 2013, 19, 864-882.	0.9	5
1770	Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways. Current Pharmaceutical Design, 2013, 19, 841-863.	0.9	12
1771	Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?. Current Cancer Drug Targets, 2013, 13, 30-47.	0.8	10
1772	Treating pediatric osteosarcoma: recent clinical trial evidence. Clinical Investigation, 2013, 3, 967-978.	0.0	1
1773	Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. Oncology Letters, 2013, 5, 68-72.	0.8	5
1774	Targeting angiogenesis in non-small-cell lung cancer: a focus on current approaches and future developments. Clinical Practice (London, England), 2013, 10, 503-517.	0.1	0
1775	Effects of low-frequency ultrasound and microbubbles on angiogenesis-associated proteins in subcutaneous tumors of nude mice. Oncology Reports, 2013, 30, 842-850.	1.2	14

#	Article	IF	Citations
1776	Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. Journal of Thoracic Oncology, 2013, 8, 783-787.	0.5	76
1777	Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. Liver Transplantation, 2013, 19, 507-520.	1.3	21
1778	Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anti-Cancer Drugs, 2013, 24, 212-218.	0.7	32
1779	Early increase in Î±-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2013, 25, 683-689.	0.8	73
1780	Sorafenib Induces Autophagy in Human Myeloid Dendritic Cells and Prolongs Survival of Skin Allografts. Transplantation, 2013, 95, 791-800.	0.5	15
1781	Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells. Oncology Reports, 2013, 29, 1895-1901.	1.2	4
1782	A new model to evaluate Raf signaling in hematopoietic cells. International Journal of Oncology, 2013, 43, 903-910.	1.4	0
1783	Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy. Journal of Nanomedicine & Nanotechnology, 2013, 04, .	1.1	52
1784	RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma. Oncology Letters, 2013, 6, 480-486.	0.8	13
1785	Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. Oncology Letters, 2013, 5, 440-446.	0.8	14
1786	The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1Î± expression. Oncology Reports, 2013, 29, 917-924.	1.2	19
1787	Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1235-1247.	2.3	12
1788	A Case of Nasal/Paranasal Metastatic Renal Cell Carcinoma with VEGF Targeted Therapy. Practica Otologica, Supplement, 2013, 137, 52-53.	0.0	0
1789	Liver Transplantation for Hepatocellular Carcinoma. , 0, , .		0
1790	Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma. Yonsei Medical Journal, 2013, 54, 1178.	0.9	27
1791	Sorafenib Inhibits Epithelial-Mesenchymal Transition through an Epigenetic-Based Mechanism in Human Lung Epithelial Cells. PLoS ONE, 2013, 8, e64954.	1.1	30
1792	Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e65726.	1.1	35
1793	Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis. PLoS ONE, 2013, 8, e75414.	1.1	43

#	Article	IF	Citations
1794	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e77240.	1.1	20
1795	Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis. Gut and Liver, 2013, 7, 696-703.	1.4	68
1796	Genetics of melanoma. Frontiers in Genetics, 2012, 3, 330.	1.1	27
1797	Template-Based de Novo Design for Type II Kinase Inhibitors and Its Extended Application to Acetylcholinesterase Inhibitors. Molecules, 2013, 18, 13487-13509.	1.7	3
1798	Quantification of Plasma Cell-Free DNA¹in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma. Disease Markers, 2013, 34, 105-111.	0.6	36
1799	In a â€˜Real-Worldâ€™, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 393-396.	1.8	21
1800	Advanced medullary thyroid cancer: pathophysiology and management. Cancer Management and Research, 2013, 5, 57.	0.9	15
1801	BRAF mutations in human cancer: biologic and therapeutic implications. , 0, , 272-277.		0
1802	Neoadjuvant Chemotherapy for Hepatocellular Carcinoma. , 2013, , .		3
1803	Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. Oncology Reports, 2014, 31, 1147-1156.	1.2	15
1804	Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE, 2014, 9, e100305.	1.1	91
1805	The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent. PLoS ONE, 2014, 9, e101889.	1.1	10
1806	Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3). PLoS ONE, 2014, 9, e102110.	1.1	29
1807	An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e112530.	1.1	24
1808	NSK-01105, a Novel Sorafenib Derivative, Inhibits Human Prostate Tumor Growth via Suppression of VEGFR2/EGFR-Mediated Angiogenesis. PLoS ONE, 2014, 9, e115041.	1.1	13
1809	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. Journal of Hepatocellular Carcinoma, 2014, 1, 85.	1.8	17
1810	Comparison of effects of anti-angiogenic agents in the zebrafish efficacy–toxicity model for translational anti-angiogenic drug discovery. Drug Design, Development and Therapy, 2014, 8, 1107.	2.0	60
1811	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence. Lung Cancer: Targets and Therapy, 2014, 5, 51.	1.3	2

#	Article	IF	Citations
1812	MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma, 2014, 61, 680-689.	0.7	63
1813	Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World Journal of Gastroenterology, 2014, 20, 4115.	1.4	361
1814	Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evidence, 2014, 9, 81.	4.7	20
1815	Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Design, Development and Therapy, 2014, 8, 255.	2.0	26
1816	Liver Abscess in Advanced Hepatocellular Carcinoma after Sorafenib Treatment. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2014, 63, 47.	0.2	3
1817	Targeted Therapies in the Management of Breast Cancer. Journal of Integrative Oncology, 2014, 04, .	0.3	1
1818	Inhibition of autophagy signiï¬cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World Journal of Gastroenterology, 2014, 20, 4953.	1.4	59
1819	Advances and new perspectives in the treatment of metastatic colon cancer. World Journal of Gastrointestinal Oncology, 2014, 6, 211.	0.8	25
1820	Molecular Pathogenesis and Targeted Therapies in Well-Differentiated Thyroid Carcinoma. Endocrinology and Metabolism, 2014, 29, 211.	1.3	11
1821	DiagnÃ³stico, tratamento e seguimento do carcinoma medular de tireoide: recomendaÃ§Ãµes do Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 667-700.	1.3	27
1822	Regorafenib in gastrointestinal stromal tumors. Future Oncology, 2014, 10, 1581-1587.	1.1	6
1823	Sorafenib and thyroid cancer. Expert Review of Endocrinology and Metabolism, 2014, 9, 561-570.	1.2	29
1824	An Inducible Hepatocellular Carcinoma Model for Preclinical Evaluation of Antiangiogenic Therapy in Adult Mice. Cancer Research, 2014, 74, 4157-4169.	0.4	23
1825	Second-Line Treatment for Advanced Thyroid Cancer: An Indication in Need of Randomized Clinical Trials. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1995-1997.	1.8	3
1826	Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma. Digestive Diseases, 2014, 32, 733-739.	0.8	7
1827	Past, current and future approaches to querying MAPK pathway activation: status and clinical implications. Personalized Medicine, 2014, 11, 745-760.	0.8	0
1828	Chloroquine and hydroxychloroquine for cancer therapy. Molecular and Cellular Oncology, 2014, 1, e29911.	0.3	154
1829	The preclinical development of regorafenib for the treatment of colorectal cancer. Expert Opinion on Drug Discovery, 2014, 9, 1087-1101.	2.5	27

#	Article	IF	Citations
1830	Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. Cancer Biology and Therapy, 2014, 15, 22-25.	1.5	14
1831	Regorafenib in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2014, 14, 255-265.	1.1	20
1832	B-Raf Regulation of Integrin Î±4Î²1-mediated Resistance to Shear Stress through Changes in Cell Spreading and Cytoskeletal Association in T Cells. Journal of Biological Chemistry, 2014, 289, 23141-23153.	1.6	11
1833	Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer, 2014, 14, 756.	1.1	23
1834	FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 675-691.	0.8	6
1835	Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis. Clinical Cancer Research, 2014, 20, 3472-3484.	3.2	93
1836	RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis, 2014, 35, 2807-2814.	1.3	20
1837	Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. British Journal of Cancer, 2014, 111, 640-645.	2.9	99
1838	Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo. Cell Death and Disease, 2014, 5, e1030-e1030.	2.7	56
1839	Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1771-1780.	0.9	0
1840	Novel therapies for thyroid cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 2641-2652.	0.9	9
1841	The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death and Disease, 2014, 5, e1278-e1278.	2.7	211
1842	Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers, 2014, 6, 494-525.	1.7	23
1843	Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 2014, 7, 1420-1426.	0.8	7
1844	Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomedical Reports, 2014, 2, 41-52.	0.9	85
1845	Impact of the Prolymphangiogenic Crosstalk in the Tumor Microenvironment on Lymphatic Cancer Metastasis. BioMed Research International, 2014, 2014, 1-14.	0.9	22
1846	Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. Clinical Science, 2014, 126, 243-252.	1.8	23
1847	Data-Derived Modeling Characterizes Plasticity of MAPK Signaling in Melanoma. PLoS Computational Biology, 2014, 10, e1003795.	1.5	20

#	Article	IF	Citations
1848	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. International Journal of Molecular Sciences, 2014, 15, 10578-10604.	1.8	60
1849	Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science, 2014, 126, 377-400.	1.8	40
1850	Combined therapeutic efficacy of 188Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells. Molecular and Clinical Oncology, 2014, 2, 380-384.	0.4	14
1851	Pathway-Driven Discovery of Rare Mutational Impact on Cancer. BioMed Research International, 2014, 2014, 1-10.	0.9	3
1852	The Oncogenic Potential of Human Cytomegalovirus and Breast Cancer. Frontiers in Oncology, 2014, 4, 230.	1.3	51
1853	Fish Oil Suppresses Cell Growth and Metastatic Potential by Regulating PTEN and NF-ÎºB Signaling in Colorectal Cancer. PLoS ONE, 2014, 9, e84627.	1.1	19
1854	A Case of Retinal Tear Associated with Use of Sorafenib. Frontiers in Oncology, 2014, 4, 196.	1.3	8
1855	Costâ€“effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 131-138.	0.7	15
1856	Sorafenib for the treatment of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 189-204.	4.2	7
1857	Application of Genomic Principles to Pharmacotherapy of Cancer. American Journal of Pharmaceutical Education, 2014, 78, 55.	0.7	10
1858	Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. Future Oncology, 2014, 10, 1571-1579.	1.1	45
1859	Metronomic Chemotherapy. , 2014, , .		3
1860	The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. Cell Cycle, 2014, 13, 884-889.	1.3	19
1861	Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transplantation, 2014, 20, 261-269.	1.3	24
1862	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as firstâ€line therapy: A <scp>K</scp>orean multicenter study. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1463-1469.	1.4	26
1863	Tyrosine kinase inhibitorâ€induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. Histopathology, 2014, 64, 484-493.	1.6	14
1864	Sorafenib: Targeting Multiple Tyrosine Kinases in Cancer. Recent Results in Cancer Research, 2014, 201, 145-164.	1.8	35
1865	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research, 2014, 20, 5641-5651.	3.2	31

#	Article	IF	Citations
1866	Smarter drugs emerging in pancreatic cancer therapy. Annals of Oncology, 2014, 25, 1260-1270.	0.6	72
1867	Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK. Molecular Cancer Therapeutics, 2014, 13, 221-229.	1.9	27
1868	Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma. Clinical Case Reports (discontinued), 2014, 2, 4-6.	0.2	5
1869	Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous Tâ€cell lymphoma. British Journal of Haematology, 2014, 167, 141-144.	1.2	9
1870	Prospective randomized doubleâ€blind multicentre phase <scp>II</scp> study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: <scp>SUSE</scp> (<scp>AUOâ€AB</scp> 31/05). BJU International, 2014, 113, 429-436.	1.3	72
1871	Identification of Zinc Finger, MYMâ€type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 633-639.	1.4	0
1872	Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0â€“B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. American Journal of Gastroenterology, 2014, 109, 1891-1899.	0.2	60
1873	Sorafenib is tolerable and improves clinical outcomes in patients with FLT3â€ITD acute myeloid leukemia prior to stem cell transplant and after relapse postâ€transplant. American Journal of Hematology, 2014, 89, 936-938.	2.0	35
1874	Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF. Oncogene, 2014, 33, 5397-5404.	2.6	27
1875	Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. Biomedicine and Pharmacotherapy, 2014, 68, 1015-1022.	2.5	7
1876	Involvement of Extracellular Vesicle Long Noncoding RNA (linc-VLDLR) in Tumor Cell Responses to Chemotherapy. Molecular Cancer Research, 2014, 12, 1377-1387.	1.5	250
1877	Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib. Clinical and Experimental Dermatology, 2014, 39, 232-233.	0.6	8
1878	Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. British Journal of Cancer, 2014, 110, 1148-1154.	2.9	49
1879	Sorafenib use in the transplant setting. Liver Transplantation, 2014, 20, 1021-1028.	1.3	12
1880	Regorafenib for treatment of advanced gastrointestinal stromal tumors. Expert Opinion on Pharmacotherapy, 2014, 15, 549-558.	0.9	19
1881	Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib. BMC Cancer, 2014, 14, 939.	1.1	26
1882	Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. European Respiratory Review, 2014, 23, 79-91.	3.0	51
1883	Protein kinase inhibitors in renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2014, 15, 337-351.	0.9	8

#	Article	IF	Citations
1884	Systemic treatment of malignant pleural mesothelioma. Current Opinion in Oncology, 2014, 26, 171-181.	1.1	24
1885	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. Anti-Cancer Drugs, 2014, 25, 723-728.	0.7	10
1886	Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma. Japanese Journal of Clinical Oncology, 2014, 44, 570-578.	0.6	27
1887	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. Seminars in Liver Disease, 2014, 34, 444-455.	1.8	112
1889	VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib. Cancer Discovery, 2014, 4, 640-641.	7.7	10
1890	Heterotypic Cellular Interactions in the Ovarian Tumor Microenvironment: Biological Significance and Therapeutic Implications. Frontiers in Oncology, 2014, 4, 18.	1.3	14
1891	Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. BioMed Research International, 2014, 2014, 1-11.	0.9	10
1892	A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma. Future Oncology, 2014, 10, 1941-1951.	1.1	11
1893	Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth. Journal of Biological Chemistry, 2014, 289, 26804-26816.	1.6	9
1894	Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatology Research, 2014, 44, 1268-1276.	1.8	24
1895	KLIFS: A Knowledge-Based Structural Database To Navigate Kinaseâ€“Ligand Interaction Space. Journal of Medicinal Chemistry, 2014, 57, 249-277.	2.9	243
1896	Molecular-targeted Therapy for Renal Cell Carcinoma. , 2014, , 115-127.		3
1897	Management of Common Adverse Events in Patients Treated With Sorafenib: Nurse and Pharmacist Perspective. Seminars in Oncology, 2014, 41, S17-S28.	0.8	32
1898	Phase I/II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 94-100.	1.1	17
1899	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease, 2014, 46, 182-186.	0.4	40
1900	CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelialâ€“mesenchymal transition. Cancer Letters, 2014, 348, 77-87.	3.2	111
1901	The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. European Journal of Pharmaceutical Sciences, 2014, 51, 96-109.	1.9	49
1902	Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. Journal of Gastroenterology, 2014, 49, 517-526.	2.3	15

#	Article	IF	Citations
1903	Quercetin and Sorafenib as a Novel and Effective Couple in Programmed Cell Death Induction in Human Gliomas. Neurotoxicity Research, 2014, 26, 64-77.	1.3	44
1904	A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Gastric Cancer, 2014, 17, 161-172.	2.7	18
1905	Dysphonia induced by anti-angiogenic compounds. Investigational New Drugs, 2014, 32, 774-782.	1.2	19
1906	Fibroblast Growth Factor Receptor-2 IIIc as a Novel Molecular Target in Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 20-26.	1.0	0
1907	Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Targeted Oncology, 2014, 9, 273-277.	1.7	23
1908	Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. Journal of Gastroenterology, 2014, 49, 1421-1429.	2.3	17
1909	Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery, 2014, 4, 730-743.	7.7	165
1910	Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Investigational New Drugs, 2014, 32, 362-368.	1.2	36
1911	Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721. Journal of Molecular Histology, 2014, 45, 205-216.	1.0	3
1912	Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2014, 21, 1616-1623.	0.7	60
1913	Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. Journal of Experimental and Clinical Cancer Research, 2014, 33, 15.	3.5	33
1914	Alteration in the Balance of Prosurvival and Proapoptotic Signalling Pathways Leads to Sequence-Dependent Synergism Between Docetaxel and Sorafenib in Human Non-small Cell Lung Cancer Cell Lines. Cell Biochemistry and Biophysics, 2014, 68, 411-418.	0.9	4
1915	Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?. International Journal of Clinical Oncology, 2014, 19, 1029-1036.	1.0	4
1916	Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib. Cancer Chemotherapy and Pharmacology, 2014, 73, 223-229.	1.1	16
1917	Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International, 2014, 14, 4.	1.8	6
1918	Regorafenib (BAY 73â€4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer. International Journal of Cancer, 2014, 135, 1487-1496.	2.3	103
1919	VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment. Cell Biochemistry and Biophysics, 2014, 69, 151-156.	0.9	14
1920	Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy. Cellular Signalling, 2014, 26, 1743-1752.	1.7	76

#	Article	IF	Citations
1921	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, The, 2014, 384, 319-328.	6.3	1,295
1922	Update on the molecular diagnosis and targeted therapy of thyroid cancer. Medical Oncology, 2014, 31, 973.	1.2	11
1923	Molecular Testing in Cancer. , 2014, , .		2
1924	Targeting B-RAF. , 2014, , 529-563.		1
1925	A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. International Journal of Cancer, 2014, 135, 2972-2983.	2.3	18
1926	Identification of Type <scp>II</scp> Inhibitors Targeting <scp>BRAF</scp> Using Privileged Pharmacophores. Chemical Biology and Drug Design, 2014, 83, 27-36.	1.5	9
1927	<scp>ABT</scp>â€263 enhances sorafenibâ€induced apoptosis associated with <scp>A</scp>kt activity and the expression of <scp>B</scp>ax and p21⁽<scp>^{CIP1/WAF1}</scp>⁾ in human cancer cells. British Journal of Pharmacology, 2014, 171, 3182-3195.	2.7	24
1928	Incidence and Risk of Sorafenibâ€Induced Hypertension: A Systematic Review and Metaâ€Analysis. Journal of Clinical Hypertension, 2014, 16, 177-185.	1.0	59
1929	Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib. Hepatology Research, 2014, 44, 1320-1328.	1.8	10
1930	Enhanced Therapeutic Efficacy of Combined Use of Sorafenib and Transcatheter Arterial Chemoembolization for Treatment of Advanced Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology, 2014, 44, 711-717.	0.6	6
1931	Sorafenib Cardiotoxicity Increases Mortality After Myocardial Infarction. Circulation Research, 2014, 114, 1700-1712.	2.0	69
1932	Insight into the Structural Features of Pyrazolopyrimidineâ€and Pyrazolopyridineâ€based Bâ€Raf^{V600E} Kinase Inhibitors by Computational Explorations. Chemical Biology and Drug Design, 2014, 83, 643-655.	1.5	4
1933	Endometrial Adult/Progenitor Stem Cells: Pathogenetic Theory and New Antiangiogenic Approach for Endometriosis Therapy. Reproductive Sciences, 2014, 21, 296-304.	1.1	30
1934	Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001â€“2011). Chemical Reviews, 2014, 114, 2432-2506.	23.0	3,798
1935	Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. British Journal of Cancer, 2014, 110, 2655-2661.	2.9	52
1936	Effect of treatment with branchedâ€chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma. Hepatology Research, 2014, 44, 302-312.	1.8	25
1937	Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatology Research, 2014, 44, 296-301.	1.8	23
1938	Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer. Future Oncology, 2014, 10, 1167-1173.	1.1	5

#	Article	IF	Citations
1939	Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia, 2014, 28, 1543-1545.	3.3	81
1940	Sorafenib-Induced Tumor Response in a Patient With Metastatic Epithelioid Angiomyolipoma. Journal of Clinical Oncology, 2014, 32, e42-e45.	0.8	6
1941	â€œRecyclingâ€•Classical Drugs for Malaria. Chemical Reviews, 2014, 114, 11164-11220.	23.0	104
1942	Design, synthesis and biological evaluation of (1,3-diphenyl-1H-pyrazol-4-yl) methyl benzoate derivatives as potential BRAF^{V600E} inhibitors. RSC Advances, 2014, 4, 52702-52711.	1.7	10
1943	Mechanisms that influence tumour response to VEGF-pathway inhibitors. Biochemical Society Transactions, 2014, 42, 1601-1607.	1.6	7
1944	SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo. Cancer Letters, 2014, 355, 297-309.	3.2	34
1945	Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. Clinical Radiology, 2014, 69, e553-e561.	0.5	43
1946	Sorafenib regulating ERK signals pathway in gastric cancer cell. Environmental Toxicology and Pharmacology, 2014, 38, 438-443.	2.0	1
1947	Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression. Cancer Letters, 2014, 355, 61-69.	3.2	9
1948	Monitoring Chemotherapeutic Response by Hyperpolarized 13C-Fumarate MRS and Diffusion MRI. Cancer Research, 2014, 74, 686-694.	0.4	39
1949	Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. Journal of Histochemistry and Cytochemistry, 2014, 62, 547-555.	1.3	45
1950	Systemic treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 921-935.	1.0	9
1951	Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents. European Journal of Medicinal Chemistry, 2014, 87, 782-793.	2.6	59
1952	Drugging the undruggable RAS: Mission Possible?. Nature Reviews Drug Discovery, 2014, 13, 828-851.	21.5	1,484
1953	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Review of Proteomics, 2014, 11, 237-249.	1.3	9
1954	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature Reviews Cancer, 2014, 14, 455-467.	12.8	683
1955	Notable Decrease of Malignant Pleural Effusion After Treatment with Sorafenib in Radioiodine-Refractory Follicular Thyroid Carcinoma. Thyroid, 2014, 24, 1179-1183.	2.4	13
1956	Evolving treatment strategies in patients with high-risk acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 2438-2448.	0.6	10

#	Article	IF	Citations
1957	Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently. Surgery, 2014, 156, 263-269.	1.0	17
1958	Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery, 2014, 156, 270-279.	1.0	61
1959	RAF signaling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2014, 40, 974-979.	3.4	21
1960	Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Letters, 2014, 352, 245-252.	3.2	60
1961	SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma. Neoplasia, 2014, 16, 595-605.	2.3	42
1962	The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 349-358.	0.6	25
1963	Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma. International Journal of Urology, 2014, 21, 702-706.	0.5	5
1964	Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Molecular Cancer, 2014, 13, 158.	7.9	24
1965	Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. Journal of Zhejiang University: Science B, 2014, 15, 713-719.	1.3	9
1966	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology, 2014, 59, 1435-1447.	3.6	178
1967	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Archives of Toxicology, 2014, 88, 1189-1203.	1.9	47
1968	A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2014, 32, 723-728.	1.2	11
1969	A phase I/II trial of capecitabine combined with peginterferon Î±-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. Investigational New Drugs, 2014, 32, 762-768.	1.2	5
1970	The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors. Molecular and Cellular Biochemistry, 2014, 392, 239-247.	1.4	7
1971	Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. Expert Opinion on Investigational Drugs, 2014, 23, 37-53.	1.9	15
1972	An update on molecular biology of thyroid cancers. Critical Reviews in Oncology/Hematology, 2014, 90, 233-252.	2.0	83
1973	Copper-free azideâ€“alkyne cycloaddition of targeting peptides toÂporous silicon nanoparticles for intracellular drug uptake. Biomaterials, 2014, 35, 1257-1266.	5.7	94
1974	Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. Expert Opinion on Investigational Drugs, 2014, 23, 599-610.	1.9	13

#	Article	IF	Citations
1975	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology, 2014, 16, 1408-1416.	0.6	175
1976	Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?. Radiologia Medica, 2014, 119, 476-482.	4.7	7
1977	Advances in managing hepatocellular carcinoma. Frontiers of Medicine, 2014, 8, 175-189.	1.5	8
1978	Neutrophilâ€“lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Medical Oncology, 2014, 31, 969.	1.2	34
1979	Exposureâ€“Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma. Clinical Pharmacokinetics, 2014, 53, 185-196.	1.6	73
1980	Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterology, 2014, 14, 84.	0.8	97
1981	Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. BMC Cancer, 2014, 14, 219.	1.1	53
1982	Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer, 2014, 14, 351.	1.1	35
1983	Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report. BMC Endocrine Disorders, 2014, 14, 26.	0.9	2
1984	Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. Molecular Cancer, 2014, 13, 122.	7.9	18
1985	Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway. Journal of Cardiothoracic Surgery, 2014, 9, 81.	0.4	8
1986	Versatile Reticular Polyethylenimine Derivative-Mediated Targeted Drug and Gene Codelivery for Tumor Therapy. Molecular Pharmaceutics, 2014, 11, 3307-3321.	2.3	18
1987	A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	6.9	10
1988	Guanidinium-based derivatives: Searching for new kinase inhibitors. European Journal of Medicinal Chemistry, 2014, 81, 427-441.	2.6	22
1989	A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 167-177.e2.	0.9	21
1990	Xuefuzhuyu decoction inhibition of angiogenesis attenuates liver fibrosis induced by CCl4 in mice. Journal of Ethnopharmacology, 2014, 153, 659-666.	2.0	45
1992	1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib. Biomedicine and Pharmacotherapy, 2014, 68, 335-341.	2.5	8
1993	Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. Life Sciences, 2014, 104, 38-46.	2.0	17

#	Article	IF	Citations
1994	Extracellular vesicleâ€mediated transfer of long nonâ€coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio, 2014, 4, 458-467.	1.0	383
1995	BRAF inhibitors: From the laboratory to clinical trials. Critical Reviews in Oncology/Hematology, 2014, 90, 220-232.	2.0	35
1996	Sorafenib tosylate as a radiosensitizer in malignant astrocytoma. Journal of Clinical Neuroscience, 2014, 21, 131-136.	0.8	8
1997	Small-molecule clinical trial candidates for the treatment of glioma. Drug Discovery Today, 2014, 19, 1298-1308.	3.2	13
1998	Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer, 2014, 120, 3122-3130.	2.0	33
1999	Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Molecular Oncology, 2014, 8, 1339-1354.	2.1	14
2000	Targeted polytherapy in small cell sarcoma and its association with doxorubicin. Molecular Oncology, 2014, 8, 1458-1468.	2.1	12
2001	The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharmaceutica Sinica B, 2014, 4, 105-111.	5.7	48
2002	A Quantitative HPLC-UV Method for Determination of Serum Sorafenib and Sorafenib <i>N</i>-Oxide and Its Application in Hepatocarcinoma Patients. Tohoku Journal of Experimental Medicine, 2014, 233, 103-112.	0.5	17
2003	Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats. Journal of Toxicological Sciences, 2014, 39, 237-242.	0.7	8
2004	Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules, 2014, 19, 13848-13877.	1.7	97
2005	Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future. Liver Cancer, 2014, 3, 9-17.	4.2	52
2006	Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo. Oncology Reports, 2014, 32, 1913-1922.	1.2	20
2007	Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines. International Journal of Oncology, 2014, 45, 1450-1456.	1.4	8
2008	Biomarkers in Myelodysplastic Syndrome. , 2014, , 807-836.		0
2009	The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells. Oncology Reports, 2014, 32, 2421-2128.	1.2	11
2010	ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells. International Journal of Oncology, 2014, 44, 977-985.	1.4	73
2011	Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor Î±. International Journal of Oncology, 2014, 45, 2167-2175.	1.4	16

#	Article	IF	Citations
2012	Emerging targeted therapies for melanoma treatment (Review). International Journal of Oncology, 2014, 45, 516-524.	1.4	39
2013	Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition. Oncology Reports, 2014, 31, 540-550.	1.2	43
2014	Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. Molecular Medicine Reports, 2015, 11, 547-554.	1.1	2
2015	Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC. Expert Opinion on Pharmacotherapy, 2015, 16, 2773-2780.	0.9	17
2016	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. Digestive Diseases, 2015, 33, 668-674.	0.8	10
2017	Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults. The Cochrane Library, 0, , .	1.5	0
2018	Paclitaxel/carboplatin with or without sorafenib in the firstâ€line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. Cancer Medicine, 2015, 4, 673-681.	1.3	53
2019	Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. Cancer Medicine, 2015, 4, 1214-1223.	1.3	21
2020	<scp>FTY</scp>720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenibâ€mediated cytotoxicity. Pharmacology Research and Perspectives, 2015, 3, e00171.	1.1	17
2021	Regorafenib Is Transported by the Organic Anion Transporter 1B1 and the Multidrug Resistance Protein 2. Biological and Pharmaceutical Bulletin, 2015, 38, 582-586.	0.6	30
2022	A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Molecular and Clinical Oncology, 2015, 3, 1099-1102.	0.4	4
2025	Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions. Biological and Pharmaceutical Bulletin, 2015, 38, 986-991.	0.6	55
2026	The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells. Molecular Medicine Reports, 2015, 11, 797-804.	1.1	4
2028	Sorafenib inhibits cancer side population cells by targeting c-Jun N-terminal kinase signaling. Molecular Medicine Reports, 2015, 12, 8247-8252.	1.1	7
2029	Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Molecular Medicine, 2015, 7, 608-627.	3.3	36
2030	Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutrition Journal, 2015, 14, 67.	1.5	37
2031	Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts. Journal of Translational Medicine, 2015, 13, 191.	1.8	10
2032	Hypertension in cancer patients treated with anti-angiogenic based regimens. Cardio-Oncology, 2015, 1, 6.	0.8	25

#	Article	IF	Citations
2033	Apoptosis in liver carcinogenesis and chemotherapy. Hepatic Oncology, 2015, 2, 381-397.	4.2	13
2034	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Management, 2015, 2, 241-254.	0.1	10
2035	Systemic therapies for hepatocellular carcinoma. Drug Discoveries and Therapeutics, 2015, 9, 352-362.	0.6	50
2036	Sorafenib enriches epithelial cell adhesion moleculeâ€“positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2â€“AKT cascade. Hepatology, 2015, 62, 1791-1803.	3.6	54
2037	A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation. Anti-Cancer Drugs, 2015, 26, 1004-1007.	0.7	24
2038	Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2015, 27, 853-859.	0.8	41
2039	1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/Î²-catenin pathway and receptor tyrosine kinases. Journal of Pharmacy and Pharmacology, 2015, 67, 1393-1405.	1.2	16
2040	Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 1020-1028.	1.1	34
2041	Safety profile of combined therapy inhibiting <scp>EFGR</scp> and <scp>VEGF</scp> pathways in patients with advanced nonâ€smallâ€cell lung cancer: A metaâ€analysis of 15 phase II/III randomized trials. International Journal of Cancer, 2015, 137, 409-419.	2.3	22
2042	Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drugâ€Loaded Magnetic Solid Lipid Nanoparticles. Advanced Healthcare Materials, 2015, 4, 1681-1690.	3.9	81
2043	Discovery of New 4â€Alkoxyquinazolineâ€Based Derivatives as Potent <scp>VEGFR</scp>2 Inhibitors. Chemical Biology and Drug Design, 2015, 86, 1323-1329.	1.5	7
2044	Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of Granulosa Cell Tumors of the Ovary. International Journal of Gynecological Cancer, 2015, 25, 1224-1231.	1.2	11
2045	Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World Journal of Hepatology, 2015, 7, 787.	0.8	140
2046	A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma. Keio Journal of Medicine, 2015, 64, 62-64.	0.5	6
2047	Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. OncoTargets and Therapy, 2015, 8, 3193.	1.0	1
2048	Liver Cell Carcinoma in Poland: Data Reported to the National Health Fund in the Years 2008-2012. Journal of Liver, 2015, 04, .	0.3	2
2049	Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virusâ€Infected Retinal Pigment Epithelial Cells. , 2015, 56, 5162.		22
2050	Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Journal of Hepatocellular Carcinoma, 2015, 2, 39.	1.8	24

#	Article	IF	Citations
2051	TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget, 2015, 6, 24163-24177.	0.8	54
2052	Targeted Cancer Therapy: The Next Generation of Cancer Treatment. Current Drug Discovery Technologies, 2015, 12, 3-20.	0.6	429
2053	Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K. Frontiers in Cell and Developmental Biology, 2015, 3, 47.	1.8	9
2054	Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World Journal of Hepatology, 2015, 7, 1041.	0.8	42
2055	Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. Diagnostic and Interventional Radiology, 2015, 21, 235-240.	0.7	13
2056	Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib. PLoS ONE, 2015, 10, e0141395.	1.1	7
2057	Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Molecular and Clinical Oncology, 2015, 3, 929-935.	0.4	12
2058	Serum concentrations of Flt-3 ligand in rheumatic diseases. BioScience Trends, 2015, 9, 342-349.	1.1	3
2059	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. Yonsei Medical Journal, 2015, 56, 1296.	0.9	33
2060	The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Management and Research, 2015, 7, 265.	0.9	33
2061	Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4. International Journal of Biological Markers, 2015, 30, 111-121.	0.7	2
2062	The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients. International Journal of Endocrinology, 2015, 2015, 1-8.	0.6	15
2064	Current and future treatments for hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 8478.	1.4	140
2065	The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer. Gastrointestinal Cancer: Targets and Therapy, 0, , 79.	5.5	1
2066	Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 12022.	1.4	62
2067	Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma. Current Gene Therapy, 2015, 15, 97-108.	0.9	8
2068	Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget, 2015, 6, 28296-28311.	0.8	75
2069	New Therapies for Dedifferentiated Papillary Thyroid Cancer. International Journal of Molecular Sciences, 2015, 16, 6153-6182.	1.8	49

#	Article	IF	Citations
2072	Linifanib: current status and future potential in cancer therapy. Expert Review of Anticancer Therapy, 2015, 15, 677-687.	1.1	21
2073	Discovery of molecular mechanisms of lignan justicidin A using L1000 gene expression profiles and the Library of Integrated Network-based Cellular Signatures database. Journal of Functional Foods, 2015, 16, 81-93.	1.6	5
2074	Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. Journal of Controlled Release, 2015, 211, 118-133.	4.8	36
2075	Transgenic Plants as Low-Cost Platform for Chemotherapeutic Drugs Screening. International Journal of Molecular Sciences, 2015, 16, 2174-2186.	1.8	10
2076	Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head and Neck, 2015, 37, 182-187.	0.9	76
2077	First-Generation Tyrosine Kinase Inhibitors: Clinical Results. , 2015, , 177-205.		1
2078	IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterology, 2015, 15, 50.	0.8	47
2079	The relationship between hand hygiene and health care-associated infection: it’s complicated. Infection and Drug Resistance, 2015, 8, 7.	1.1	39
2080	Raf/MEK/ERK Signaling. , 2015, , 275-305.		0
2082	Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer, 2015, 4, 263-273.	4.2	26
2083	The Adverse Effects of Sorafenib in Patients with Advanced Cancers. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 216-221.	1.2	123
2084	Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. Journal of Translational Medicine, 2015, 13, 150.	1.8	12
2085	Angiokinase inhibitors in non-small-cell lung cancer. Clinical Investigation, 2015, 5, 47-59.	0.0	0
2086	Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells. Biomacromolecules, 2015, 16, 3784-3791.	2.6	29
2087	Monotherapy Administration of Sorafenib in Patients With Nonâ€“Small Cell Lung Cancer (MISSION) Trial. Journal of Thoracic Oncology, 2015, 10, 1745-1753.	0.5	100
2088	Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival. Medicine (United States), 2015, 94, e1361.	0.4	13
2089	CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanomaâ€”Kinase Inhibition Redux. Clinical Cancer Research, 2015, 21, 5412-5414.	3.2	1
2090	Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncology Reports, 2015, 33, 1994-2000.	1.2	41

#	Article	IF	Citations
2091	Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells. Oncology Reports, 2015, 33, 2537-2544.	1.2	23
2092	RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis. Oncology Reports, 2015, 33, 3006-3014.	1.2	28
2093	Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis. Oncology Reports, 2015, 34, 2142-2150.	1.2	18
2094	Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncology Reports, 2015, 34, 2319-2324.	1.2	15
2095	Liver function assessment according to the Albuminâ€“Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2015, 33, 1257-1262.	1.2	75
2096	Mechanisms for SU5416 as a radiosensitizer of endothelial cells. International Journal of Oncology, 2015, 47, 1440-1450.	1.4	5
2097	Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 115-125.	4.2	19
2098	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncology, The, 2015, 16, 98-107.	5.1	270
2099	SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2015, 33, 559-566.	0.8	479
2100	Synthesis of quinolinylaminopyrimidines and quinazolinylmethylaminopyrimidines with antiproliferative activity against melanoma cell line. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 607-614.	2.5	5
2101	Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. Targeted Oncology, 2015, 10, 199-213.	1.7	46
2102	The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in <scp>A</scp>sian patients with hepatocellular carcinoma: Final results of the <scp>START</scp> trial. International Journal of Cancer, 2015, 136, 1458-1467.	2.3	109
2103	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 2015, 372, 621-630.	13.9	1,526
2104	Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opinion on Pharmacotherapy, 2015, 16, 573-583.	0.9	30
2105	The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opinion on Drug Discovery, 2015, 10, 427-439.	2.5	48
2106	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Letters, 2015, 359, 20-35.	3.2	67
2107	Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft. Head and Neck, 2015, 37, 1326-1335.	0.9	7
2108	Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy. Acta Biomaterialia, 2015, 16, 206-214.	4.1	78

#	Article	IF	Citations
2109	Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. , 2015, 149, 139-149.		27
2110	Hepatitis <scp>B</scp> viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1024-1031.	1.4	17
2111	Expression of <scp>pERK</scp> and <scp>VEGFR</scp>â€2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver International, 2015, 35, 2001-2008.	1.9	49
2112	Perivascular Interstitial Cells of Cajal in Human Colon. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 102-119.	2.3	13
2113	Design and synthesis of novel 1,2,3-triazoleâ€“pyrimidineâ€“urea hybrids as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1124-1128.	1.0	82
2114	The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resistance Updates, 2015, 18, 1-17.	6.5	590
2116	Molecular Basis for Treating Cutaneous Melanoma. , 2015, , 591-600.e3.		0
2117	Angiogenesis in primary hyperparathyroidism. Annals of Diagnostic Pathology, 2015, 19, 91-98.	0.6	6
2118	BIRC6 promotes hepatocellular carcinogenesis: Interaction of <scp>BIRC</scp>6 with p53 facilitating p53 degradation. International Journal of Cancer, 2015, 136, E475-87.	2.3	42
2119	Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials. Oncology, 2015, 88, 345-352.	0.9	31
2120	Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. Molecular Imaging and Biology, 2015, 17, 29-37.	1.3	48
2122	Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Scientific Reports, 2014, 4, 7518.	1.6	31
2123	Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma. International Cancer Conference Journal, 2015, 4, 147-150.	0.2	4
2124	Effectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective study. Journal of Pharmaceutical Health Care and Sciences, 2015, 1, 6.	0.4	5
2125	Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Targeted Oncology, 2015, 10, 311-324.	1.7	20
2126	Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2015, 33, 894-900.	0.8	114
2127	YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models. Scientific Reports, 2015, 4, 6031.	1.6	31
2128	Renal effects of targeted anticancer therapies. Nature Reviews Nephrology, 2015, 11, 354-370.	4.1	95

#	Article	IF	Citations
2129	Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. Journal of Radiation Research, 2015, 56, 37-45.	0.8	6
2130	Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. Leukemia and Lymphoma, 2015, 56, 2690-2698.	0.6	6
2131	Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World Journal of Hepatology, 2015, 7, 1553.	0.8	37
2132	Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer, 2015, 88, 289-296.	0.9	16
2133	PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Scientific Reports, 2015, 5, 9384.	1.6	116
2134	Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells. International Journal of Pharmaceutics, 2015, 493, 75-85.	2.6	34
2135	SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology, 2015, 68, 837-847.	0.9	116
2136	Medullary Thyroid Cancer. , 2015, , 389-401.		0
2137	Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors. Lung Cancer, 2015, 90, 22-31.	0.9	15
2138	Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report. Oncology Letters, 2015, 9, 1633-1636.	0.8	9
2139	A phase II study of sorafenib, oxaliplatin, and 2Âdays of high-dose capecitabine in advanced pancreas cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 317-323.	1.1	9
2140	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7243-7248.	3.3	65
2141	Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Frontiers in Oncology, 2015, 5, 54.	1.3	87
2142	Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opinion on Investigational Drugs, 2015, 24, 1045-1058.	1.9	1
2143	Sorafenib: 10 years after the first pivotal trial. Future Oncology, 2015, 11, 1863-1880.	1.1	40
2144	Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. Reproductive Sciences, 2015, 22, 1171-1180.	1.1	28
2145	BRAF inhibitors: the current and the future. Current Opinion in Pharmacology, 2015, 23, 68-73.	1.7	37
2146	Targeting the VEGF pathway in metastatic bladder cancer. Expert Opinion on Investigational Drugs, 2015, 24, 913-927.	1.9	35

#	Article	IF	Citations
2147	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncology Letters, 2015, 9, 1628-1632.	0.8	25
2148	Identification of signalling cascades involved in red blood cell shrinkage and vesiculation. Bioscience Reports, 2015, 35, .	1.1	37
2149	Systemic Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 421-432.	1.0	36
2150	Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Research, 2015, 75, 2510-2519.	0.4	72
2151	Preparation and characterization of solid dispersion using a novel amphiphilic copolymer to enhance dissolution and oral bioavailability of sorafenib. Powder Technology, 2015, 283, 260-265.	2.1	51
2152	Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. Expert Review of Anticancer Therapy, 2015, 15, 579-594.	1.1	17
2153	Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 1099-1114.	1.1	13
2154	Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. European Radiology, 2015, 25, 380-390.	2.3	24
2155	Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 55-66.	1.4	12
2156	First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. International Journal of Clinical Oncology, 2015, 20, 952-959.	1.0	24
2157	Sorafenib treatment in Childâ€“Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Investigational New Drugs, 2015, 33, 729-739.	1.2	75
2158	Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma. Targeted Oncology, 2015, 10, 171-178.	1.7	9
2159	Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. Endocrine, 2015, 49, 726-734.	1.1	12
2160	Axitinib in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 499-507.	1.1	13
2161	Iodide- and Glucose-Handling Gene Expression Regulated by Sorafenib or Cabozantinib in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1771-1779.	1.8	28
2162	Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives. Cancer Chemotherapy and Pharmacology, 2015, 76, 219-233.	1.1	30
2164	Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodineâ€Refractory Patients. Oncologist, 2015, 20, 113-126.	1.9	57
2165	Lenvatinib and radioiodine-refractory thyroid cancers. Nature Reviews Endocrinology, 2015, 11, 325-327.	4.3	9

#	Article	IF	Citations
2166	The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Scientific Reports, 2015, 5, 9149.	1.6	63
2167	Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer, 2015, 15, 184.	1.1	45
2168	Biomarkers in Oncology. , 2015, , 185-188.		0
2169	Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas. Journal of the Association for Laboratory Automation, 2015, 20, 423-437.	2.8	35
2170	A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam. NeuroToxicology, 2015, 50, 101-107.	1.4	10
2171	Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opinion on Investigational Drugs, 2015, 24, 1571-1596.	1.9	12
2172	Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 517-527.	0.8	16
2173	Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Leukemia Research, 2015, 39, 1421-1427.	0.4	36
2174	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). Annals of Oncology, 2015, 26, 2168-2173.	0.6	93
2175	Field practice study of halfâ€dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. Hepatology Research, 2015, 45, 279-287.	1.8	25
2176	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocrine-Related Cancer, 2015, 22, 877-887.	1.6	58
2177	Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study. Clinical Genitourinary Cancer, 2015, 13, 156-164.e1.	0.9	30
2178	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 777-784.	1.1	17
2179	Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 6497-6509.	1.4	105
2180	Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Reports in Oncology, 2015, 8, 83-87.	0.3	24
2181	Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond. Future Oncology, 2015, 11, 2263-2266.	1.1	17
2182	Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biology and Therapy, 2015, 16, 610-622.	1.5	27
2183	Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging. British Journal of Radiology, 2015, 88, 20150163.	1.0	23

#	Article	IF	Citations
2184	RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochimica Et Biophysica Sinica, 2015, 48, gmv090.	0.9	30
2185	A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance. Japanese Journal of Clinical Oncology, 2015, 45, 953-962.	0.6	26
2186	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2015, 16, 1344-1354.	5.1	809
2187	Probing a 3,4â€²-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4287-4292.	1.0	8
2188	Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nature Reviews Drug Discovery, 2015, 14, 693-720.	21.5	181
2189	Design, synthesis and antitumor activity of novel 6,7-dimethoxyquinazoline derivatives containing diaryl urea moiety. Chemical Research in Chinese Universities, 2015, 31, 766-773.	1.3	1
2190	Potent anti-angiogenic component in Croton crassifolius and its mechanism of action. Journal of Ethnopharmacology, 2015, 175, 185-191.	2.0	32
2191	Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancers. Clinical Lung Cancer, 2015, 16, 514-522.	1.1	10
2192	Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin. Critical Reviews in Oncology/Hematology, 2015, 96, 195-205.	2.0	7
2193	Embolization biomaterial reinforced with nanotechnology for an in-situ release of anti-angiogenic agent in the treatment of hyper-vascularized tumors and arteriovenous malformations. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 396-408.	2.0	12
2194	Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. Clinical Drug Investigation, 2015, 35, 751-759.	1.1	26
2195	Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity scoreâ€based weighting. Journal of Digestive Diseases, 2015, 16, 143-151.	0.7	12
2196	K20E, an oxidative-coupling compound of methyl caffeate, exhibits anti-angiogenic activities through down-regulations of VEGF and VEGF receptor-2. Toxicology and Applied Pharmacology, 2015, 282, 215-226.	1.3	6
2198	Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2015, 33, 172-179.	0.8	517
2199	The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth. Cancer Letters, 2015, 356, 392-403.	3.2	4
2200	Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study. Medical Oncology, 2015, 32, 335.	1.2	36
2201	Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis. Biochemical Pharmacology, 2015, 93, 110-124.	2.0	19
2202	Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. Clinical and Translational Oncology, 2015, 17, 121-132.	1.2	21

#	Article	IF	Citations
2203	Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemotherapy and Pharmacology, 2015, 75, 161-171.	1.1	14
2205	Review of angiogenesis in hepatocellular carcinoma. Hepatology Research, 2015, 45, 1-9.	1.8	85
2206	Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. European Journal of Medicinal Chemistry, 2015, 90, 170-183.	2.6	40
2207	NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways. Tumor Biology, 2015, 36, 2143-2153.	0.8	28
2208	Arabidopsis Putative MAP Kinase Kinase Kinases Raf10 and Raf11 are Positive Regulators of Seed Dormancy and ABA Response. Plant and Cell Physiology, 2015, 56, 84-97.	1.5	61
2209	Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. International Journal of Clinical Oncology, 2015, 20, 105-110.	1.0	25
2210	Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget, 2016, 7, 81926-81968.	0.8	18
2211	Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncology Reviews, 2016, 10, 298.	0.8	21
2212	Advanced Stage Hepatocellular Carcinoma with Multiple Metastasis and Vascular Thrombosis: A Case of Complete Response to Sorafenib. Acta Medica Portuguesa, 2016, 29, 139.	0.2	5
2213	Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget, 2016, 7, 43442-43460.	0.8	145
2214	OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. Journal of Korean Medical Science, 2016, 31, 1215.	1.1	27
2215	Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Design, Development and Therapy, 2016, 10, 873.	2.0	33
2216	Selective use of sorafenib in the treatment of thyroid cancer. Drug Design, Development and Therapy, 2016, 10, 1119.	2.0	54
2217	Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma. Oncotarget, 2016, 7, 29605-29619.	0.8	8
2218	Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World Journal of Clinical Oncology, 2016, 7, 331.	0.9	39
2219	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. Oncotarget, 2016, 7, 26628-26652.	0.8	25
2220	Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 610-627.	1.3	13
2221	Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Tomography, 2016, 2, 308-316.	0.8	27

#	Article	IF	Citations
2222	A Holistic <i>In silico</i> Approach to Develop Novel Inhibitors Targeting ErbB1 and ErbB2 Kinases. Tropical Journal of Pharmaceutical Research, 2016, 15, 231.	0.2	8
2223	Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell Carcinoma. Disease Markers, 2016, 2016, 1-8.	0.6	4
2224	Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. International Journal of Nanomedicine, 2016, Volume 11, 5645-5669.	3.3	108
2225	Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget, 2016, 7, 27044-27054.	0.8	28
2226	Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations. Wspolczesna Onkologia, 2016, 1, 33-38.	0.7	8
2227	Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. PLoS ONE, 2016, 11, e0167906.	1.1	13
2228	Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Frontiers in Pharmacology, 2016, 7, 151.	1.6	91
2229	A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. International Journal of Nanomedicine, 2016, 11, 179.	3.3	10
2230	Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments. Molecules, 2016, 21, 879.	1.7	7
2231	The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells. Stem Cells International, 2016, 2016, 1-10.	1.2	320
2232	A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFÎ² receptor. Oncotarget, 2016, 7, 25983-26002.	0.8	20
2233	Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget, 2016, 7, 4860-4870.	0.8	17
2234	The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget, 2016, 7, 46734-46749.	0.8	17
2235	Challenges of advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 7645.	1.4	135
2236	Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways. Anti-Cancer Drugs, 2016, 27, 192-203.	0.7	37
2237	Glycogen Synthase Kinase 3Î² Promotes the Endocytosis of Transferrin in the African Trypanosome. ACS Infectious Diseases, 2016, 2, 518-528.	1.8	12
2238	Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer, 2016, 16, 429.	1.1	28
2239	Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients. Phytomedicine, 2016, 23, 1295-1300.	2.3	12

#	Article	IF	Citations
2240	Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo. Anti-Cancer Drugs, 2016, 27, 600-608.	0.7	7
2241	FLT3 Inhibitors for Treating Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 543-549.	0.2	35
2242	Complete response to shortâ€term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. Hepatology Research, 2016, 46, 1402-1408.	1.8	9
2243	Antiangiogenic 1â€Arylâ€3â€[3â€(thieno[3,2â€b]pyridinâ€7â€ylthio)phenyl]ureas Inhibit MCFâ€7 and MDAâ€MBâ€231 Human Breast Cancer Cell Lines Through PI3K/Akt and MAPK/Erk Pathways. Journal of Cellular Biochemistry, 2016, 117, 2791-2799.	1.2	19
2244	Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-6.	1.4	51
2245	Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review. Clinical and Experimental Ophthalmology, 2016, 44, 509-519.	1.3	18
2246	Impact of branchedâ€chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort study. Hepatology Research, 2016, 46, 1002-1010.	1.8	21
2247	Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research, 2016, 22, 4870-4879.	3.2	26
2248	Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma. Liver Cancer, 2016, 5, 235-244.	4.2	43
2250	Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature. Internal Medicine, 2016, 55, 623-627.	0.3	8
2251	Sorafenib improves the postoperative effect of early stage renal cell carcinoma. Oncology Letters, 2016, 12, 4367-4370.	0.8	0
2252	Application of computational methods for anticancer drug discovery, design, and optimization. BoletÃn MÃ©dico Del Hospital Infantil De MÃ©xico, 2016, 73, 411-423.	0.2	51
2253	Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Scientific Reports, 2016, 6, 21260.	1.6	52
2254	Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. Scientific Reports, 2016, 6, 34523.	1.6	17
2255	mTOR Signaling Confers Resistance to Targeted Cancer Drugs. Trends in Cancer, 2016, 2, 688-697.	3.8	65
2256	Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Scientific Reports, 2016, 6, 22976.	1.6	27
2257	A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. BMC Cancer, 2016, 16, 543.	1.1	8
2258	Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors. Expert Opinion on Orphan Drugs, 2016, 4, 659-670.	0.5	0

#	Article	IF	Citations
2259	Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect. Journal of Vascular and Interventional Radiology, 2016, 27, 1086-1092.	0.2	9
2260	Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. AAPS Journal, 2016, 18, 923-932.	2.2	12
2262	Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology. Hepatology Research, 2016, 46, 50-57.	1.8	54
2263	Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity. Free Radical Biology and Medicine, 2016, 95, 308-322.	1.3	34
2264	A fucoidan from Nemacystus decipiens disrupts angiogenesis through targeting bone morphogenetic protein 4. Carbohydrate Polymers, 2016, 144, 305-314.	5.1	23
2265	Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Annals of Surgical Oncology, 2016, 23, 583-591.	0.7	18
2266	Iron depletion enhances the effect of sorafenib in hepatocarcinoma. Cancer Biology and Therapy, 2016, 17, 648-656.	1.5	21
2267	Purinylpyridinylamino-based DFG-in/Î±C-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling. Bioorganic and Medicinal Chemistry, 2016, 24, 2215-2234.	1.4	13
2268	Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer. Current Treatment Options in Oncology, 2016, 17, 30.	1.3	23
2269	Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. Journal of Gastroenterology, 2016, 51, 1150-1160.	2.3	44
2270	Genetics of Melanoma. , 2016, , .		3
2271	Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties. European Journal of Medicinal Chemistry, 2016, 119, 122-131.	2.6	20
2272	Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result. Oncology Letters, 2016, 12, 579-584.	0.8	16
2273	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy, 2016, 17, 1923-1936.	0.9	15
2274	Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production. Cancer Letters, 2016, 382, 157-165.	3.2	33
2275	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Medicina ClÃnica (English Edition), 2016, 146, 511.e1-511.e22.	0.1	2
2276	Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. Seminars in Oncology, 2016, 43, 446-452.	0.8	8
2277	Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. BioDrugs, 2016, 30, 421-439.	2.2	9

#	Article	IF	Citations
2278	Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. Expert Opinion on Emerging Drugs, 2016, 21, 431-440.	1.0	7
2279	Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma. Expert Review of Anticancer Therapy, 2016, 16, 1235-1245.	1.1	7
2280	Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. Journal of Vascular and Interventional Radiology, 2016, 27, 1329-1336.	0.2	20
2281	Inhibition of the Wnt/Î²-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Cancer Letters, 2016, 381, 58-66.	3.2	39
2282	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 48-59.	2.9	45
2283	Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. Cancer Science, 2016, 107, 601-608.	1.7	43
2284	Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. Cancer Science, 2016, 107, 507-513.	1.7	31
2285	Preclinical and firstâ€inâ€human phase I studies of <scp>KW</scp>â€2450, an oral tyrosine kinase inhibitor with insulinâ€like growth factor receptorâ€1/insulin receptor selectivity. Cancer Science, 2016, 107, 499-506.	1.7	22
2286	FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Digestive and Liver Disease, 2016, 48, 1492-1497.	0.4	16
2287	A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1033-1034, 261-270.	1.2	22
2288	miRâ€181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of <scp>RASSF</scp>1 expression. Cancer Science, 2016, 107, 1256-1262.	1.7	62
2289	Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin. Biochemical Pharmacology, 2016, 122, 80-89.	2.0	15
2290	Antitumour and antiangiogenic activities of [Pt(O,Oâ€²â€acac)(Î³â€acac)(DMS)] in a xenograft model of human renal cell carcinoma. British Journal of Pharmacology, 2016, 173, 2633-2644.	2.7	13
2292	Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2016, 9, 184-190.	0.4	31
2293	Synthesis, anticancer activity and photostability of novel 3-ethyl-2-mercapto-thieno[2,3- d]pyrimidin-4() Tj ETQq0 0 0 rgBT /Overlock 10	2.6	32
2294	Antitumor activity of sorafenib on colorectal cancer. Journal of Oncological Science, 2016, 2, 53-57.	0.1	11
2295	Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. OncoImmunology, 2016, 5, e1226718.	2.1	10
2296	Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells. Future Medicinal Chemistry, 2016, 8, 2197-2211.	1.1	6

#	Article	IF	Citations
2297	Sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2016, 8, 348-371.	0.9	41
2298	Cancer Drug Discovery. , 2016, , .		6
2299	Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Scientific Reports, 2016, 6, 29258.	1.6	22
2300	Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. Scientific Reports, 2016, 6, 30038.	1.6	48
2301	Î”2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions. Cell Cycle, 2016, 15, 3402-3412.	1.3	4
2302	Application of computational methods for anticancer drug discovery, design, and optimization. BoletÃn MÃ©dico Del Hospital Infantil De MÃ©xico (English Edition), 2016, 73, 411-423.	0.0	18
2303	Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials, 2016, 17, 563.	0.7	4
2304	Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib. Anti-Cancer Drugs, 2016, 27, 1028-1032.	0.7	9
2305	Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermatoâ€•oncology clinic. International Journal of Dermatology, 2016, 55, 473-478.	0.5	9
2306	A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. International Journal of Oncology, 2016, 49, 89-98.	1.4	54
2307	Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models. Nucleic Acids Research, 2016, 44, W212-W216.	6.5	27
2308	Induction Chemotherapy for Hepatocellular Carcinoma. , 2016, , 269-284.		0
2309	Sorafenib exerts an anti-keloid activity by antagonizing TGF-Î²/Smad and MAPK/ERK signaling pathways. Journal of Molecular Medicine, 2016, 94, 1181-1194.	1.7	46
2310	NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death and Disease, 2016, 7, e2269-e2269.	2.7	94
2311	Safety of available treatment options for renal cell carcinoma. Expert Opinion on Drug Safety, 2016, 15, 1097-1106.	1.0	11
2312	Induction Chemotherapy. , 2016, , .		3
2313	Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterology, 2016, 16, 50.	0.8	12
2314	Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Cell Communication and Signaling, 2016, 14, 6.	2.7	15

#	Article	IF	Citations
2315	Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. Journal of Hematology and Oncology, 2016, 9, 20.	6.9	52
2316	An optimized approach in the synthesis of imatinib intermediates and analogues. RSC Advances, 2016, 6, 61458-61467.	1.7	7
2317	Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes. Cancer Chemotherapy and Pharmacology, 2016, 77, 905-926.	1.1	15
2318	Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1381-1386.	3.3	64
2319	DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. Tumor Biology, 2016, 37, 9221-9232.	0.8	3
2320	Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Letters, 2016, 372, 187-191.	3.2	126
2321	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology, 2016, 64, 1090-1098.	1.8	567
2322	A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Annals of Oncology, 2016, 27, 680-687.	0.6	40
2323	Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. Molecular Biology Reports, 2016, 43, 107-116.	1.0	18
2324	Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 2016, 15, 385-403.	21.5	724
2325	Anti-angiogenesis in Personalized Therapy of Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 91-126.	0.8	17
2327	A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research, 2016, 22, 2368-2376.	3.2	17
2328	Clinical management of metastatic kidney cancer: the role of new molecular drugs. Future Oncology, 2016, 12, 83-93.	1.1	9
2329	Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling. Cellular and Molecular Life Sciences, 2016, 73, 1671-1683.	2.4	18
2330	Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer, 2016, 19, 31-41.	2.7	48
2331	Intracellular interactions of electrostatically mediated layer-by-layer assembled polyelectrolytes based sorafenib nanoparticles in oral cancer cells. Colloids and Surfaces B: Biointerfaces, 2016, 143, 131-138.	2.5	27
2332	Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. Radiology, 2016, 280, 425-435.	3.6	30
2333	Sorafenib for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2016, 25, 743-749.	1.9	10

#	Article	IF	Citations
2334	The lymphatic system and pancreatic cancer. Cancer Letters, 2016, 381, 217-236.	3.2	44
2335	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer, 2016, 93, 1-8.	0.9	13
2336	Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors. Targeted Oncology, 2016, 11, 263-275.	1.7	17
2337	Combinatorial immunotherapy strategies for hepatocellular carcinoma. Current Opinion in Immunology, 2016, 39, 103-113.	2.4	52
2338	Advances in Local and Systemic Therapies for Hepatocellular Cancer. Current Oncology Reports, 2016, 18, 9.	1.8	14
2339	In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy. International Journal of Pharmaceutics, 2016, 503, 150-162.	2.6	23
2341	Synthesis, in vitro and in vivo anticancer activity of novel 1-(4-imino-1-substituted-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)urea derivatives. RSC Advances, 2016, 6, 24491-24500.	1.7	20
2342	Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 635-643.	3.3	74
2343	Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2016, 21, 748-755.	1.0	6
2344	Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2016, 77, 243-250.	1.1	21
2345	Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. Journal of Gastroenterology, 2016, 51, 1011-1021.	2.3	29
2346	Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Clinical Breast Cancer, 2016, 16, 180-187.	1.1	15
2347	Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1840-1852.	1.4	36
2348	Quercetin and the mitochondria: A mechanistic view. Biotechnology Advances, 2016, 34, 532-549.	6.0	181
2349	The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Expert Opinion on Drug Safety, 2016, 15, 105-116.	1.0	14
2351	Design and synthesis of new imidazo[1,2- a]pyridine and imidazo[1,2- a]pyrazine derivatives with antiproliferative activity against melanoma cells. European Journal of Medicinal Chemistry, 2016, 108, 623-643.	2.6	30
2352	Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials. Cancer Letters, 2016, 380, 598-607.	3.2	23
2353	Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics. Human Reproduction Update, 2016, 22, 382-403.	5.2	138

#	Article	IF	Citations
2354	Laryngeal Side Effects of Tyrosine Kinase Inhibitors. Journal of Voice, 2016, 30, 606-610.	0.6	3
2355	The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 38-40.	0.3	1
2356	Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis. Nature Reviews Drug Discovery, 2016, 15, 125-142.	21.5	115
2357	Growth inhibitory effect of an injectable hyaluronic acidâ€“tyramine hydrogels incorporating human natural interferon-Î± and sorafenib on renal cell carcinoma cells. Acta Biomaterialia, 2016, 29, 103-111.	4.1	42
2358	Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene, 2016, 35, 2547-2561.	2.6	75
2359	An efficient and high-yielding protocol for the production of Regorafenib via a new synthetic strategy. Research on Chemical Intermediates, 2016, 42, 3209-3218.	1.3	5
2360	Heterogeneity of liver cancer and personalized therapy. Cancer Letters, 2016, 379, 191-197.	3.2	202
2361	Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 93-99.	2.0	55
2362	Discrete cytosolic macromolecular <scp>BRAF</scp> complexes exhibit distinct activities and composition. EMBO Journal, 2017, 36, 646-663.	3.5	52
2363	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2017, 18, 205-216.	0.9	5
2364	Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes. Biomedicine and Pharmacotherapy, 2017, 88, 459-468.	2.5	61
2365	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy, 2017, 13, 608-624.	4.3	65
2366	Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. Free Radical Biology and Medicine, 2017, 104, 1-9.	1.3	45
2367	Drug target identification at the crossroad of neuronal apoptosis and survival. Expert Opinion on Drug Discovery, 2017, 12, 249-259.	2.5	14
2368	Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells. European Journal of Cancer, 2017, 73, 9-21.	1.3	27
2369	Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Head and Neck, 2017, 39, 623-632.	0.9	14
2370	Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib. Oncologist, 2017, 22, 208-212.	1.9	11
2371	Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. Oncology Reports, 2017, 37, 227-234.	1.2	8

#	Article	IF	Citations
2372	Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix. Drug Delivery, 2017, 24, 270-277.	2.5	21
2373	Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. Radiology, 2017, 284, 583-592.	3.6	19
2374	Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. International Immunopharmacology, 2017, 46, 112-123.	1.7	24
2375	Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports, 2017, 7, 44123.	1.6	56
2376	Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation. Current Oncology Reports, 2017, 19, 21.	1.8	3
2377	Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report. World Journal of Surgical Oncology, 2017, 15, 24.	0.8	19
2378	Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors. European Journal of Medicinal Chemistry, 2017, 134, 366-378.	2.6	10
2379	Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. Biomedicine and Pharmacotherapy, 2017, 88, 395-402.	2.5	20
2380	Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. Cancer Letters, 2017, 392, 1-8.	3.2	17
2381	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Targeted Oncology, 2017, 12, 201-209.	1.7	25
2382	Management of Thyroid Nodules and Differentiated Thyroid Cancer. , 2017, , .		4
2383	Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. European Journal of Radiology, 2017, 90, 34-41.	1.2	18
2384	Modeling and optimization of nanoemulsion containing Sorafenib for cancer treatment by response surface methodology. Chemistry Central Journal, 2017, 11, 21.	2.6	26
2385	Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Molecular and Clinical Oncology, 2017, 6, 389-396.	0.4	7
2386	Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncology Letters, 2017, 13, 984-992.	0.8	18
2387	Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nature Communications, 2017, 8, 14262.	5.8	260
2388	Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Advances in Therapy, 2017, 34, 1097-1108.	1.3	8
2389	Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. Journal of the American College of Surgeons, 2017, 225, 28-40.	0.2	24

#	Article	IF	Citations
2390	Chemotherapy for Leukemia. , 2017, , .		2
2391	The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 307-318.	2.2	26
2392	Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 42-48.	1.4	34
2393	PharmGKB summary. Pharmacogenetics and Genomics, 2017, 27, 240-246.	0.7	42
2394	Design, synthesis and biological activities of quinazoline containing sorafenib analogs as antitumor agents. Wuhan University Journal of Natural Sciences, 2017, 22, 239-246.	0.2	1
2395	Proliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine. Oncology Letters, 2017, 13, 1264-1268.	0.8	3
2396	A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncology Letters, 2017, 13, 2957-2964.	0.8	19
2397	Enterohepatic Circulation Effect in Physiologically Based Pharmacokinetic Models: The Sorafenib Case. Industrial & Engineering Chemistry Research, 2017, 56, 3156-3166.	1.8	12
2398	Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC. OncoImmunology, 2017, 6, e1299301.	2.1	24
2399	A case report of apatinib in treating osteosarcoma with pulmonary metastases. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	19
2400	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 56-66.	6.3	2,771
2401	Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. Clinical and Translational Gastroenterology, 2017, 8, e98.	1.3	83
2402	Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. Therapeutic Drug Monitoring, 2017, 39, 43-54.	1.0	70
2403	Carboxyamidotriazole Synergizes with Sorafenib to Combat Nonâ€“Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 219-229.	1.3	11
2404	A multifunctional nanocomplex for enhanced cell uptake, endosomal escape and improved cancer therapeutic effect. Nanomedicine, 2017, 12, 1401-1420.	1.7	15
2405	The tobacco cembranoid (1 S ,2 E ,4 S ,7 E ,11 E)-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitory lead for the control of breast malignancies. Bioorganic and Medicinal Chemistry, 2017, 25, 3911-3921.	1.4	17
2406	Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Thyroid, 2017, 27, 1142-1148.	2.4	67
2407	A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. Drugs in R and D, 2017, 17, 381-388.	1.1	12

#	Article	IF	Citations
2408	PPARÎ´ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC. Molecular Cancer Research, 2017, 15, 1230-1242.	1.5	58
2409	The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. Stem Cell Research and Therapy, 2017, 8, 119.	2.4	21
2410	Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance. Journal of Chemical Information and Modeling, 2017, 57, 1439-1452.	2.5	6
2411	Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biology and Therapy, 2017, 18, 433-438.	1.5	91
2412	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clinical Breast Cancer, 2017, 17, 585-594.e4.	1.1	39
2413	Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. International Journal of Oncology, 2017, 51, 128-144.	1.4	18
2414	Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model. CardioVascular and Interventional Radiology, 2017, 40, 1763-1768.	0.9	3
2415	Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. Oncology Reports, 2017, 37, 2071-2078.	1.2	47
2416	Using gene expression database to uncover biology functions of 1,4-disubstituted 1,2,3-triazole analogues synthesized via a copper (I)-catalyzed reaction. European Journal of Medicinal Chemistry, 2017, 132, 90-107.	2.6	19
2417	Incorporating VEGF-targeted therapy in advanced urothelial cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 33-45.	1.4	17
2418	Sorafenib for the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 621-630.	0.9	29
2419	Systemic Therapy for Advanced Metastatic Thyroid Cancer. , 2017, , 433-450.		0
2420	Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. Nanomedicine, 2017, 12, 911-925.	1.7	27
2421	Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. Oncology Reports, 2017, 37, 2270-2276.	1.2	11
2422	New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacologica Sinica, 2017, 38, 614-622.	2.8	475
2423	Sorafenib: A Review in Hepatocellular Carcinoma. Targeted Oncology, 2017, 12, 243-253.	1.7	224
2424	Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. RSC Advances, 2017, 7, 16253-16263.	1.7	8
2425	Albuminâ€Bilirubin grade predicts prognosis of HCC patients with sorafenib use. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1975-1981.	1.4	50

#	Article	IF	Citations
2426	Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models. Acta Radiologica, 2017, 58, 1045-1053.	0.5	14
2427	Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicology and Applied Pharmacology, 2017, 315, 90-101.	1.3	50
2428	Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. Biomedicine and Pharmacotherapy, 2017, 86, 27-31.	2.5	5
2429	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. Cancer Treatment Reviews, 2017, 53, 98-110.	3.4	101
2430	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine, 2017, 57, 539-543.	1.1	10
2431	Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease. European Respiratory Review, 2017, 26, 170061.	3.0	13
2432	Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenibâ€‘incorporating nanoparticles in vivo. Oncology Letters, 2017, 14, 6163-6169.	0.8	18
2433	The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis. Scientific Reports, 2017, 7, 12189.	1.6	30
2434	Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 428-443.	1.3	17
2435	Phosphorylated <scp>ERK</scp> is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Medicine, 2017, 6, 2787-2795.	1.3	29
2436	Design, synthesis, and anticancer properties of isocorydine derivatives. Bioorganic and Medicinal Chemistry, 2017, 25, 6542-6553.	1.4	15
2437	Long-term survival of sorafenib-treated FLT3-ITDâ€“positive acute myeloid leukaemia patients relapsingÂafter allogeneic stem cell transplantation. European Journal of Cancer, 2017, 86, 233-239.	1.3	59
2438	Second-line systemic therapy in metastatic renal-cell carcinoma: A review. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 640-646.	0.8	14
2439	Regorafenib as treatment for patients with advanced hepatocellular cancer. Future Oncology, 2017, 13, 2223-2232.	1.1	9
2440	Changes in tumor oxygen state after sorafenib therapy evaluated by 18F-fluoromisonidazole hypoxia imaging of renal cell carcinoma xenografts. Oncology Letters, 2017, 14, 2341-2346.	0.8	5
2441	Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in earlyâ€“intermediate stage hepatocellular carcinoma. Medicine (United States), 2017, 96, e7655.	0.4	16
2442	Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?. Cancer Chemotherapy and Pharmacology, 2017, 80, 661-671.	1.1	6
2443	A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. EBioMedicine, 2017, 22, 58-67.	2.7	115

#	Article	IF	Citations
2444	A firstâ€inâ€human phase I, multicenter, openâ€label, doseâ€escalation study of the oral RAF/VEGFRâ€2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. Cancer Medicine, 2017, 6, 1904-1914.	1.3	24
2445	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodineâ€refractory thyroid cancer. Cancer, 2017, 123, 4114-4121.	2.0	59
2446	Proâ€angiogenic TIEâ€2â€expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. International Journal of Cancer, 2017, 141, 1011-1017.	2.3	5
2447	New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. European Journal of Cancer, 2017, 83, 56-70.	1.3	82
2448	A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. Journal of Bone Oncology, 2017, 8, 4-7.	1.0	31
2449	Recent developments in small molecule therapies for renal cell carcinoma. European Journal of Medicinal Chemistry, 2017, 142, 383-392.	2.6	27
2450	Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases. Molecular and Clinical Oncology, 2017, 7, 281-284.	0.4	9
2451	Effect of sorafenib on des-Î³-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line. Oncology Letters, 2017, 14, 2170-2176.	0.8	2
2452	Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer, 2017, 6, 275-286.	4.2	48
2454	Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clinical and Translational Immunology, 2017, 6, e161.	1.7	51
2455	Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma. International Journal of Pharmacokinetics, 2017, 2, 257-283.	0.5	1
2457	Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report. Oncology Letters, 2017, 14, 4853-4856.	0.8	6
2458	Association of the rs2071559 (T/C) polymorphism with lymphatic metastasis in patients with nasopharyngeal carcinoma. Oncology Letters, 2017, 14, 7681-7686.	0.8	5
2459	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer, 2017, 123, 3977-3985.	2.0	22
2460	High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease. SLAS Discovery, 2017, 22, 974-984.	1.4	40
2461	Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, 1043-1049.	0.4	22
2462	Sorafenib controls the epithelial-mesenchymal transition of ovarian cancer cells via EGF and the CD44-HA signaling pathway in a cell type-dependent manner. Molecular Medicine Reports, 2017, 16, 1826-1836.	1.1	16
2463	Sorafenib in Patients with Hepatocellular Carcinomaâ€"Results of the Observational INSIGHT Study. Clinical Cancer Research, 2017, 23, 5720-5728.	3.2	67

#	Article	IF	Citations
2464	Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1â€“Parkin pathway and modulate cellular drug response. Journal of Biological Chemistry, 2017, 292, 15105-15120.	1.6	70
2466	Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. BMC Gastroenterology, 2017, 17, 30.	0.8	2
2467	FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Journal of Experimental and Clinical Cancer Research, 2017, 36, 8.	3.5	124
2468	Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen. Immunotherapy, 2017, 9, 629-635.	1.0	7
2469	A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. Journal of Neuro-Oncology, 2017, 133, 435-442.	1.4	9
2470	New vaccination strategies in liver cancer. Cytokine and Growth Factor Reviews, 2017, 36, 125-129.	3.2	20
2471	Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death and Disease, 2017, 8, e2904-e2904.	2.7	69
2472	Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. Oncogene, 2017, 36, 1965-1977.	2.6	107
2473	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0
2474	Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 2017, 43, 581-593.	0.5	45
2475	Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer. Cancer Letters, 2017, 385, 108-116.	3.2	15
2476	Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 516-527.	0.6	1
2477	Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Targeted Oncology, 2017, 12, 89-95.	1.7	15
2478	Sorafenib with ASC-J9^{Â®}synergistically suppresses the HCC progressionviaaltering the pSTAT3-CCL2/Bcl2 signals. International Journal of Cancer, 2017, 140, 705-717.	2.3	25
2479	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Therapeutic Advances in Medical Oncology, 2017, 9, 106-126.	1.4	36
2480	Determination of A Novel Selective B-RafV600E Inhibitor (LXK4) in Dog Plasma by HPLCâ€“MS/MS and its Application in a Pharmacokinetic Study. Chromatographia, 2017, 80, 71-76.	0.7	0
2481	Search for Inhibitors of Ras-Driven Cancers. , 2017, , 135-154.		1
2482	Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration. Molecular Medicine Reports, 2017, 15, 941-947.	1.1	9

#	Article	IF	Citations
2483	Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. Oncology Reports, 2017, 39, 843-850.	1.2	27
2484	Consequences of Keratin Phosphorylation for Cytoskeletal Organization and Epithelial Functions. International Review of Cell and Molecular Biology, 2017, 330, 171-225.	1.6	36
2485	Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 135-146.	0.9	96
2486	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology, 2017, , .	0.8	9
2487	Clinical effects and safety of intraâ€'arterial infusion therapy of cisplatin suspension in lipiodol combined with 5â€'fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extraâ€'hepatic spread: A prospective cohort study. Molecular and Clinical Oncology, 2017, 7, 1013-1020.	0.4	27
2488	Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. Advances in Experimental Medicine and Biology, 2017, 1036, 191-211.	0.8	17
2489	Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell and Bioscience, 2017, 7, 71.	2.1	22
2490	Adult Stem Cells in the Pathogenesis and Treatment of Endometriosis. Journal of Endometriosis and Pelvic Pain Disorders, 2017, 9, 223-231.	0.3	6
2491	Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. Oncotarget, 2017, 8, 8035-8042.	0.8	50
2492	Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. Cureus, 2017, 9, e1258.	0.2	6
2493	Cancer Stem Cells and Aldehyde Dehydrogenase 1 in Liver Cancers. , 2017, , .		2
2494	Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects. International Journal of Nanomedicine, 2017, Volume 12, 1941-1958.	3.3	82
2495	Down-Regulation of TGF-Î² Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Yonsei Medical Journal, 2017, 58, 899.	0.9	18
2496	Advances in systemic therapy for hepatocellular carcinoma. , 2017, , 1502-1513.e4.		0
2497	Intracellularly Swollen Polypeptide Nanogel Assists Hepatoma Chemotherapy. Theranostics, 2017, 7, 703-716.	4.6	47
2498	Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. OncoTargets and Therapy, 2017, Volume 10, 2761-2768.	1.0	25
2499	Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. International Journal of Molecular Sciences, 2017, 18, 1937.	1.8	15
2500	A Novel Anti-Hepatitis C Virus and Antiproliferative Agent Alters Metabolic Networks in HepG2 and Hep3B Cells. Metabolites, 2017, 7, 23.	1.3	9

#	Article	IF	Citations
2501	Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies. Molecules, 2017, 22, 542.	1.7	7
2502	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Research and Treatment, 2017, 49, 851-868.	1.3	50
2503	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Frontiers in Cell and Developmental Biology, 2017, 5, 101.	1.8	65
2504	Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences, 2017, 18, 461.	1.8	61
2506	Binding kinetics in drug discovery ndash A current perspective. Frontiers in Bioscience - Landmark, 2017, 22, 21-47.	3.0	8
2507	Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics, 2017, 7, 400-412.	4.6	71
2508	The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*. Wspolczesna Onkologia, 2017, 21, 285-289.	0.7	10
2509	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. Journal of Cancer, 2017, 8, 730-736.	1.2	1
2510	Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. Therapeutics and Clinical Risk Management, 2017, Volume 13, 799-806.	0.9	21
2511	DNA Tetrahedron Delivery Enhances Doxorubicin-Induced Apoptosis of HT-29 Colon Cancer Cells. Nanoscale Research Letters, 2017, 12, 495.	3.1	40
2512	Advanced hepatocellular carcinoma with remarkable response to sorafenib dose increment: A case report. Acta Hepatologica Japonica, 2017, 58, 619-625.	0.0	1
2513	Novel multiâ€'kinase inhibitor, T03 inhibits Taxolâ€'resistant breast cancer. Molecular Medicine Reports, 2017, 17, 2373-2383.	1.1	0
2514	Kinase Inhibitors in Multitargeted Cancer Therapy. Current Medicinal Chemistry, 2017, 24, 1671-1686.	1.2	33
2515	Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2017, 47, 1175-1181.	0.6	17
2516	The Role of Novel 3d-Copper Cyanide Supramolecular Coordination Polymer in Epithelial Mesenchymal Transition Inhibition in Hepatocellular Carcinoma. Biochemistry & Pharmacology: Open Access, 2017, 06, .	0.2	0
2517	Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma. Journal of Cancer, 2017, 8, 1988-1994.	1.2	12
2518	Chemotherapy for hepatocellular carcinoma: The present and the future. World Journal of Hepatology, 2017, 9, 907.	0.8	142
2519	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2801-2811.	2.0	54

#	Article	IF	Citations
2520	Locoregional and systemic therapy for hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 215-228.	0.6	64
2521	Pediatric hepatocellular carcinoma: challenges and solutions. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 15-21.	1.8	49
2522	Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget, 2017, 8, 42252-42261.	0.8	54
2523	Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget, 2017, 8, 30742-30755.	0.8	24
2524	Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget, 2017, 8, 107096-107108.	0.8	54
2525	Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovascular Diagnosis and Therapy, 2017, 7, S165-S177.	0.7	129
2526	The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget, 2017, 8, 57707-57722.	0.8	124
2527	Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment. Urologia Internationalis, 2018, 100, 357-360.	0.6	9
2528	Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents. Bioorganic Chemistry, 2018, 77, 370-380.	2.0	29
2529	ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. , 2018, 187, 45-60.		123
2530	Current Insights of BRAF Inhibitors in Cancer. Journal of Medicinal Chemistry, 2018, 61, 5775-5793.	2.9	76
2531	Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. Cellular Oncology (Dordrecht), 2018, 41, 283-296.	2.1	16
2532	The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA Journal, 2018, 9, 77-102.	3.3	184
2533	Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 81, 727-737.	1.1	2
2534	Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatology Research, 2018, 48, 597-607.	1.8	58
2535	Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Letters, 2018, 425, 101-115.	3.2	24
2536	Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepatic Oncology, 2018, 5, HEP01.	4.2	30
2537	Mitogenic activity of Artocarpus lingnanensis lectin and its apoptosis induction in Jurkat T cells. Journal of Natural Medicines, 2018, 72, 745-756.	1.1	5

#	Article	IF	Citations
2538	Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. Journal of Gastrointestinal Cancer, 2018, 49, 107-115.	0.6	27
2540	Current state and prospects of nano-delivery systems for sorafenib. International Journal of Polymeric Materials and Polymeric Biomaterials, 2018, 67, 1105-1115.	1.8	22
2541	Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles. Biomaterials Science, 2018, 6, 893-900.	2.6	19
2542	Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. Future Medicinal Chemistry, 2018, 10, 823-835.	1.1	17
2543	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. Cell Death and Disease, 2018, 9, 112.	2.7	94
2544	Cell death-based treatment of lung adenocarcinoma. Cell Death and Disease, 2018, 9, 117.	2.7	434
2545	MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components. Prostate, 2018, 78, 343-352.	1.2	11
2546	Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib. Scientific Reports, 2018, 8, 2238.	1.6	13
2547	Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication. Gut, 2018, 67, 1206-1207.	6.1	9
2548	A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nature Chemical Biology, 2018, 14, 291-298.	3.9	56
2549	Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut, 2018, 67, 1328-1341.	6.1	77
2550	Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFÎ²1/Smad3 pathway. Digestive and Liver Disease, 2018, 50, 381-388.	0.4	17
2551	A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs. EBioMedicine, 2018, 27, 225-236.	2.7	81
2552	PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 557-567.	1.7	57
2553	Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?. Journal of Medicinal Chemistry, 2018, 61, 5073-5092.	2.9	79
2555	Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Neoplasia, 2018, 20, 197-206.	2.3	34
2556	Immune Regulation in HCC and the Prospect of Immunotherapy. Molecular Pathology Library, 2018, , 175-194.	0.1	0
2557	Sorafenib-Induced Acute Pancreatitis in a Patient with Differentiated Thyroid Cancer. European Thyroid Journal, 2018, 7, 145-148.	1.2	6

#	Article	IF	Citations
2558	Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence. Liver Transplantation, 2018, 24, 932-945.	1.3	23
2559	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer, 2018, 18, 307.	1.1	18
2560	Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer. Oncogene, 2018, 37, 4443-4454.	2.6	12
2561	Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma. Life Sciences, 2018, 206, 10-21.	2.0	25
2562	Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. Molecular Medicine Reports, 2018, 17, 8101-8110.	1.1	7
2563	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Neoplasia, 2018, 20, 467-477.	2.3	13
2564	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene, 2018, 37, 3183-3199.	2.6	317
2565	Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. European Journal of Cancer, 2018, 94, 87-94.	1.3	31
2566	Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells. Oncology Letters, 2018, 15, 5620-5626.	0.8	10
2567	Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. Seminars in Oncology, 2018, 45, 116-123.	0.8	9
2568	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
2569	Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. Carcinogenesis, 2018, 39, 681-688.	1.3	37
2570	Serum HMGB1 concentrations at 4Âweeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. Journal of Gastroenterology, 2018, 53, 107-118.	2.3	17
2571	Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment. Cell Adhesion and Migration, 2018, 12, 19-27.	1.1	13
2572	Cysteine-based 3-substituted 1,5-benzoxathiepin derivatives: Two new classes of anti-proliferative agents. Arabian Journal of Chemistry, 2018, 11, 426-441.	2.3	7
2573	Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation. Platelets, 2018, 29, 277-287.	1.1	8
2574	Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging. European Radiology, 2018, 28, 372-381.	2.3	13
2575	Precision diagnosis and treatment of liver cancer in China. Cancer Letters, 2018, 412, 283-288.	3.2	226

#	Article	IF	Citations
2576	Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks. Hepatology Research, 2018, 48, 5-14.	1.8	26
2577	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology, 2018, 136, 79-86.	1.4	21
2578	Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Letters, 2018, 413, 82-93.	3.2	23
2579	Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. Cellular Oncology (Dordrecht), 2018, 41, 85-91.	2.1	22
2580	Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up. Acta Radiologica, 2018, 59, 765-772.	0.5	9
2581	Design, synthesis and biological evaluation of phenylpicolinamide sorafenib derivatives as antitumor agents. Medicinal Chemistry Research, 2018, 27, 374-387.	1.1	3
2582	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Investigational New Drugs, 2018, 36, 332-339.	1.2	52
2583	Synthesis and bioevaluation study of novel N -methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 245-256.	1.4	18
2584	Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutationâ€“Positive Acute Myeloid Leukemia. Annals of Pharmacotherapy, 2018, 52, 364-369.	0.9	4
2585	Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08). European Journal of Cancer, 2018, 89, 82-89.	1.3	16
2586	Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling. Acta Pharmacologica Sinica, 2018, 39, 438-448.	2.8	38
2587	Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clinical Cancer Research, 2018, 24, 1090-1102.	3.2	16
2588	Current and future therapeutic approaches for osteosarcoma. Expert Review of Anticancer Therapy, 2018, 18, 39-50.	1.1	539
2589	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget, 2018, 9, 16701-16717.	0.8	44
2590	Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals. International Journal of Molecular Medicine, 2018, 41, 2893-2900.	1.8	9
2591	Antiâ€cancer effects of a novel Panâ€RAF inhibitor in a hepatocellular carcinoma cell line. Molecular Medicine Reports, 2018, 17, 6185-6193.	1.1	5
2592	Ultrafast monolithic HPLC method for simultaneous quantification of the anticancer agents, imatinib and sorafenib: Application to tablet dosage forms. Tropical Journal of Pharmaceutical Research, 2018, 17, 1127.	0.2	6
2593	Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway. Pharmaceutical Biology, 2018, 56, 665-671.	1.3	47

#	Article	IF	Citations
2594	Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital. Journal of Gastrointestinal Oncology, 2018, 9, 833-839.	0.6	4
2595	Exceptional Response to Cabozantinib in a Patient With Multiply Relapsed Wilms Tumor. JCO Precision Oncology, 2018, 2, 1-5.	1.5	4
2596	Impressive Response of Advanced Hepatocellular Carcinoma to Cisplatin Combined with Sorafenib, Nivolumab, and PG2 Immunomodulatory Injection: A Case Report. Journal of Clinical Case Reports, 2018, 08, .	0.0	1
2597	Omegaâ€3 and omegaâ€3/curcuminâ€enriched fruit juices decrease tumour growth and reduce muscle wasting in tumourâ€bearing mice. JCSM Rapid Communications, 2018, 1, 1-10.	0.6	5
2598	Evaluating Uncertainty in Signaling Networks Using Logical Modeling. Frontiers in Physiology, 2018, 9, 1335.	1.3	6
2599	Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy. International Journal of Molecular Sciences, 2018, 19, 3684.	1.8	44
2600	A Low-Cost Flash Photographic System for Visualization of Droplets in Drop-on-Demand Inkjet. Journal of Imaging Science and Technology, 2018, 62, 060502-1-060502-9.	0.3	3
2601	Manipulating Eryptosis of Human Red Blood Cells: A Novel Antimalarial Strategy?. Frontiers in Cellular and Infection Microbiology, 2018, 8, 419.	1.8	47
2602	Current and emerging therapies for corneal neovascularization. Ocular Surface, 2018, 16, 398-414.	2.2	124
2603	Runs of homozygosity associate with decreased risks of lung cancer in never-smoking East Asian females. Journal of Cancer, 2018, 9, 3858-3866.	1.2	1
2604	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Frontiers in Pharmacology, 2018, 9, 1300.	1.6	602
2605	Remission of psoriasis during treatment with sorafenib. JAAD Case Reports, 2018, 4, 1065-1067.	0.4	10
2606	SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer. BMC Cancer, 2018, 18, 956.	1.1	22
2607	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
2608	Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. Cancer Biology and Therapy, 2018, 19, 1057-1064.	1.5	15
2609	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. Journal of Cancer, 2018, 9, 3394-3399.	1.2	5
2610	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Seminars in Liver Disease, 2018, 38, 379-388.	1.8	62
2611	Recent Advances in Herbal Medicines for Digestive System Malignancies. Frontiers in Pharmacology, 2018, 9, 1249.	1.6	10

#	Article	IF	Citations
2612	Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers, 2018, 10, 412.	1.7	138
2613	Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 1941-1948.	0.9	17
2614	Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences, 2018, 19, 3234.	1.8	13
2615	Establishment of a novel patient-derived Ewingâ€™s sarcoma cell line, NCC-ES1-C1. In Vitro Cellular and Developmental Biology - Animal, 2018, 54, 770-778.	0.7	5
2616	SUSTAINED RELEASE TABLETS OF SORAFENIB-SILIBININ COMBINATIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA. International Journal of Applied Pharmaceutics, 2018, 10, 117.	0.3	7
2617	Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell International, 2018, 18, 133.	1.8	28
2618	Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Scientific Reports, 2018, 8, 12914.	1.6	14
2619	The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. Internal Medicine, 2018, 57, 1345-1353.	0.3	29
2620	Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains. Integrative Biology (United Kingdom), 2018, 10, 646-657.	0.6	10
2621	Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environmental Toxicology, 2018, 33, 1237-1244.	2.1	19
2622	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. International Journal of Molecular Medicine, 2018, 42, 2551-2559.	1.8	12
2623	Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2018, 17, 2610-2621.	1.9	18
2624	Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochemical and Biophysical Research Communications, 2018, 504, 878-884.	1.0	10
2625	Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 382-394.	0.7	2
2626	Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials. OncoTargets and Therapy, 2018, Volume 11, 5195-5201.	1.0	7
2627	Structure-based optimization of tyrosine kinase inhibitors: a molecular docking study. Network Modeling Analysis in Health Informatics and Bioinformatics, 2018, 7, 1.	1.2	5
2628	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1090, 43-51.	1.2	16
2629	Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2018, 155, 210-228.	2.6	32

#	Article	IF	Citations
2630	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	3.4	124
2631	Autophagy activation contributes to glutathione transferase Mu 1â€‘mediated chemoresistance in hepatocellular carcinoma. Oncology Letters, 2018, 16, 346-352.	0.8	12
2632	Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas. , 2018, , 323-332.		4
2633	Cellular and viral oncogenes: the key to unlocking unknowns of Kaposiâ€™s sarcoma-associated herpesvirus pathogenesis. Archives of Virology, 2018, 163, 2633-2643.	0.9	15
2634	Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-Î²/STAT3 Pathway. Cellular Physiology and Biochemistry, 2018, 47, 1751-1768.	1.1	26
2635	Drug Class Analysis. , 2018, , 441-511.		1
2636	Modelling signalling networks from perturbation data. Bioinformatics, 2018, 34, 4079-4086.	1.8	25
2637	Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. PLoS ONE, 2018, 13, e0200878.	1.1	26
2638	Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases. Annals of Hepato-biliary-pancreatic Surgery, 2018, 22, 136.	0.1	6
2639	Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?. Cancer Management and Research, 2018, Volume 10, 425-437.	0.9	47
2640	MicroRNA-129-5p Regulates Glycolysis and Cell Proliferation by Targeting the Glucose Transporter SLC2A3 in Gastric Cancer Cells. Frontiers in Pharmacology, 2018, 9, 502.	1.6	59
2641	DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer. Oncology Reports, 2018, 40, 1203-1222.	1.2	46
2642	Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. OncoTargets and Therapy, 2018, Volume 11, 3407-3413.	1.0	21
2643	Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells. Oncology Letters, 2018, 15, 5081-5086.	0.8	3
2644	Targeting FLT3 Mutations in Acute Myeloid Leukemia. Cells, 2018, 7, 4.	1.8	28
2645	Platelet-Derived Growth Factor Receptor (PDGF-R) as the Target for Herbal-Based Anticancer Agents. , 2018, , 411-427.		0
2646	Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. International Journal of Molecular Sciences, 2018, 19, 739.	1.8	44
2647	Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. Cell Systems, 2018, 7, 161-179.e14.	2.9	53

#	Article	IF	Citations
2648	Sequenceâ€'dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action. International Journal of Molecular Medicine, 2018, 42, 1695-1715.	1.8	26
2649	Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses. Antiviral Research, 2018, 157, 57-67.	1.9	38
2650	Sorafenib Combined with 5â€azacytidine in Older Patients with Untreated FLT3â€ITD Mutated Acute Myeloid Leukemia. American Journal of Hematology, 2018, 93, 1136-1141.	2.0	95
2651	Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response. British Journal of Cancer, 2018, 119, 450-461.	2.9	15
2652	Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Medicine, 2018, 7, 2641-2653.	1.3	163
2653	Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery. Nanoscale Research Letters, 2018, 13, 17.	3.1	32
2654	Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Research Notes, 2018, 11, 21.	0.6	38
2655	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 2018, 135, 239-258.	3.1	154
2656	The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. Current Cancer Drug Targets, 2018, 18, 430-441.	0.8	1
2657	Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment. Journal of Cancer, 2018, 9, 2408-2414.	1.2	6
2658	Successful treatment using apatinib in intractable brain edema: A case report and literatures review. Cancer Biology and Therapy, 2018, 19, 1093-1096.	1.5	14
2659	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2018, 19, 1247-1258.	5.1	79
2660	Inï¿½vivo acquired sorafenibâ€'resistant patientâ€'derived tumor model displays alternative angiogenic pathways, multiâ€'drug resistance and chromosome instability. Oncology Letters, 2018, 16, 3439-3446.	0.8	5
2661	The Stem Cells in Liver Cancers and the Controversies. , 2018, , 273-287.		0
2662	New (Medical) Treatment for Thyroid Carcinoma. Endocrinology, 2018, , 645-670.	0.1	0
2663	Selective targeting of antiapoptotic BCLâ€2 proteins in cancer. Medicinal Research Reviews, 2019, 39, 146-175.	5.0	53
2664	Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. Journal of Cellular Physiology, 2019, 234, 692-708.	2.0	45
2665	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2019, 54, 519-530.	1.3	54

#	Article	IF	Citations
2666	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	6.1	195
2667	FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer. Molecular Cancer Therapeutics, 2019, 18, 2194-2206.	1.9	65
2668	Prevention Strategies for Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 255-289.	0.4	2
2669	Neuroblastoma rat sarcoma mutated melanoma: Thatâ€™s what we got so far. Pigment Cell and Melanoma Research, 2019, 32, 744-752.	1.5	4
2670	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. Journal of Cancer, 2019, 10, 3914-3925.	1.2	27
2671	New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers, 2019, 11, 1086.	1.7	41
2673	Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. Journal of Clinical and Experimental Hepatology, 2019, 9, 588-596.	0.4	43
2674	Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. Targeted Oncology, 2019, 14, 541-550.	1.7	18
2675	Spectroscopic, quantum chemical, molecular docking and inÂvitro anticancer activity studies on 5-Methoxyindole-3-carboxaldehyde. Journal of Molecular Structure, 2019, 1197, 134-146.	1.8	38
2676	Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers, 2019, 11, 861.	1.7	25
2677	Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2019, 141, 125-138.	2.0	36
2678	Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. European Journal of Medicinal Chemistry, 2019, 179, 916-935.	2.6	42
2679	Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity. Internal Medicine, 2019, 58, 2803-2808.	0.3	2
2680	Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma. Molecules, 2019, 24, 2350.	1.7	29
2681	Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). OncoImmunology, 2019, 8, 1615817.	2.1	85
2682	Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea. Frontiers in Endocrinology, 2019, 10, 384.	1.5	28
2683	Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Frontiers in Oncology, 2019, 9, 345.	1.3	10
2684	Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors. Current Fungal Infection Reports, 2019, 13, 86-98.	0.9	34

#	Article	IF	Citations
2685	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinomaâ€"Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers, 2019, 11, 1517.	1.7	30
2686	The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma . OncoTargets and Therapy, 2019, Volume 12, 8217-8227.	1.0	16
2687	Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 151-166.	1.8	25
2688	Not the comfy chair! Cancer drugs that act against multiple active sites. Expert Opinion on Therapeutic Targets, 2019, 23, 893-901.	1.5	15
2689	Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells. International Journal of Pharmaceutics, 2019, 572, 118782.	2.6	115
2690	Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinomaï¼šA Propensity Score Matching Analysis . Cancer Management and Research, 2019, Volume 11, 9321-9330.	0.9	19
2691	Preparation and evaluation of folate-decorated human serum albumin nanoparticles for the targeted delivery of sorafenib to enhance antihepatocarcinoma efficacy. Journal of Drug Delivery Science and Technology, 2019, 54, 101349.	1.4	6
2692	Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo. Anticancer Research, 2019, 39, 5973-5982.	0.5	35
2693	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. Thyroid, 2019, 29, 1820-1827.	2.4	15
2694	The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Review of Anticancer Therapy, 2019, 19, 971-991.	1.1	31
2695	Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion. Frontiers in Oncology, 2019, 9, 1065.	1.3	18
2696	Identification of Hepatocellular Carcinoma-Related Potential Genes and Pathways Through Bioinformatic-Based Analyses. Genetic Testing and Molecular Biomarkers, 2019, 23, 766-777.	0.3	19
2697	Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Journal of Cancer, 2019, 10, 4671-4678.	1.2	7
2698	Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Review of Clinical Pharmacology, 2019, 12, 1121-1127.	1.3	24
2699	The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Molecular Cancer, 2019, 18, 147.	7.9	249
2700	The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 5266.	1.8	39
2701	Variational approach to Arnold diffusion. Science China Mathematics, 2019, 62, 2103-2130.	0.8	2
2702	Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control, 2019, 26, 107327481987221.	0.7	17

#	Article	IF	Citations
2703	A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo, 2019, 33, 1411-1420.	0.6	45
2704	Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma. British Journal of Cancer, 2019, 121, 567-577.	2.9	6
2705	Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer . Cancer Management and Research, 2019, Volume 11, 7787-7803.	0.9	33
2706	Design, synthesis, in vitro potent antiproliferative activity, and kinase inhibitory effects of new triarylpyrazole derivatives possessing different heterocycle terminal moieties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1534-1543.	2.5	7
2707	A new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy. Translational Andrology and Urology, 2019, 8, 339-345.	0.6	2
2708	JCPyV-Induced MAPK Signaling Activates Transcription Factors during Infection. International Journal of Molecular Sciences, 2019, 20, 4779.	1.8	14
2709	Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 4728.	1.8	15
2710	Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status. International Journal of Oncology, 2019, 55, 1069-1076.	1.4	14
2711	Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. Genes, 2019, 10, 709.	1.0	71
2712	Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. Neoplasia, 2019, 21, 257-268.	2.3	37
2713	Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Rasâ€“ERK Pathway Activation in Hypoxia. Molecular Cancer Research, 2019, 17, 1220-1232.	1.5	22
2714	Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib. Anticancer Research, 2019, 39, 695-701.	0.5	8
2715	<scp>TARBP</scp>2â€mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Molecular Oncology, 2019, 13, 928-945.	2.1	24
2717	Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. European Journal of Medicinal Chemistry, 2019, 179, 707-722.	2.6	36
2719	Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility. Cancers, 2019, 11, 787.	1.7	8
2720	Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	2.0	32
2721	Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Letters, 2019, 460, 1-9.	3.2	156
2722	Sorafenib kills liver cancer cells by disrupting SCD1â€mediated synthesis of monounsaturated fatty acidsviathe ATPâ€AMPKâ€mTORâ€SREBP1 signaling pathway. FASEB Journal, 2019, 33, 10089-10103.	0.2	78

#	Article	IF	Citations
2723	Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study. Internal Medicine, 2019, 58, 1835-1844.	0.3	12
2724	Antiâ€angiogenic therapies for gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 208-217.	0.7	31
2725	Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Molecular Therapy, 2019, 27, 1483-1494.	3.7	100
2726	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 248-260.	1.8	8
2727	Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers, 2019, 11, 681.	1.7	33
2728	Promotion of growth factor signaling as a critical function of Î²-catenin during HCC progression. Nature Communications, 2019, 10, 1909.	5.8	75
2729	Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma. Cancer Investigation, 2019, 37, 185-198.	0.6	14
2730	Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles. Cancers, 2019, 11, 571.	1.7	25
2731	Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer. Cancers, 2019, 11, 574.	1.7	8
2732	Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid. Journal of Pharmacy and Pharmacology, 2019, 71, 1119-1132.	1.2	12
2733	The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression. Cancers, 2019, 11, 398.	1.7	8
2734	Treatment Strategies for Hepatocellular Carcinoma â€“ a Multidisciplinary Approach. International Journal of Molecular Sciences, 2019, 20, 1465.	1.8	158
2735	Expression of total and phospho 4EBP1 in metastatic and nonâ€'metastatic renal cell carcinoma. Oncology Letters, 2019, 17, 3910-3918.	0.8	2
2736	Synthesis and biological evaluation of phenyl-amino-pyrimidine and indole/oxindole conjugates as potential BCR-ABL inhibitors. Medicinal Chemistry Research, 2019, 28, 633-645.	1.1	6
2737	Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans. Current Treatment Options in Oncology, 2019, 20, 29.	1.3	25
2738	Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology. Anticancer Research, 2019, 39, 2183-2191.	0.5	6
2739	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chemico-Biological Interactions, 2019, 306, 1-9.	1.7	15
2740	Autophagy inhibition overcomes sorafenib resistance in S45Fâ€mutated desmoid tumors. Cancer, 2019, 125, 2693-2703.	2.0	21

#	Article	IF	Citations
2741	Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors. , 2019, , 169-185.		1
2742	RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. Journal of Cellular Physiology, 2019, 234, 14951-14965.	2.0	188
2743	Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1-a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links. Journal of Medicinal Chemistry, 2019, 62, 2404-2418.	2.9	21
2744	Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation. Cellular Oncology (Dordrecht), 2019, 42, 369-380.	2.1	12
2745	Sorafenib. Profiles of Drug Substances, Excipients and Related Methodology, 2019, 44, 239-266.	3.5	82
2746	Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion on Investigational Drugs, 2019, 28, 351-363.	1.9	14
2747	Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Reports, 2019, 12, e227625.	0.2	2
2748	Expanding the Surgical Pool for Hepatic Resection to Treat Biliary and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 763-782.	0.6	1
2749	Autophagy Machinery as a Promising Therapeutic Target in Endometrial Cancer. Frontiers in Oncology, 2019, 9, 1326.	1.3	27
2750	Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma. Scientific Reports, 2019, 9, 17259.	1.6	23
2751	Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study. Journal of Computer Assisted Tomography, 2019, 43, 499-506.	0.5	2
2752	Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma. Anti-Cancer Drugs, 2019, 30, 425-427.	0.7	3
2753	Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2019, 31, 1250-1255.	0.8	20
2754	A new model for assessing the impact of cloud computing on customer retention. International Journal of Electronic Customer Relationship Management, 2019, 12, 124.	0.1	0
2755	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 61.	7.1	436
2756	Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 649-654.	0.6	21
2757	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. Oncologist, 2019, 24, 857-863.	1.9	15
2758	Localization dynamics of endogenous fluorescently labeled RAF1 in EGF-stimulated cells. Molecular Biology of the Cell, 2019, 30, 506-523.	0.9	12

#	Article	IF	Citations
2759	Peptideâ€Coated Platinum Nanoparticles with Selective Toxicity against Liver Cancer Cells. Angewandte Chemie, 2019, 131, 4955-4959.	1.6	2
2760	Peptideâ€Coated Platinum Nanoparticles with Selective Toxicity against Liver Cancer Cells. Angewandte Chemie - International Edition, 2019, 58, 4901-4905.	7.2	64
2761	KIT as a therapeutic target for non-oncological diseases. , 2019, 197, 11-37.		14
2762	Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2019, 62, 875-892.	2.9	20
2763	Sorafenib: key lessons from over 10 years of experience. Expert Review of Anticancer Therapy, 2019, 19, 177-189.	1.1	72
2764	Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 42-47.	0.6	25
2765	TKIs in Renal Cell Carcinoma. , 2019, , 551-563.		0
2766	Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Current Treatment Options in Oncology, 2019, 20, 3.	1.3	26
2767	Therapeutic Targets for Bone and Soft-Tissue Sarcomas. International Journal of Molecular Sciences, 2019, 20, 170.	1.8	52
2768	Identification of Functional MKK3/6 and MEK1/2 Homologs from Echinococcus granulosus and Investigation of Protoscolecidal Activity of Mitogen-Activated Protein Kinase Signaling Pathway Inhibitors In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	25
2769	Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Research, 2019, 79, 231-241.	0.4	24
2770	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	3.2	390
2771	Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature. Clinical Journal of Gastroenterology, 2019, 12, 128-134.	0.4	12
2772	Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation. Pediatric Blood and Cancer, 2019, 66, e27493.	0.8	7
2773	Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERÎ± and VEGFR-2. European Journal of Medicinal Chemistry, 2019, 161, 445-455.	2.6	22
2774	Prediction of sorafenib treatmentâ€"related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation. European Radiology, 2019, 29, 2272-2282.	2.3	14
2775	Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. Hepatology, 2019, 70, 824-839.	3.6	62
2776	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 110-119.	5.1	238

#	Article	IF	Citations
2777	Improvement of physicochemical properties of nanocolloidal carrier loaded with low water solubility drug for parenteral cancer treatment by Response Surface Methodology. Materials Science and Engineering C, 2019, 94, 841-849.	3.8	11
2778	Systemic therapy of metastatic renal cell carcinoma: Review of the current literature. Urologia, 2019, 86, 3-8.	0.3	12
2779	Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature. Journal of Gastrointestinal Cancer, 2019, 50, 137-142.	0.6	5
2780	Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. Acta Clinica Belgica, 2020, 75, 362-369.	0.5	3
2781	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Investigational New Drugs, 2020, 38, 172-180.	1.2	57
2782	Dermatologic Toxicities of Anticancer Therapy. , 2020, , 621-648.e5.		3
2783	Cancer of the Kidney. , 2020, , 1361-1381.e4.		0
2784	Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/Î²-catenin-driven hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 104-118.	1.8	88
2785	LC-ESI-QTOF-MS analysis utilizing gas-phase fragmentation reactions subjected to ESI-IS-CID and ESI-CID-MS/MS conditions to study the degradation behaviour of sorafenib tosylate: NMR and in vitro cytotoxicity and apoptosis detection studies of hydrolytic degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2020, 177, 112881.	1.4	8
2786	Activation of extracellular signalâ€regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. Hepatology Research, 2020, 50, 353-364.	1.8	9
2787	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 300-306.	2.0	36
2788	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
2789	Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. International Journal of Pharmaceutics, 2020, 573, 118785.	2.6	21
2790	Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells. Biochemical Pharmacology, 2020, 171, 113680.	2.0	57
2791	Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma. DNA and Cell Biology, 2020, 39, 355-367.	0.9	13
2792	Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Frontiers of Medicine, 2020, 14, 273-283.	1.5	9
2793	Prevention of relapse after allogeneic stem cell transplantation in acute myeloid leukemia: Updates and challenges. Advances in Cell and Gene Therapy, 2020, 3, e77.	0.6	3
2794	Molecular targeted study in tumors: From western medicine to active ingredients of traditional Chinese medicine. Biomedicine and Pharmacotherapy, 2020, 121, 109624.	2.5	18

#	Article	IF	Citations
2795	Investigating the antiangiogenic potential of Rumex vesicarius (humeidh), anticancer activity in cancer cell lines and assessment of developmental toxicity in zebrafish embryos. Saudi Journal of Biological Sciences, 2020, 27, 611-622.	1.8	11
2796	Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma. Biomacromolecules, 2020, 21, 716-724.	2.6	20
2797	Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. Journal of Cancer Research and Clinical Oncology, 2020, 146, 711-720.	1.2	15
2798	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer, 2020, 9, 148-155.	4.2	27
2799	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 755-769.	1.0	9
2800	Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 547-554.	0.6	5
2801	The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution . Drug Design, Development and Therapy, 2020, Volume 14, 3941-3950.	2.0	6
2802	Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1712-1726.	2.5	17
2803	Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?. Frontiers in Oncology, 2020, 10, 1642.	1.3	52
2804	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. Drug Metabolism and Disposition, 2020, 48, 1257-1263.	1.7	16
2805	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers, 2020, 12, 2961.	1.7	8
2806	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 719-737.	1.0	29
2807	Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Annals of Oncology, 2020, 31, 1169-1177.	0.6	70
2808	Preparation and characterization of sorafenib-loaded microprecipitated bulk powder for enhancing oral bioavailability. International Journal of Pharmaceutics, 2020, 589, 119836.	2.6	10
2810	Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy. Asian Journal of Pharmaceutical Sciences, 2020, 16, 318-336.	4.3	23
2811	Natural products and other inhibitors of F1FO ATP synthase. European Journal of Medicinal Chemistry, 2020, 207, 112779.	2.6	22
2812	Targeting the HIF2â€“VEGF axis in renal cell carcinoma. Nature Medicine, 2020, 26, 1519-1530.	15.2	248
2813	Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy. , 2020, , .		2

#	Article	IF	Citations
2814	Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2020, 63, 12403-12428.	2.9	48
2815	KRAS: From undruggable to a druggable Cancer Target. Cancer Treatment Reviews, 2020, 89, 102070.	3.4	136
2816	Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs, 2020, 80, 1203-1210.	4.9	21
2817	CDK4/6 and MAPKâ€"Crosstalk as Opportunity for Cancer Treatment. Pharmaceuticals, 2020, 13, 418.	1.7	28
2818	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Seminars in Cancer Biology, 2022, 79, 180-196.	4.3	64
2819	Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo. Head and Neck, 2020, 42, 3678-3684.	0.9	5
2820	Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. Frontiers in Cell and Developmental Biology, 2020, 8, 758.	1.8	97
2821	Four component synthesis of pyrrolo[3,2-c]pyridin-4-one derivatives. Tetrahedron Letters, 2020, 61, 152253.	0.7	6
2822	Metabolic implication of tigecycline as an efficacious secondâ€line treatment for sorafenibâ€resistant hepatocellular carcinoma. FASEB Journal, 2020, 34, 11860-11882.	0.2	13
2823	The hypertensive effect of sorafenib is abolished by sildenafil. Cardio-Oncology, 2020, 6, 7.	0.8	2
2824	Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization. Molecules, 2020, 25, 3468.	1.7	16
2825	Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. International Journal of Molecular Sciences, 2020, 21, 6885.	1.8	156
2826	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. Crystals, 2020, 10, 725.	1.0	4
2827	Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy. Theranostics, 2020, 10, 10498-10512.	4.6	13
2828	The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World Journal of Surgical Oncology, 2020, 18, 243.	0.8	18
2829	Primary Treatment with Molecularâ€Targeted Agents for Hepatocellular Carcinoma: A Propensity Scoreâ€matching Analysis. Hepatology Communications, 2020, 4, 1218-1228.	2.0	21
2830	Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients . Cancer Management and Research, 2020, Volume 12, 5365-5372.	0.9	8
2831	Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study). Pediatric Blood and Cancer, 2020, 67, e28655.	0.8	10

#	Article	IF	Citations
2832	Sorafenib as secondâ€line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. JGH Open, 2020, 4, 1135-1139.	0.7	14
2833	Prognostic Performance of Albuminâ€“Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Oncology, 2020, 10, 525461.	1.3	15
2834	Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. Biomolecules, 2020, 10, 1673.	1.8	43
2835	Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. Current Oncology, 2020, 27, 152-164.	0.9	14
2836	Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Communications, 2020, 40, 681-693.	3.7	40
2838	Kinetic Study of Glucosamine Production Using Aspergillus sydowii BCRC 31742 under Solid-State Fermentation. Molecules, 2020, 25, 4832.	1.7	5
2839	Synthesis and biological evaluation of a new series of 1-aryl-3-[4-(pyridin-2-ylmethoxy)phenyl]urea derivatives as new anticancer agents. Medicinal Chemistry Research, 2020, 29, 1413-1423.	1.1	4
2840	KinomeRun: An interactive utility for kinome target screening and interaction fingerprint analysis towards holistic visualization on kinome tree. Chemical Biology and Drug Design, 2020, 96, 1162-1175.	1.5	2
2841	Molecular targeting of renal cell carcinoma by an oral combination. Oncogenesis, 2020, 9, 52.	2.1	8
2842	Navigating the new landscape of secondâ€line treatment in advanced hepatocellular carcinoma. Liver International, 2020, 40, 1800-1811.	1.9	33
2843	MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib . OncoTargets and Therapy, 2020, Volume 13, 3557-3570.	1.0	23
2844	Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1243.	1.7	11
2845	Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. Molecular and Cellular Proteomics, 2020, 19, 884-899.	2.5	29
2846	Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 892-908.e11.	7.2	92
2847	Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 487-505.	8.2	458
2848	Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-Î°B signaling. BMC Cancer, 2020, 20, 386.	1.1	13
2849	The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduction and Targeted Therapy, 2020, 5, 87.	7.1	433
2850	Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients. Journal of Clinical Medicine, 2020, 9, 1765.	1.0	22

#	Article	IF	Citations
2851	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Clinical Cancer Research, 2020, 26, 4478-4484.	3.2	20
2852	A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. Clinical Journal of Gastroenterology, 2020, 13, 902-906.	0.4	2
2853	Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 1875.	1.8	20
2854	Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells. Biochemical Pharmacology, 2020, 176, 113902.	2.0	22
2855	Pro-angiogenic activity of Tongnao decoction on HUVECs in vitro and zebrafish in vivo. Journal of Ethnopharmacology, 2020, 254, 112737.	2.0	7
2856	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 269-285.	2.3	14
2857	Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib. Cardiovascular Toxicology, 2020, 20, 380-389.	1.1	7
2858	Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. Cells, 2020, 9, 1619.	1.8	60
2859	Clinicopathological and molecular analysis of SIRT7 in hepatocellular carcinoma. Pathology, 2020, 52, 529-537.	0.3	6
2860	Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2. Hormone and Metabolic Research, 2020, 52, 588-597.	0.7	9
2861	A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. British Journal of Cancer, 2020, 122, 963-970.	2.9	17
2862	Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers, 2020, 12, 491.	1.7	213
2863	Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma. Investigational New Drugs, 2020, 38, 1559-1569.	1.2	31
2864	Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound. Technology in Cancer Research and Treatment, 2020, 19, 153303381988689.	0.8	2
2865	Antiâ€angiogenic effects of the blueâ€green alga Arthrospira platensis on pancreatic cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 2402-2415.	1.6	10
2866	TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. Biomedicine and Pharmacotherapy, 2020, 126, 109862.	2.5	22
2867	Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo. Journal of Ethnopharmacology, 2020, 256, 112664.	2.0	8
2868	Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs - Real World Outcomes, 2020, 7, 141-149.	0.7	33

#	Article	IF	Citations
2869	Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells. Gene, 2020, 737, 144428.	1.0	22
2870	Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies. Journal of Receptor and Signal Transduction Research, 2020, 40, 67-76.	1.3	23
2871	Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date . Cancer Management and Research, 2020, Volume 12, 151-163.	0.9	22
2872	Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1. Frontiers in Oncology, 2020, 9, 1431.	1.3	12
2874	A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2020, 85, 593-604.	1.1	36
2875	Introduction of Mercaptoethyl at Sorafenib Pyridine-2-Amide Motif as a Potentially Effective Chain to Further get Sorafenib-PEG-DGL. Molecules, 2020, 25, 573.	1.7	0
2876	Mini-Review on Targeted Treatment of Desmoplastic Small Round Cell Tumor. Frontiers in Oncology, 2020, 10, 518.	1.3	20
2877	Interleukinâ€1Î² augments the angiogenesis of endothelial progenitor cells in an NFâ€ºB/CXCR7â€dependent manner. Journal of Cellular and Molecular Medicine, 2020, 24, 5605-5614.	1.6	17
2878	Time Course of Changes in Sorafenibâ€Treated Hepatocellular Carcinoma Cells Suggests Involvement of Phosphoâ€Regulated Signaling in Ferroptosis Induction. Proteomics, 2020, 20, 2000006.	1.3	21
2879	High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4302-4312.	3.2	10
2880	Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. Acta Pharmacologica Sinica, 2020, 41, 1609-1620.	2.8	36
2881	Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells. BMC Cancer, 2020, 20, 332.	1.1	19
2882	A Sweet Connection? Fructoseâ€™s Role in Hepatocellular Carcinoma. Biomolecules, 2020, 10, 496.	1.8	11
2883	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers, 2020, 12, 927.	1.7	6
2884	Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells. Journal of Cancer, 2020, 11, 2993-3001.	1.2	18
2885	Drug-pathway association prediction: from experimental results to computational models. Briefings in Bioinformatics, 2021, 22, .	3.2	30
2886	MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma. Cancer Gene Therapy, 2021, 28, 126-140.	2.2	30
2887	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology, 2021, 68, 209-229.	4.3	39

#	Article	IF	Citations
2888	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro-Oncology, 2021, 23, 264-276.	0.6	48
2889	Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma. Cancer Letters, 2021, 496, 169-178.	3.2	34
2890	Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells. European Journal of Medicinal Chemistry, 2021, 210, 113081.	2.6	13
2891	Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Expert Opinion on Investigational Drugs, 2021, 30, 143-152.	1.9	15
2892	Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1317-1325.	1.4	22
2893	Enhancement of Anticancer Efficacy and Tumor Penetration of Sorafenib by Ionic Liquids. Advanced Healthcare Materials, 2021, 10, e2001455.	3.9	20
2894	ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1150-1161.	3.2	42
2895	The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1689.	3.3	11
2896	LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. Clinical Cancer Research, 2021, 27, 2061-2073.	3.2	39
2897	FMSâ€like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Science, 2021, 112, 314-322.	1.7	8
2898	Doseâ€escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAFâ€mutated advanced cancers. Cancer, 2021, 127, 391-402.	2.0	6
2899	Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine. Biomaterials, 2021, 265, 120416.	5.7	74
2900	CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. European Radiology, 2021, 31, 1608-1619.	2.3	4
2901	Fungal Infections in the Setting of Biological Therapies (in the Non-Transplant Host). , 2021, , 803-812.		0
2902	Therapy targeting angiogenic potential of tumor. , 2021, , 113-139.		0
2903	A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy. Biomaterials Science, 2021, 9, 2508-2518.	2.6	5
2904	Liver Cancer (Current Therapies). , 2022, , 112-125.		1
2905	Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma. In Vivo, 2021, 35, 1057-1064.	0.6	6

#	Article	IF	Citations
2906	Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 2021, 135, 71-100.	1.8	46
2907	Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110169.	1.4	74
2908	Computational Prediction of Chemical Tools for Identification and Validation of Synthetic Lethal Interaction Networks. Methods in Molecular Biology, 2021, 2381, 333-358.	0.4	0
2909	Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. Anticancer Research, 2021, 41, 567-582.	0.5	11
2910	Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110136.	1.4	18
2911	Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study. Cancer Medicine, 2021, 10, 914-922.	1.3	10
2912	Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2127-2135.	1.2	2
2913	HSP90Î± Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia. Cancers, 2021, 13, 243.	1.7	23
2914	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery, 2021, 11, 1716-1735.	7.7	30
2915	Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Annals of Translational Medicine, 2021, 9, 283-283.	0.7	13
2916	Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. Oncologist, 2021, 26, 362-e724.	1.9	4
2917	cDNA cloning of a novel lectin that induce cell apoptosis from Artocarpus hypargyreus. Chinese Journal of Natural Medicines, 2021, 19, 81-89.	0.7	0
2918	New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells. International Journal of Molecular Sciences, 2021, 22, 2243.	1.8	9
2919	Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients. BMC Gastroenterology, 2021, 21, 55.	0.8	6
2920	From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review. Frontiers in Veterinary Science, 2021, 8, 623800.	0.9	49
2921	â€œComplimenting the Complementâ€• Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 627701.	1.3	22
2922	LXRÎ± activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nature Cancer, 2021, 2, 201-217.	5.7	27
2923	Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease. Oncology Reviews, 2021, 15, 530.	0.8	9

#	Article	IF	Citations
2924	Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition. Biomolecules and Therapeutics, 2021, 29, 434-444.	1.1	5
2925	Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics. Current Oncology Reports, 2021, 23, 31.	1.8	28
2926	Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action. International Journal of Molecular Sciences, 2021, 22, 2806.	1.8	34
2927	Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals, 2021, 14, 280.	1.7	11
2928	Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors. European Journal of Medicinal Chemistry, 2021, 213, 113192.	2.6	16
2929	Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3027-e3036.	1.8	15
2931	Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. Scientific Reports, 2021, 11, 4834.	1.6	1
2932	Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3Î² signaling axis in hepatocellular carcinoma cells. Anti-Cancer Drugs, 2021, 32, 727-733.	0.7	6
2933	Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model. Journal of Clinical Imaging Science, 2021, 11, 15.	0.4	1
2934	7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a â€œCut and Glueâ€•Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors. Molecules, 2021, 26, 1611.	1.7	3
2935	Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1343-1354.	0.9	5
2936	How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals, 2021, 14, 233.	1.7	9
2937	Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2021, 88, 143-153.	1.1	7
2938	Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib. Cancers, 2021, 13, 2064.	1.7	3
2939	Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 4804.	1.8	10
2940	Dabrafenib Promotes Schwann Cell Differentiation by Inhibition of the MEK-ERK Pathway. Molecules, 2021, 26, 2141.	1.7	4
2941	Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. Bioorganic Chemistry, 2021, 109, 104715.	2.0	8
2942	A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physicianâ€™s Choice in a New Therapeutic Scenario. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 241-251.	1.8	12

#	Article	IF	Citations
2943	Effect of Allium senescens Extract on Sorafenib Resistance in Hepatocarcinoma Cells. Applied Sciences (Switzerland), 2021, 11, 3696.	1.3	0
2944	Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression. Life Sciences, 2021, 271, 119149.	2.0	8
2945	Pathway-Based Drug Repurposing with DPNetinfer: A Method to Predict Drugâ€“Pathway Associations via Network-Based Approaches. Journal of Chemical Information and Modeling, 2021, 61, 2475-2485.	2.5	8
2946	Pt(IV) Prodrugs Designed to Embed in Nanotubes of a Polysaccharide for Drug Delivery. ACS Applied Bio Materials, 2021, 4, 4841-4848.	2.3	5
2947	Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future. Anti-Cancer Drugs, 2021, 32, 593-601.	0.7	3
2948	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. Oral Oncology, 2021, 115, 105222.	0.8	11
2949	Integrated computational approaches on pyrazoline derivatives as B-Raf kinase inhibitors for the development of novel anticancer agents. Journal of Molecular Structure, 2021, 1230, 129861.	1.8	2
2950	The Future of Clinical Trial Design in Oncology. Cancer Discovery, 2021, 11, 822-837.	7.7	32
2951	The effect of interleukinâ€17F on vasculogenic mimicry in oral tongue squamous cell carcinoma. Cancer Science, 2021, 112, 2223-2232.	1.7	8
2952	Sorafenib Modulates the LPS- and AÎ²-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice. Frontiers in Immunology, 2021, 12, 684344.	2.2	14
2953	Targeting the VEGF Pathway in Osteosarcoma. Cells, 2021, 10, 1240.	1.8	24
2954	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental and Clinical Cancer Research, 2021, 40, 172.	3.5	104
2955	Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer, 2021, 21, 569.	1.1	17
2956	Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Scientific Reports, 2021, 11, 9587.	1.6	10
2957	Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Cancers, 2021, 13, 2279.	1.7	10
2958	Live-imaging of endothelial Erk activity reveals dynamic and sequential signalling events during regenerative angiogenesis. ELife, 2021, 10, .	2.8	24
2959	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 477-492.	1.8	15
2960	Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. Journal of Thrombosis and Haemostasis, 2021, 19, 1852-1863.	1.9	17

#	Article	IF	Citations
2961	Heart Failure With Targeted Cancer Therapies. Circulation Research, 2021, 128, 1576-1593.	2.0	33
2962	KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup. Frontiers in Oncology, 2021, 11, 672612.	1.3	38
2963	Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer. Frontiers in Endocrinology, 2021, 12, 667798.	1.5	8
2964	Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives. Frontiers in Pharmacology, 2021, 12, 647591.	1.6	7
2965	Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs. Anticancer Research, 2021, 41, 2569-2573.	0.5	2
2966	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	2.2	20
2967	Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity. Journal of Medicinal Chemistry, 2021, 64, 6877-6901.	2.9	15
2968	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 650486.	2.2	26
2969	Label-Free Quantitative Proteomics Analysis of the Sorafenib Resistance in HepG2 Cells. Journal of Analysis and Testing, 0, , 1.	2.5	1
2970	Rational Design of Novel Inhibitors of Î±-Glucosidase: An Application of Quantitative Structure Activity Relationship and Structure-Based Virtual Screening. Pharmaceuticals, 2021, 14, 482.	1.7	22
2971	RAF-MEK-ERK pathway in cancer evolution and treatment. Seminars in Cancer Biology, 2022, 85, 123-154.	4.3	113
2972	Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Management and Research, 2021, Volume 13, 4013-4029.	0.9	10
2973	Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 186.	3.5	77
2974	A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. Cancers, 2021, 13, 2913.	1.7	60
2975	Magnetic stimulation of the angiogenic potential of mesenchymal stromal cells in vascular tissue engineering. Science and Technology of Advanced Materials, 2021, 22, 461-480.	2.8	17
2976	Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value. Biomedicine and Pharmacotherapy, 2021, 138, 111529.	2.5	16
2977	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesisâ€"New insight and futuristic vision. International Journal of Biological Macromolecules, 2021, 180, 739-752.	3.6	39
2978	YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports, 2021, 11, 13482.	1.6	13

#	Article	IF	Citations
2979	Validation of ion mobility spectrometry â€•mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase. Rapid Communications in Mass Spectrometry, 2021, , e9130.	0.7	4
2980	Hydrogen Bonds, Topologies, Energy Frameworks and Solubilities of Five Sorafenib Salts. International Journal of Molecular Sciences, 2021, 22, 6682.	1.8	3
2981	Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective. International Journal of Molecular Sciences, 2021, 22, 6538.	1.8	18
2982	TKI-Resistant Renal Cancer Secretes Low-Level Exosomal miR-549a to Induce Vascular Permeability and Angiogenesis to Promote Tumor Metastasis. Frontiers in Cell and Developmental Biology, 2021, 9, 689947.	1.8	26
2983	The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine, 2021, 10, 5395-5404.	1.3	0
2984	The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers, 2021, 13, 3740.	1.7	23
2985	New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1201-1212.	0.9	5
2986	Forward Chemical Genetic Screen for Oxygenâ€Dependent Cytotoxins Uncovers New Covalent Fragments that Target GPX4. ChemBioChem, 2022, 23, .	1.3	5
2987	Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2021, , 1.	1.1	2
2988	SAR131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis through Bcl-2/Bax/Cyto c Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	0.9	2
2989	Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets?. International Journal of Molecular Sciences, 2021, 22, 7138.	1.8	35
2990	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 741-757.	1.8	29
2991	USP29-mediated HIF1Î± stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis. Oncogenesis, 2021, 10, 52.	2.1	33
2992	Anti-angiogenesis in cancer therapeutics: the magic bullet. Journal of the Egyptian National Cancer Institute, 2021, 33, 15.	0.6	32
2993	Whatâ€™s new in musculoskeletal oncology. BMC Musculoskeletal Disorders, 2021, 22, 704.	0.8	8
2994	New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Pharmacological Research, 2021, 170, 105732.	3.1	43
2995	Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles. Digestive and Liver Disease, 2021, 53, 1059-1061.	0.4	0
2996	Research Progress on the Natural Product Aloperine and Its Derivatives. Mini-Reviews in Medicinal Chemistry, 2022, 22, 729-742.	1.1	4

#	Article	IF	Citations
2997	Expression of Cancer Stem Cell Markers EpCAM and CD90 Is Correlated with Anti- and Pro-Oncogenic EphA2 Signaling in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 8652.	1.8	10
2998	An efficient domino strategy for synthesis of 3-substituted 4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine derivatives in water. Molecular Diversity, 2022, 26, 1663-1674.	2.1	3
2999	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	0.8	3
3000	Super-Resolution Ultrasound Localization Microscopy on a Rabbit Liver VX2 Tumor Model: An Initial Feasibility Study. Ultrasound in Medicine and Biology, 2021, 47, 2416-2429.	0.7	20
3001	Identification of key genes affecting porcine fat deposition based on co-expression network analysis of weighted genes. Journal of Animal Science and Biotechnology, 2021, 12, 100.	2.1	22
3002	Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. Journal of Medicinal Chemistry, 2021, 64, 11747-11773.	2.9	13
3003	Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anti-Cancer Drugs, 2022, 33, e813-e817.	0.7	4
3004	Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers, 2021, 13, 4343.	1.7	8
3005	Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review. European Journal of Medicinal Chemistry, 2021, 226, 113867.	2.6	17
3006	Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current. Oncology Letters, 2021, 22, 807.	0.8	2
3007	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. Anti-Cancer Drugs, 2021, 32, 779-785.	0.7	2
3008	Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer, 2021, 10, 561-571.	4.2	11
3009	Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Frontiers in Cell and Developmental Biology, 2021, 9, 694363.	1.8	42
3010	Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. Frontiers in Oncology, 2021, 11, 719623.	1.3	5
3011	Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers. Frontiers in Molecular Medicine, 2021, 1, .	0.6	1
3012	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 4215-4228.	0.5	7
3013	Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals, 2021, 14, 995.	1.7	9
3014	Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2951-2958.	0.5	0

#	Article	IF	Citations
3015	Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2. Bioorganic Chemistry, 2021, 116, 105334.	2.0	6
3016	Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Surgical Oncology, 2021, 39, 101663.	0.8	12
3017	Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer. Journal of Colloid and Interface Science, 2022, 607, 229-241.	5.0	5
3018	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. Journal of Gynecologic Oncology, 2021, 32, e37.	1.0	5
3019	Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells. Anticancer Research, 2021, 41, 645-660.	0.5	2
3020	A Bi₂S₃-embedded gellan gum hydrogel for localized tumor photothermal/antiangiogenic therapy. Journal of Materials Chemistry B, 2021, 9, 3224-3234.	2.9	20
3021	Ras and Ras Signaling as a Therapeutic Target in Cancer. , 2021, , .		0
3022	Predicting HCC Response to Multikinase Inhibitors With InÂVivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1313-1325.	2.3	12
3023	Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 323-337.	1.2	9
3024	Proteogenomic approach to drug targets in osteosarcomas with different original sites. Journal of Electrophoresis, 2021, 65, 1-11.	0.2	1
3026	Follow-up of Oncology Patients Undergoing Chemotherapy. , 2006, , 77-88.		3
3027	Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML). , 2010, , 123-138.		2
3028	Combination Therapies in the Treatment of Primary Liver Cancers. , 2013, , 339-343.		1
3029	The Biology of Thyroid Oncogenesis. Cancer Treatment and Research, 2010, 153, 3-21.	0.2	6
3030	Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 47-67.	0.1	2
3032	Targeted Therapies in Melanoma. Current Clinical Pathology, 2015, , 211-227.	0.0	4
3033	Small Molecule Agents. , 2007, , 337-356.		1
3034	Altered Apoptosis in AML. , 2007, , 133-161.		1

#	Article	IF	Citations
3035	Ras/Raf/MEK Inhibitors. , 2008, , 55-73.		3
3036	The Role of Lymphangiogenesis in Regional Lymph Node Metastasis: Animal Models. , 2009, , 211-226.		1
3037	Receptor Tyrosine Kinase Inhibitors in Rodent Pulmonary Hypertension. Advances in Experimental Medicine and Biology, 2010, 661, 419-434.	0.8	8
3038	Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion. Advances in Experimental Medicine and Biology, 2020, 1202, 151-178.	0.8	27
3039	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 211-226.		5
3040	Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 65-91.	0.1	2
3041	The Ras Signalling Pathway as a Target in Cancer Therapy. , 2007, 172, 125-153.		9
3042	The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatment. , 2007, 172, 155-167.		13
3043	Vascular Endothelial Growth Factor. , 2008, , 395-423.		5
3044	Sorafenib. Recent Results in Cancer Research, 2010, 184, 61-70.	1.8	39
3045	Targeted Agents and Systemic Therapy in Hepatocellular Carcinoma. Recent Results in Cancer Research, 2013, 190, 225-246.	1.8	21
3046	Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. , 2015, , 7-27.		2
3047	Hepatic, Pancreatic and Biliary Cancers. , 2014, , 611-629.		1
3048	Small Molecule-Targeted Therapies for GI Cancers: Success and Failures. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 43-57.	0.2	1
3049	Axitinib for the Management of Metastatic Renal Cell Carcinoma. Drugs in R and D, 2011, 11, 113-126.	1.1	2
3050	Liver and Bile Duct Cancer. , 2008, , 1569-1594.		1
3051	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). Clinical Colorectal Cancer, 2020, 19, 301-310.e1.	1.0	9
3052	Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. European Journal of Medicinal Chemistry, 2020, 200, 112482.	2.6	14

#	Article	IF	Citations
3054	The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian Journal of Andrology, 2010, 12, 527-534.	0.8	12
3056	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 582-587.	0.5	12
3057	Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 125-129.	0.6	10
3058	Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 179-187.	0.6	13
3060	Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHOâ€1701. Cancer Science, 2020, 111, 1774-1784.	1.7	11
3062	The evolving biology and treatment of prostate cancer. Journal of Clinical Investigation, 2007, 117, 2351-2361.	3.9	119
3063	New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation, 2007, 117, 2740-2750.	3.9	180
3064	MicroRNA-106a-3p Induces Apatinib Resistance and Activates Janus-Activated Kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) by Targeting the SOCS System in Gastric Cancer. Medical Science Monitor, 2019, 25, 10122-10128.	0.5	19
3065	Therapeutic strategies for targeting the ovarian tumor stroma. World Journal of Clinical Cases, 2014, 2, 194.	0.3	16
3066	Disrupting the Rb-Raf-1 Interaction: A Potential Therapeutic Target for Cancer. Drug News and Perspectives, 2008, 21, 331.	1.9	21
3067	Cancer Genomics Identifies Regulatory Gene Networks Associated with the Transition from Dysplasia to Advanced Lung Adenocarcinomas Induced by c-Raf-1. PLoS ONE, 2009, 4, e7315.	1.1	33
3068	RAF Kinase Activity Regulates Neuroepithelial Cell Proliferation and Neuronal Progenitor Cell Differentiation during Early Inner Ear Development. PLoS ONE, 2010, 5, e14435.	1.1	36
3069	Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). PLoS ONE, 2012, 7, e26331.	1.1	39
3070	Establishment of HRASG12V Transgenic Medaka as a Stable Tumor Model for In Vivo Screening of Anticancer Drugs. PLoS ONE, 2013, 8, e54424.	1.1	10
3071	Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e55945.	1.1	41
3072	Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells. PLoS ONE, 2013, 8, e61603.	1.1	34
3073	Small Molecule R1498 as a Well-Tolerated and Orally Active Kinase Inhibitor for Hepatocellular Carcinoma and Gastric Cancer Treatment via Targeting Angiogenesis and Mitosis Pathways. PLoS ONE, 2013, 8, e65264.	1.1	15
3074	Recombinant Human Acid Sphingomyelinase as an Adjuvant to Sorafenib Treatment of Experimental Liver Cancer. PLoS ONE, 2013, 8, e65620.	1.1	25

#	Article	IF	Citations
3075	Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLoS ONE, 2013, 8, e69748.	1.1	3
3076	BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib. PLoS ONE, 2013, 8, e83627.	1.1	63
3077	The Relevance of Testing the Efficacy of Anti-Angiogenesis Treatments on Cells Derived from Primary Tumors: A New Method for the Personalized Treatment of Renal Cell Carcinoma. PLoS ONE, 2014, 9, e89449.	1.1	20
3078	Silencing Alpha-Fetoprotein Inhibits VEGF and MMP-2/9 Production in Human Hepatocellular Carcinoma Cell. PLoS ONE, 2014, 9, e90660.	1.1	31
3079	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	1.1	24
3080	Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. PLoS ONE, 2015, 10, e0135165.	1.1	5
3081	Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology, 2017, XX, 1-14.	0.7	16
3082	Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib. Aging, 2019, 11, 12452-12475.	1.4	12
3083	Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.. Oncoscience, 2015, 2, 395-409.	0.9	25
3084	Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget, 2016, 7, 49091-49098.	0.8	35
3085	Elevated expression of eukaryotic translation initiation factor 3H is associated with proliferation, invasion and tumorigenicity in human hepatocellular carcinoma. Oncotarget, 2016, 7, 49888-49901.	0.8	30
3086	Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling. Oncotarget, 2016, 7, 48517-48532.	0.8	11
3087	Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget, 2016, 7, 64400-64409.	0.8	3
3088	Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget, 2016, 7, 83806-83816.	0.8	24
3089	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). Oncotarget, 2016, 7, 73984-73994.	0.8	23
3090	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3Î² phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget, 2013, 4, 1618-1631.	0.8	42
3091	Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. Oncotarget, 2017, 8, 17246-17257.	0.8	26
3092	LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget, 2017, 8, 9251-9266.	0.8	56

#	Article	IF	Citations
3093	Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. Oncotarget, 2017, 8, 23265-23276.	0.8	26
3094	Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Oncotarget, 2017, 8, 29771-29784.	0.8	30
3095	NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget, 2017, 8, 45687-45697.	0.8	7
3096	Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget, 2017, 8, 59601-59608.	0.8	10
3097	Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. Oncotarget, 2017, 8, 80804-80819.	0.8	24
3098	Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. Oncotarget, 2017, 8, 101520-101534.	0.8	8
3099	IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines. Oncotarget, 2017, 8, 103465-103476.	0.8	23
3100	Agrin para-secreted by PDGF-activated human hepatic stellate cells promotes hepatocarcinogenesis in vitro and in vivo. Oncotarget, 2017, 8, 105340-105355.	0.8	30
3101	Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic â€œdual-hitâ€•option. Oncotarget, 2018, 9, 3605-3618.	0.8	25
3102	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget, 2018, 9, 6630-6643.	0.8	42
3103	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget, 2011, 2, 135-164.	0.8	509
3104	Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget, 2018, 9, 16988-16995.	0.8	19
3105	CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget, 2018, 9, 26032-26045.	0.8	26
3106	BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications. Oncotarget, 2014, 5, 11752-11777.	0.8	83
3107	Synergistic antitumor effect of a Î³-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma. Oncotarget, 2018, 9, 34996-35007.	0.8	22
3108	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget, 2015, 6, 41339-41349.	0.8	79
3109	Identification of the Î²-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells. Oncotarget, 2015, 6, 38999-39017.	0.8	17
3110	Sorafenib-induced defective autophagy promotes cell death by necroptosis. Oncotarget, 2015, 6, 37066-37082.	0.8	53

#	Article	IF	Citations
3111	Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma. Oncotarget, 2016, 7, 8253-8267.	0.8	40
3112	SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma. Oncotarget, 2016, 7, 22193-22205.	0.8	6
3113	Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib. Oncotarget, 2016, 7, 35181-35187.	0.8	11
3114	Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. Oncotarget, 2016, 7, 48586-48599.	0.8	14
3115	The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget, 0, 7, 41067-41080.	0.8	14
3116	Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget, 2016, 7, 38292-38305.	0.8	46
3117	Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. Oncotarget, 2016, 7, 38762-38774.	0.8	3
3118	From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers. Cancer Biology and Medicine, 2019, 16, 435-461.	1.4	15
3119	Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 24-24.	1.5	38
3120	Emerging role of MAP kinase pathways as therapeutic targets in COPD. International Journal of COPD, 2006, 1, 137-150.	0.9	57
3121	Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors. Current Medicinal Chemistry, 2014, 21, 1938-1955.	1.2	6
3122	Development of Formulation Methods and Physical Characterization of Injectable Sodium Selenite Nanoparticles for the Delivery of Sorafenib tosylate. Current Pharmaceutical Biotechnology, 2020, 21, 659-666.	0.9	7
3123	Bench to Bedside Targeting of FLT3 in Acute Leukemia. Current Drug Targets, 2010, 11, 781-789.	1.0	33
3124	Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy. Current Drug Targets, 2010, 11, 1000-1017.	1.0	318
3125	Review on EGFR Inhibitors: Critical Updates. Mini-Reviews in Medicinal Chemistry, 2016, 16, 1134-1166.	1.1	150
3126	Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. Current Vascular Pharmacology, 2019, 17, 618-634.	0.8	17
3127	Research Progress of Diphenyl Urea Derivatives as Anticancer Agents and Synthetic Methodologies. Mini-Reviews in Organic Chemistry, 2019, 16, 617-630.	0.6	8
3128	Fluorescent Cascade and Direct Assays for Characterization of RAF Signaling Pathway Inhibitors. Current Chemical Genomics, 2008, 1, 43-53.	2.0	10

#	Article	IF	Citations
3129	The Therapeutic Promise of Anti-Cancer Drugs Against the Ras/Raf/MEK/ERK Pathway. , 2013, , 63-94.		2
3130	Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. Anticancer Research, 2017, 37, 2593-2599.	0.5	17
3131	Recent advances in molecularly targeted therapy in advanced renal cell carcinoma. Therapy: Open Access in Clinical Medicine, 2009, 6, 309-320.	0.2	2
3132	Efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients: a multicenter study of Kanagawa Liver Study Group. Acta Hepatologica Japonica, 2010, 51, 411-417.	0.0	5
3133	A case of hepatocellular carcinoma obtained marked anti-tumor effect by low dose sorafenib after the progression of the disease during high-dose of sorafenib. Acta Hepatologica Japonica, 2012, 53, 564-569.	0.0	3
3134	Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Investigation, 2011, 29, 460-71.	0.6	11
3135	Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer. Ochsner Journal, 2019, 19, 138-151.	0.5	26
3136	Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Disease Markers, 2013, 34, 105-11.	0.6	20
3137	2018 Korean Liver Cancer Associationâ€“National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2019, 20, 1042.	1.5	189
3138	Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Clinical and Molecular Hepatology, 2013, 19, 288.	4.5	15
3139	Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clinical and Molecular Hepatology, 2015, 21, 287.	4.5	30
3140	Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line. Clinical and Molecular Hepatology, 2020, 26, 45-53.	4.5	17
3141	The effect of sorafenib on hepatic stellate cells: implication of its effect on tumor microenvironment. The Korean Journal of Hepatology, 2010, 16, 418.	1.5	1
3142	Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World Journal of Gastroenterology, 2008, 14, 1.	1.4	98
3143	Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World Journal of Gastroenterology, 2008, 14, 2461.	1.4	30
3144	Evolution of systemic therapy of advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 6437.	1.4	55
3145	Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World Journal of Gastroenterology, 2008, 14, 7021.	1.4	11
3146	Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World Journal of Gastroenterology, 2009, 15, 4464.	1.4	46

#	Article	IF	Citations
3147	TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies. World Journal of Gastroenterology, 2009, 15, 5924.	1.4	33
3148	Exploiting novel molecular targets in gastrointestinal cancers. World Journal of Gastroenterology, 2007, 13, 5845.	1.4	16
3149	New approaches in angiogenic targeting for colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5857.	1.4	50
3150	Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib. World Journal of Gastroenterology, 2011, 17, 2450.	1.4	25
3151	Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World Journal of Gastroenterology, 2011, 17, 3922.	1.4	77
3152	Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot study. World Journal of Gastroenterology, 2011, 17, 1045.	1.4	25
3153	Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: A pilot study. World Journal of Gastroenterology, 2012, 18, 5753.	1.4	25
3154	Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications. World Journal of Gastroenterology, 2012, 18, 498.	1.4	52
3155	Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. World Journal of Gastroenterology, 2013, 19, 7316.	1.4	36
3156	Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World Journal of Gastroenterology, 2014, 20, 3135.	1.4	13
3157	Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World Journal of Gastroenterology, 2014, 20, 4151.	1.4	27
3158	p38Î± MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World Journal of Gastroenterology, 2014, 20, 9744.	1.4	181
3159	Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 14505.	1.4	7
3160	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	1.4	41
3161	Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy. World Journal of Gastroenterology, 2014, 20, 15269.	1.4	27
3162	Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World Journal of Gastroenterology, 2017, 23, 7478-7488.	1.4	23
3163	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 3704-3721.	1.4	107
3164	Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma. Radiation Oncology Journal, 2017, 35, 289-294.	0.7	6

#	Article	IF	Citations
3165	Antitumor effects of aconitine in A2780Âcells via estrogen receptor Î²â€‘mediated apoptosis, DNA damage and migration. Molecular Medicine Reports, 2020, 22, 2318-2328.	1.1	12
3166	Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells. Oncology Letters, 2017, 14, 517-524.	0.8	15
3167	Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma. Mathematical Biosciences and Engineering, 2019, 16, 6319-6334.	1.0	13
3168	Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients. Biomedical and Environmental Sciences, 2018, 31, 586-595.	0.2	11
3169	Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. Journal of Gastrointestinal Oncology, 2013, 4, 231-8.	0.6	18
3170	Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. Translational Gastrointestinal Cancer, 2013, 2, 130-144.	3.0	27
3171	Chinese guidelines on the management of renal cell carcinoma (2015 edition). Annals of Translational Medicine, 2015, 3, 279.	0.7	13
3172	Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. Biomolecules and Therapeutics, 2011, 19, 371-389.	1.1	7
3173	Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future. Indian Journal of Urology, 2009, 25, 427.	0.2	11
3175	Management of Hepatocellular Carcinoma: Updated Review. Journal of Cancer Therapy, 2013, 04, 536-545.	0.1	13
3176	Hepatocellular Carcinoma: The Final Moments of Life. Journal of Cancer Therapy, 2013, 04, 377-383.	0.1	3
3177	Metastatic sarcomatoid renal cell carcinoma to the mandible treated with Sorafenib. Open Journal of Stomatology, 2012, 02, 222-227.	0.1	2
3178	Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2020, 12, 663-676.	0.8	13
3179	Current approach in the treatment of hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2010, 2, 348.	0.8	82
3180	Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?. World Journal of Gastrointestinal Oncology, 2015, 7, 172.	0.8	6
3181	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World Journal of Gastrointestinal Oncology, 2016, 8, 389.	0.8	20
3182	Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. World Journal of Hepatology, 2014, 6, 752.	0.8	34
3183	Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World Journal of Hepatology, 2015, 7, 1460.	0.8	16

#	Article	IF	Citations
3184	Biological features and biomarkers in hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 2020.	0.8	12
3185	Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 2309.	0.8	10
3186	Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma: A Case Report. Gut and Liver, 2010, 4, 543-546.	1.4	17
3187	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut and Liver, 2017, 11, 693-701.	1.4	5
3188	2018 Korean Liver Cancer Associationâ€"National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut and Liver, 2019, 13, 227-299.	1.4	255
3189	Synthesis and Antiproliferative Activities of Pyrrolo[2,3-d]pyrimidine Derivatives for Melanoma Cell. Bulletin of the Korean Chemical Society, 2008, 29, 2231-2236.	1.0	15
3190	Synthesis and Antiproliferative Activities of 1-Substituted-3-(3-chloro-5-methoxyphenyl)-4-pyridinylpyrazole Derivatives Against Melanoma Cell Line. Bulletin of the Korean Chemical Society, 2009, 30, 2027-2031.	1.0	12
3191	Design and Synthesis of 3-(3-Chloro-4-substituted phenyl)-4-(pyridin-4-yl)-1Hpyrazole- 1-carboxamide Derivatives and Their Antiproliferative Activity Against Melanoma Cell Line. Bulletin of the Korean Chemical Society, 2011, 32, 821-828.	1.0	15
3192	Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone. European Journal of Chemistry, 2016, 7, 19-29.	0.3	9
3193	Evolving role of Sorafenib in the management of hepatocellular carcinoma. World Journal of Clinical Oncology, 2017, 8, 203.	0.9	32
3194	Drug Interaction between Ginseng Extract (GE) and Sorafenib. Journal of Life Science, 2011, 21, 1518-1525.	0.2	1
3195	Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment. , 0, , .		1
3196	The Involvement of the ERK-Hypoxia-Angiogenesis Signaling Axis and HIF-1 in Hepatocellular Carcinoma. , 0, , .		1
3197	Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. Clinics, 2012, 67, 1093-1099.	0.6	13
3198	Risk of Treatment-related Mortality with Sorafenib in Patients with Cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6681-6686.	0.5	9
3199	Efficacy and Safety of Sorafenib for Advanced Non-Small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5691-5696.	0.5	9
3200	Long Non-coding RNAs and Drug Resistance. Asian Pacific Journal of Cancer Prevention, 2016, 16, 8067-8073.	0.5	43
3201	Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3595-3604.	0.5	77

#	Article	IF	Citations
3202	Metastatic melanoma â€“ a review of current and future drugs. Drugs in Context, 2012, 2012, 1-17.	1.0	25
3203	Engineering of HN3 increases the tumor targeting specificity of exosomes and upgrade the anti-tumor effect of sorafenib on HuH-7 cells. PeerJ, 2020, 8, e9524.	0.9	6
3204	A New Therapeutic Strategy for Hepatocellular Carcinoma by Molecular Targeting Agents via Inhibition of Cellular Stress Defense Mechanisms. Journal of UOEH, 2014, 36, 229-235.	0.3	5
3205	Targeted Therapy. UNIPA Springer Series, 2021, , 181-206.	0.1	0
3206	Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38Î±, and B-Raf. Journal of Medicinal Chemistry, 2021, 64, 15651-15670.	2.9	6
3207	Improved Immunotherapy Efficacy by Vascular Modulation. Cancers, 2021, 13, 5207.	1.7	12
3208	Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection. Cellular and Molecular Bioengineering, 2021, 14, 471-486.	1.0	0
3209	Induction of Apoptosis by Isoalantolactone in Human Hepatocellular Carcinoma Hep3B Cells through Activation of the ROS-Dependent JNK Signaling Pathway. Pharmaceutics, 2021, 13, 1627.	2.0	14
3210	Sorafenib treatment of metastatic melanoma with câ€‘Kit aberration reduces tumor growth and promotes survival. Oncology Letters, 2021, 22, 827.	0.8	7
3211	ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology. Journal of Cellular and Molecular Medicine, 2021, 25, 10591-10603.	1.6	7
3212	Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterology, 2021, 21, 393.	0.8	18
3213	Cytokine Expression and Signaling in Brain Tumors. , 2005, , 193-242.		1
3214	Anti-Ras Strategies for Cancer Treatment. , 2006, , 353-380.		0
3216	Chemotherapy of Liver Tumors. , 2007, , 1298-1311.		0
3217	Retinal Angiogenesis and Growth Factors. , 2007, , 38-77.		0
3218	Antiangiogenic Therapy for Lung Cancer: Small-Molecule Inhibitors. Translational Medicine Series, 2007, , 45-72.	0.0	0
3219	TRAIL Modulators. , 2007, , 219-234.		0
3220	Signal Transduction Inhibitors in Renal Cell Carcinoma. , 2008, , 399-413.		0

#	Article	IF	Citations
3222	HER Family of Receptors as Treatment Targets in Pancreatic Cancer. , 2008, , 609-634.		0
3223	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
3224	Nonsurgical Management of Metastatic Renal Cell Carcinoma. , 2008, , 281-297.		0
3225	Hepatocellular carcinoma: future perspectives. , 2008, , 241-258.		0
3226	MolÃ©cules inhibitrices des rÃ©cepteurs du VEGF. , 2008, , 65-78.		0
3228	Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization. International Journal of Oncology, 0, , .	1.4	2
3229	Therapeutic Targeting of the Melanoma Stem Cell Population. Translational Medicine Series, 2008, , 83-98.	0.0	0
3230	Targeting BRAF Activity as a NovelParadigm for Melanoma Therapy. Translational Medicine Series, 2008, , 67-82.	0.0	0
3232	Grundlagen der systemischen Therapie. , 2009, , 123-167.		0
3233	Targeting Signaling Pathways in Cancer Therapy. , 2009, , 309-326.		0
3234	Signal Transduction Inhibitors in the Treatment of Breast Cancer. , 2009, , 177-201.		0
3235	Tumor Lymphangiogenesis: What We Know and Don't Know. , 2009, , 93-104.		0
3236	Sorafenib in Renal Cell Carcinoma. , 2009, , 167-187.		0
3237	Molecular Pathogenesis of Urothelial Carcinoma and the Development of Novel Therapeutic Strategies. , 2009, , 277-294.		0
3238	CELL CYCLE PHARMACOLOGY, ANTIPROLIFERATION, AND APOPTOSIS. , 2009, , 83-90.		0
3239	Developments in the Management of Genitourinary Malignancies: Prostate Cancer and Renal Cell Carcinoma. , 2009, , 533-544.		0
3240	Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview. , 2009, , 1-12.		0
3241	Molecular Therapeutics of Melanoma. , 2009, , 967-976.		0

#	Article	IF	Citations
3242	Molecular Targeted Therapies for HCC. , 2009, , 589-614.		0
3243	Lymphangiogenesis and Imaging of the Lymphatics in Cancer. Cancer Metastasis - Biology and Treatment, 2009, , 159-184.	0.1	1
3244	Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Use of a Targeted Approach. Current Oncology, 2009, 16, 44-47.	0.9	2
3245	Inherent Resistance to Epidermal Growth Factor Receptor Antibodies in Refractory Metastatic Colorectal Cancer. Journal of Medical Sciences (Faisalabad, Pakistan), 2009, 9, 165-174.	0.0	1
3246	New onset of multiple keratoacanthomas and palmoplantar hyperkeratosis caused by the treatment of metastatic renal cell carcinoma with a new generation multi-kinase inhibitor. BMJ Case Reports, 2009, 2009, bcr0320091687-bcr0320091687.	0.2	1
3247	Angiogenesis Inhibitors in Lung Cancer. , 2010, , 227-252.		1
3248	Evolving treatments of virus-associated HCC new targets and drugs. Frontiers in Bioscience - Scholar, 2010, S2, 439-453.	0.8	0
3249	Chemotherapeutic Agents. , 2010, , 353-372.		0
3250	Application of molecular medicine to pancreatic cancer. Suizo, 2010, 25, 35-45.	0.1	0
3251	Severe hepatic encephalopathy and decrease in enhancement of hepatocellular carcinoma treatedwith sorafenib. International Journal of Case Reports and Images, 2010, 1, 16.	0.0	0
3252	Esophageal metastases of hepatocellular carcinoma following liver transplantation. International Journal of Case Reports and Images, 2010, 1, 7.	0.0	1
3253	Drug Evaluations in Pancreatic Cancer Culture Systems. , 2010, , 1-27.		0
3254	Phase I trial of vinorelbine and sorafenib in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2010, 28, e13576-e13576.	0.8	0
3255	Challenges and Successes in Developing Effective Anti-angiogenic Agents. , 2011, , 347-401.		0
3256	Inhibitors of Tumor Angiogenesis. , 2011, , 331-340.		0
3257	Sorafenib for advanced renal cell carcinoma in real-life practice: a literature review. Health, 2011, 03, 86-92.	0.1	0
3260	Hepatocellular carcinoma showing tumor stain disappearance with sorafenib treatment and reappearance after treatment reduction and interruption. Acta Hepatologica Japonica, 2011, 52, 50-55.	0.0	5
3261	Treatment of Disseminated Melanoma. , 2011, , 629-633.		0

#	Article	IF	Citations
3262	Head and Neck Melanoma. , 2011, , 533-546.		1
3263	Understanding Melanocyte Transformation â€“ A Work in Progress. , 0, , .		0
3264	Meso Porous Silica Nanospheres For Delivery of Multikinase Inhibitor Sorafenib in Chemotherapy- an Invitro Study. Indian Journal of Applied Research, 2011, 4, 203-205.	0.0	0
3266	Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations. , 2012, , 249-264.		0
3267	Molecular-Targeted Therapy for Melanoma. , 2012, , 265-279.		0
3268	KIT as a Therapeutic Target for Melanoma. , 2012, , 43-61.		0
3269	Angiogenesis Inhibitor Therapy in Renal Cell Cancer. , 2012, , 197-207.		0
3270	Abstract B237: Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.. , 2011, , .		0
3271	Anti-Angiogenesis Therapy for Melanoma. , 2012, , 281-294.		0
3272	STAT3 and Src Signaling in Melanoma. , 2012, , 89-105.		0
3273	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.		0
3274	Exploitation of Aberrant Signalling Pathways as Useful Targets for Renal Clear Cell Carcinoma Therapy. , 0, , .		0
3275	Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials. Clinical Investigation, 2011, 1, 1651-1661.	0.0	0
3276	Advances in systemic therapy for hepatocellular carcinoma. , 2012, , 1444-1452.e3.		0
3277	Targeting the VEGF Pathway in Renal Cell Carcinoma. , 2012, , 115-133.		0
3278	Treatment of HCC: Resection, Local-Regional Therapy, Systemic Therapy, and Liver Transplantation. , 2012, , 199-214.		0
3279	Early Efficacy of Sorafenib Therapy in Advanced Hepatocellular Carcinoma. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2012, 37, 158-163.	0.0	0
3280	Current Trends and Future Directions in Clinical Trials for Malignant Melanoma Treatment Using Anti-Angiogenic Strategies. Journal of Cancer Therapy, 2012, 03, 312-320.	0.1	0

#	Article	IF	Citations
3281	Melanoma and Other Skin Cancers. , 2012, , 439-468.		0
3282	Mutations and Tumorigenesis Pathways Driving Personalized Treatment in Non-Small Cell Lung Cancer. , 2012, 02, .		0
3283	Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma. , 2012, , 135-160.		0
3284	New Therapeutic Strategies in Small Cell Lung Cancer: The Stem Cell Target. , 0, , .		0
3285	The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls. , 0, , .		0
3286	Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e15080-e15080.	0.8	0
3287	Overcoming VEGF resistance in renal cancer: biologic and therapeutic implications. Clinical Investigation, 2012, 2, 615-621.	0.0	1
3288	Induktionschemotherapie bei hepatozellulÃren Karzinomen. , 2013, , 225-236.		0
3289	A Case of Nasal/Paranasal Metastatic Renal Cell Carcinoma with VEGF Targeted Therapy. Practica Otologica, 2013, 106, 423-429.	0.0	0
3290	Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 483-495.	0.9	8
3291	Mechanisms of Resistance to Targeted B-Raf Therapies. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 69-88.	0.1	0
3292	Biologic and Systemic Therapies for the Treatment of Hepatocellular Carcinoma. , 2013, , 363-372.		0
3293	A retrospective study of initial dose of sorafenib therapy in Japanese patients with unresectable hepatocellular carcinoma -experiences from a single center. Acta Hepatologica Japonica, 2013, 54, 169-177.	0.0	1
3294	Review on Targeted Treatment of Patients with Advanced-Stage Renal Cell Carcinoma: A Medical Oncologist's Perspective. Asian Pacific Journal of Cancer Prevention, 2013, 14, 609-617.	0.5	7
3295	Economic Impact of Sunitinib and Sorafenib Use in Metastatic Renal Cell Carcinoma Treatment in Veneto Region, Italy. The Open Pharmacology Journal, 2013, 7, 2-8.	0.4	1
3296	Systemic Therapy for Rare Tumours of the Skin and Soft Tissue Tumour. , 2014, , 475-485.		0
3297	Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics. , 2014, , 29-57.		0
3299	Novel Therapeutic Strategies to Combat HCC. , 2014, , 51-63.		0

#	Article	IF	Citations
3300	Liver and Bile Duct Cancer. , 2014, , 1373-1396.e8.		5
3301	Complete Response of Hepatocellular Carcinoma to Sorafenib: A Case Report and Review of Literatures. Journal of Liver, 2014, 03, .	0.3	0
3302	Pharmacogenomics in Molecular Oncology. , 2014, , 405-421.		0
3303	Clinical Activity of Metronomic Chemotherapy in Liver Cancers. , 2014, , 189-202.		0
3304	Cancer of the Kidney. , 2014, , 1416-1444.e5.		1
3305	The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations. Journal of Patient-centered Research and Reviews, 2014, 1, 21-26.	0.6	0
3306	Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma. Journal of the Advanced Practitioner in Oncology, 2014, 5, 47-50.	0.2	5
3307	Liver Metastases from Kidney Cancer. , 2015, , 33-48.		1
3308	Third-Generation TKIs (Axitinib, Tivozanib) in RCC: Enhanced Efficacy and Diminished Toxicity?. , 2015, , 217-236.		1
3309	Medical Management of Metastatic Renal Cell Carcinoma. , 2015, , 401-412.		0
3310	Angiogenesis Inhibitor Therapy in Renal Cell Cancer. , 2015, , 281-294.		0
3311	The Effect of Human Placental Extracts in Suppressing Tumor Cell and Preventing Normal Cell Damage. Japanese Journal of Complementary and Alternative Medicine, 2015, 12, 65-71.	1.0	1
3314	Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies. , 2015, , 555-575.		0
3315	Pharmacology and Clinical Development of New Molecularly Targeted Agents. Current Clinical Pathology, 2015, , 9-29.	0.0	0
3316	Angiogenesis Inhibition in Breast Cancer. , 2016, , 589-616.		0
3317	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
3318	Sorafenib Acts through VEGFR-2 Inhibition in a Metastatic Clear-Cell Sarcoma of the Kidney. Journal of Cancer Therapy, 2016, 07, 487-493.	0.1	0
3319	Systemic Therapy. , 2016, , 335-390.		0

#	Article	IF	Citations
3320	Targeted Therapy in Melanoma. , 2016, , 237-265.		0
3321	Targeted Therapies for Hepatocellular Carcinoma. , 2016, , 513-529.		0
3323	FLT3 Inhibitors. , 2017, , 167-179.		0
3324	Overcoming Treatment Resistance in Hepatocellular Carcinoma: Regorafenib and Lessons from Other Malignancies. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 133-142.	0.1	0
3325	Anti-Angiogenics in Pancreatic Cancer Therapy. , 2017, , 1-20.		0
3326	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 117-131.	0.1	0
3327	A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. Journal of Clinical and Translational Hepatology, 2017, XX, 1-7.	0.7	4
3328	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget, 2017, 8, 47555-47564.	0.8	1
3329	Role of Sunitinib-Induced Hypothyroidism in Oncological Patients. Endocrinology&Metabolism International Journal, 2017, 5, .	0.1	0
3330	New (Medical) Treatment for Thyroid Carcinoma. Endocrinology, 2018, , 1-26.	0.1	0
3331	Management of Distant Metastasis in Differentiated Thyroid Cancer. , 2018, , 121-140.		0
3334	â€œThyroid disfunction induced by sunitinb treatment in oncological patientsâ€• Endocrinology&Metabolism International Journal, 2018, 6, .	0.1	0
3335	Targeted Molecular Therapy. , 2019, , 647-654.		2
3336	DC-Based Immunotherapy Using Vascular Endothelial Cells Cultured in Conditioned Medium as a Vaccine Antigen Exerts an Anti-Tumor Effect by Inhibiting Angiogenesis. BPB Reports, 2019, 2, 99-105.	0.1	1
3337	RET in breast cancer: pathogenic implications and mechanisms of drug resistance. , 2019, 2, 1136-1152.		6
3338	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 1-16.		0
3339	Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report. The Showa University Journal of Medical Sciences, 2019, 31, 373-378.	0.1	0
3340	Angiogenesis Inhibition in Breast Cancer. , 2019, , 507-528.		0

#	Article	IF	Citations
3341	KRAS as Potential Target in Colorectal Cancer Therapy. , 2019, , 389-424.		1
3342	Anti-angiogenics in Pancreatic Cancer Therapy. , 2019, , 415-434.		0
3343	Role of Heat Shock Protein 90 in Mammary Tumorigenesis. Heat Shock Proteins, 2019, , 103-124.	0.2	0
3344	An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era. Journal of Liver Cancer, 2019, 19, 117-127.	0.3	0
3345	Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis. Oncology Letters, 2020, 19, 261-270.	0.8	1
3346	Antitumor mechanism of MAP30 in bladder cancer T24 cells, and its potential toxic effects in mice. Cellular and Molecular Biology, 2020, 66, 42-48.	0.3	5
3348	Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2021, 55, 169-173.	1.1	4
3349	Carnosic acid increases sorafenib-induced inhibition of ERK1/2 and STAT3 signaling which contributes to reduced cell proliferation and survival of hepatocellular carcinoma cells. Oncotarget, 2020, 11, 3129-3143.	0.8	4
3350	Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-31.	1.9	9
3351	Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules. Journal of Clinical Medicine Research, 2020, 12, 26-35.	0.6	1
3352	Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. Topics in Medicinal Chemistry, 2020, , 125-153.	0.4	0
3353	Vaccines as Immunotherapy. , 2021, , 31-61.		1
3354	Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation. Journal of Liver Cancer, 2020, 20, 84-89.	0.3	0
3355	Targeted therapy for gastrointestinal and pancreatic neuroendocrine tumors. Malignant Tumours, 2020, 9, 49-58.	0.1	1
3356	CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1323-1338.	1.8	12
3357	Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy. Cancer Diagnosis & Prognosis, 2021, 1, 491-498.	0.3	1
3358	Aryl hydrocarbon receptor nuclear translocator promotes the proliferation and invasion of clear cell renal cell carcinoma cells potentially by affecting the glycolytic pathway. Oncology Letters, 2020, 20, 56.	0.8	2
3360	Targeted Therapies for Prostate Cancer. , 2008, , 263-290.		0

#	Article	IF	Citations
3364	Therapeutic Counseling for the Medical Management of Renal Cell Carcinoma. , 2008, , 515-534.		0
3366	Clinical Development of Sorafenib (BAY 43â€“9006) VEGFR and RAF Inhibitor. , 2008, , 655-671.		1
3367	Imaging of Treated Liver Tumors and Assessment of Tumor Response to Cytostatic Therapy and Post-Treatment Changes in the Liver. Medical Radiology, 2021, , 349-373.	0.0	0
3368	Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World Journal of Hepatology, 2020, 12, 766-774.	0.8	10
3369	Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis. Anti-Cancer Drugs, 2021, 32, 82-87.	0.7	7
3370	Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 239-46.	0.7	8
3371	Renal cell carcinoma and the use of sorafenib. Therapeutics and Clinical Risk Management, 2006, 2, 87-98.	0.9	12
3372	Current management of advanced hepatocellular carcinoma. Gastrointestinal Cancer Research: GCR, 2008, 2, 64-70.	0.8	18
3373	Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. Gastrointestinal Cancer Research: GCR, 2007, 1, S85-9.	0.8	0
3375	The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics: Targets and Therapy, 2007, 1, 407-14.	3.0	6
3376	Targeted therapy in melanoma. Biologics: Targets and Therapy, 2009, 3, 475-84.	3.0	12
3380	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Annals of Thoracic and Cardiovascular Surgery, 2009, 15, 213-20.	0.3	9
3381	Systems approaches to polypharmacology and drug discovery. Current Opinion in Drug Discovery & Development, 2010, 13, 297-309.	1.9	115
3382	Preclinical molecular imaging of tumor angiogenesis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 291-308.	0.4	29
3383	New horizons in melanoma treatment: targeting molecular pathways. Ochsner Journal, 2010, 10, 93-8.	0.5	1
3386	Angiogenesis and melanoma - from basic science to clinical trials. American Journal of Cancer Research, 2011, 1, 852-68.	1.4	21
3387	Metastatic medullary thyroid carcinoma: A case report. Journal of Research in Medical Sciences, 2011, 16, 568-73.	0.4	3
3389	Systemic therapy for metastatic renal cell carcinoma: a review and update. Reviews in Urology, 2012, 14, 65-78.	0.9	18

#	Article	IF	Citations
3392	The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P and T, 2013, 38, 96-108.	1.0	69
3393	RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. International Journal of Clinical and Experimental Pathology, 2014, 7, 1085-92.	0.5	14
3394	Valproic acid overcomes transforming growth factor-Î²-mediated sorafenib resistance in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 1299-313.	0.5	13
3395	Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 259-64.	0.6	10
3396	Right cervical lymphadenopathy: a rare presentation of metastatic hepatocellular carcinoma. Gastroenterology and Hepatology From Bed To Bench, 2014, 7, 177-82.	0.6	6
3397	A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression. Journal of Gastrointestinal Oncology, 2014, 5, E121-4.	0.6	2
3398	FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. Nagoya Journal of Medical Science, 2015, 77, 7-17.	0.6	37
3399	Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy. Translational Lung Cancer Research, 2012, 1, 72-7.	1.3	3
3400	Biomarkers for tyrosine kinase inhibitors in renal cell cancer. Translational Andrology and Urology, 2012, 1, 216-22.	0.6	0
3401	The effect of sorafenib on liver regeneration and angiogenesis after partial hepatectomy in rats. Hippokratia, 2015, 19, 249-55.	0.3	2
3403	Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. Journal of Nature and Science, 2018, 4, .	1.1	5
3404	Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre. International Journal of Hematology-Oncology and Stem Cell Research, 2018, 12, 197-203.	0.3	0
3405	New Treatment Options for Metastatic Thyroid Cancer. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 21S-26S.	0.6	2
3406	Current and Future Systemic Therapies for Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2019, 15, 266-272.	0.2	9
3408	Silencing reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging, 2020, 12, 22975-23003.	1.4	0
3409	Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis. EXCLI Journal, 2021, 20, 1-16.	0.5	0
3410	Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 337-349.	1.4	0
3411	Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 1745-1745.	0.7	2

#	Article	IF	Citations
3412	Regulated Cell Death in Urinary Malignancies. Frontiers in Cell and Developmental Biology, 2021, 9, 789004.	1.8	11
3413	Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. Cancers, 2021, 13, 5896.	1.7	15
3414	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high <scp>NANOG</scp> expression. Kaohsiung Journal of Medical Sciences, 2022, 38, 157-164.	0.8	1
3415	PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors. Pharmacogenomics Journal, 2022, 22, 82-88.	0.9	7
3416	PET/MR in recurrent glioblastoma patients treated with regorafenib: [¹⁸F]FET and DWI-ADC for response assessment and survival prediction. British Journal of Radiology, 2022, 95, 20211018.	1.0	13
3417	Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. Frontiers in Pharmacology, 2021, 12, 772510.	1.6	42
3418	Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World Journal of Gastrointestinal Oncology, 2021, 13, 1813-1832.	0.8	11
3419	Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. Journal of Cancer Research and Practice, 2021, 8, 127.	0.2	2
3420	Comparing the Effectiveness and Safety of Sorafenib Plus TACE with Apatinib Plus Tace for Treating Patients with Unresectable Hepatocellular Carcinoma: A Multicentre Propensity Score Matching Study. SSRN Electronic Journal, 0, , .	0.4	0
3421	MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death and Disease, 2022, 13, 35.	2.7	22
3422	Nimbolide-encapsulated PLGA nanoparticles induces Mesenchymal-to-Epithelial Transition by dual inhibition of AKT and mTOR in pancreatic cancer stem cells. Toxicology in Vitro, 2022, 79, 105293.	1.1	12
3423	Hypoxia signaling and oxygen metabolism in cardio-oncology. Journal of Molecular and Cellular Cardiology, 2022, 165, 64-75.	0.9	6
3424	Sorafenib resistance and autophagy in hepatocellular carcinoma: A concealed threat. Journal of Cancer Research and Practice, 2019, 6, 107.	0.2	5
3425	Silencing <italic>KIF14</italic> reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging, 2020, 12, 22975-23003.	1.4	6
3426	Progress in the Treatment of Hepatocellular Carcinoma Based on Hepatic Arterial Infusion Chemotherapy. Advances in Clinical Medicine, 2022, 12, 587-592.	0.0	0
3427	Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Science Advances, 2022, 8, eabh2635.	4.7	35
3428	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 2022, 14, 621.	1.7	34
3429	Synthesis, Structural Characterization and Anticancer Activity of New 5-Trifluoromethyl-2-thioxo-thiazolo[4,5-d]pyrimidine Derivatives. Pharmaceuticals, 2022, 15, 92.	1.7	4

#	Article	IF	Citations
3430	Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy. Cancer Chemotherapy and Pharmacology, 2022, 89, 331-346.	1.1	14
3431	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 71-90.	2.3	248
3432	Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker Research, 2022, 10, 3.	2.8	94
3433	New approaches for patients with advanced radioiodine-refractory thyroid cancer. World Journal of Clinical Oncology, 2022, 13, 9-27.	0.9	8
3434	Identification of Potential Candidate Genes From Co-Expression Module Analysis During Preadipocyte Differentiation in Landrace Pig. Frontiers in Genetics, 2021, 12, 753725.	1.1	2
3435	Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment. Journal of Translational Medicine, 2022, 20, 62.	1.8	7
3436	Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition. Biochemical Pharmacology, 2022, 197, 114914.	2.0	1
3437	Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. Hepatoma Research, 0, , .	0.6	3
3438	Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review. Musculoskeletal Surgery, 2023, 107, 7-18.	0.7	11
3439	Zinc supplementation ameliorates sorafenib-induced cognitive impairment through ROS/JNK signaling pathway. Biological Trace Element Research, 2023, 201, 324-337.	1.9	4
3440	Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell International, 2022, 22, 73.	1.8	21
3441	Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. Frontiers in Molecular Biosciences, 2021, 8, 810251.	1.6	2
3442	Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 134-144.	0.6	19
3443	Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 780798.	1.3	1
3444	Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. International Journal of Molecular Sciences, 2021, 22, 13627.	1.8	16
3445	Investigating the Association between COMMD3 Expression and the Prognosis of Hepatocellular Carcinoma. Journal of Cancer, 2022, 13, 1871-1881.	1.2	5
3446	Single-center Clinical Experience of Diarrhea in Patients Treated With Sorafenib Shows Rare Development of Pancreatic Atrophy. , 2022, 1, 296-298.		0
3447	Design, Synthesis and Biological Evaluation of Novel Indole-Containing Sorafenib Derivatives. Heterocycles, 2022, 104, 667.	0.4	0

#	Article	IF	Citations
3448	In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition. European Journal of Surgical Oncology, 2022, 48, 1527-1535.	0.5	7
3449	Fibroblasts from Patients with Melorheostosis Promote Angiogenesis in Healthy Endothelial Cells through Secreted Factors. Journal of Investigative Dermatology, 2022, 142, 2406-2414.e5.	0.3	2
3450	Comparison of External Beam Radiation Therapy Modalities for Hepatocellular Carcinoma With Macrovascular Invasion: A Meta-Analysis and Systematic Review. Frontiers in Oncology, 2022, 12, 829708.	1.3	2
3451	Ferroptosis in Cancer Immunotherapyâ€"Implications for Hepatocellular Carcinoma. Immuno, 2022, 2, 185-217.	0.6	3
3452	Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. Neurotherapeutics, 2022, 19, 616-634.	2.1	12
3453	Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. Journal of Clinical Medicine, 2022, 11, 1444.	1.0	12
3454	BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. Frontiers in Oncology, 2022, 12, 863043.	1.3	16
3455	A guide to enzyme kinetics in early drug discovery. FEBS Journal, 2023, 290, 2292-2305.	2.2	7
3456	Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria. Journal of Liver Cancer, 2022, 22, 63-68.	0.3	2
3457	Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Frontiers in Endocrinology, 2022, 13, 864253.	1.5	17
3458	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 869672.	1.3	30
3459	Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterology, 2022, 22, 135.	0.8	9
3460	Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions. Current Topics in Medicinal Chemistry, 2022, 22, 891-920.	1.0	7
3461	Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer. Frontiers in Molecular Biosciences, 2022, 9, 753318.	1.6	7
3462	Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 116.	3.5	19
3463	The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-9.	0.7	4
3464	Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. European Journal of Medicinal Chemistry, 2022, 232, 114205.	2.6	66
3465	Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers, 2022, 14, 1826.	1.7	23

#	Article	IF	Citations
3466	miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. Pathology Research and Practice, 2022, 233, 153886.	1.0	53
3467	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clinical Cancer Research, 2022, 28, 748-755.	3.2	9
3468	Stress Granules in the Anti-Cancer Medications Mechanism of Action: A Systematic Scoping Review. Frontiers in Oncology, 2021, 11, 797549.	1.3	3
3469	Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer. Biomedicines, 2022, 10, 77.	1.4	12
3470	Treatment of AML Relapse After Allo-HCT. Frontiers in Oncology, 2021, 11, 812207.	1.3	16
3471	Sempervirine Inhibits Proliferation and Promotes Apoptosis by Regulating Wnt/Î²-Catenin Pathway in Human Hepatocellular Carcinoma. Frontiers in Pharmacology, 2021, 12, 806091.	1.6	8
3472	Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World Journal of Gastrointestinal Oncology, 2021, 13, 1919-1938.	0.8	15
3473	A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. Frontiers in Oncology, 2021, 11, 788635.	1.3	9
3474	Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 31-40.	1.9	1
3475	Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics, 2022, 14, 41.	2.0	27
3477	Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Annals of Hepatology, 2022, , 100710.	0.6	5
3488	KSR2-14â€“3-3Î¶ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma. Biomarker Research, 2022, 10, 25.	2.8	0
3490	Targeted therapy in melanoma. Biologics: Targets and Therapy, 2009, 3, 475.	3.0	4
3491	Anti-tumor activity of motesanib in a medullary thyroid cancer model. Journal of Endocrinological Investigation, 2012, 35, 181-90.	1.8	16
3497	Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model. Medical Oncology, 2022, 39, 87.	1.2	0
3498	ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression. Frontiers in Pharmacology, 2022, 13, .	1.6	5
3499	Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking. Bioorganic Chemistry, 2022, 125, 105861.	2.0	11
3500	Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity. European Journal of Medicinal Chemistry, 2022, 238, 114434.	2.6	7

#	Article	IF	Citations
3501	Increased migration and motility in XIAP-null cells mediated by the C-RAF protein kinase. Scientific Reports, 2022, 12, 7943.	1.6	0
3502	Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review. Medicina (Lithuania), 2022, 58, 666.	0.8	1
3503	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. International Journal of Molecular Sciences, 2022, 23, 5731.	1.8	9
3505	Lycopene in Combination With Sorafenib Additively Inhibits Tumor Metastasis in Mice Xenografted With Lewis Lung Carcinoma Cells. Frontiers in Nutrition, 2022, 9, .	1.6	5
3506	<scp>SREBF2â€“STARD4</scp> axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. Cancer Science, 2023, 114, 477-489.	1.7	8
3507	Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors. Frontiers in Veterinary Science, 0, 9, .	0.9	5
3508	Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-ÎºB pathways and LncRNA-AF085935/GPC3 axis. Life Sciences, 2022, 303, 120675.	2.0	42
3509	Microvesicles: the functional mediators in sorafenib resistance. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0.784314 rgBT /Overlock	0.9	0
3510	Perindopril sensitizes hepatocellular carcinoma to chemotherapy: A possible role of leptin / Wnt/ Î²-catenin axis with subsequent inhibition of liver cancer stem cells. Saudi Pharmaceutical Journal, 2022, 30, 1170-1180.	1.2	3
3511	Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, â€œNakedâ€•Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells. International Journal of Molecular Sciences, 2022, 23, 6641.	1.8	12
3512	Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in coreâ€“shell protein nanoparticle. Drug Delivery and Translational Research, 2022, 12, 2824-2837.	3.0	10
3513	Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression. Cell Death Discovery, 2022, 8, .	2.0	12
3514	Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Science, 2022, 113, 3193-3210.	1.7	5
3515	Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes. Computers in Biology and Medicine, 2022, 148, 105701.	3.9	7
3516	Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR. , 2022, , 83-102.		0
3517	Molecular Phenotypes of Endothelial Cells in Malignant Tumors. , 2022, , 31-52.		3
3518	The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2022, , .	0.1	0
3519	Tivozanib for the treatment of advanced renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2022, 23, 1135-1142.	0.9	1

#	Article	IF	Citations
3520	Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. , 2023, , 109-132.		0
3521	Painful Rashes on the Palms and Soles. Annals of the Academy of Medicine, Singapore, 2016, 45, 479-480.	0.2	1
3522	Hypertension in Cancer Survivors. Current Hypertension Reports, 0, , .	1.5	0
3523	Rhamnazin Inhibits Hepatocellular Carcinoma Cell Aggressiveness in Vitro via Glutathione Peroxidase 4-Dependent Ferroptosis. Tohoku Journal of Experimental Medicine, 2022, 258, 111-120.	0.5	11
3524	Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells. Cancer Biology and Medicine, 2022, 19, 1061-1077.	1.4	3
3525	RET signaling pathway and RET inhibitors in human cancer. Frontiers in Oncology, 0, 12, .	1.3	22
3526	Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. Frontiers in Genetics, 0, 13, .	1.1	10
3527	Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma. Cancer Cell International, 2022, 22, .	1.8	2
3528	Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification. ACS Applied Materials & Interfaces, 2022, 14, 37540-37552.	4.0	22
3530	Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. Cancers, 2022, 14, 4028.	1.7	25
3531	Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights. Antioxidants, 2022, 11, 1645.	2.2	26
3532	Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4115-e4123.	1.8	6
3533	Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinomaâ€"Future or the Past?. Cancers, 2022, 14, 3777.	1.7	6
3534	Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Current Oncology, 2022, 29, 5489-5507.	0.9	19
3535	Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2022, 153, 113540.	2.5	3
3536	Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity. Cancer Letters, 2022, 547, 215880.	3.2	18
3537	Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma. International Immunopharmacology, 2022, 112, 109110.	1.7	10
3538	Pyridine ring as an important scaffold in anticancer drugs. , 2023, , 375-410.		1

#	Article	IF	Citations
3539	Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy. Theranostics, 2022, 12, 6576-6594.	4.6	31
3540	Inhibitory effects of Thai herbal extracts on the cytochrome P450 3A-mediated the metabolism of gefitinib, lapatinib and sorafenib. Toxicology Reports, 2022, 9, 1846-1852.	1.6	0
3541	Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling. Translational Cancer Research, 2022, 11, 2553-2561.	0.4	2
3542	An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors. Frontiers in Oncology, 0, 12, .	1.3	12
3543	Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Molecules, 2022, 27, 5537.	1.7	9
3544	Breast Tumor Cell-Stimulated Bone Marrow-Derived Mesenchymal Stem Cells Promote the Sprouting Capacity of Endothelial Cells by Promoting VEGF Expression, Mediated in Part through HIF-1Î± Increase. Cancers, 2022, 14, 4711.	1.7	3
3545	A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology, 2022, 29, 6445-6462.	0.9	6
3546	Computer-Aided Drug Design Boosts RAS Inhibitor Discovery. Molecules, 2022, 27, 5710.	1.7	6
3547	Urea-based anticancer agents. Exploring 100-years of research with an eye to the future. Frontiers in Chemistry, 0, 10, .	1.8	11
3548	ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression. Frontiers in Pharmacology, 0, 13, .	1.6	14
3549	An insight on the different synthetic routes for the facile synthesis of O/S-donor carbamide/thiocarbamide analogs and their miscellaneous pharmacodynamic applications. Journal of Sulfur Chemistry, 2023, 44, 90-147.	1.0	1
3550	FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 137-147.	1.2	4
3551	Unfolded protein response at the cross roads of tumourigenesis, oxygen sensing and drug resistance in clear cell renal cell carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188814.	3.3	4
3552	Application of genomic selection and experimental techniques to predict cell death and immunotherapeutic efficacy of ferroptosis-related CXCL2 in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
3553	Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2022, 23, 12708.	1.8	6
3554	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
3555	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 583-705.	4.5	102
3556	Anticancer Tetrahydrocarbazoles: A Wide Journey from 2000 Till Date. Letters in Drug Design and Discovery, 2024, 21, 421-439.	0.4	0

#	Article	IF	Citations
3557	Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Communications, 2023, 43, 42-74.	3.7	9
3558	Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study. Scientific Reports, 2022, 12, .	1.6	4
3559	Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib. Cancer Research, 2022, 82, 3665-3667.	0.4	4
3560	Sorafenib-Entrapped, Self-Assembled Pullulanâ€“Stearic Acid Biopolymer-Derived Drug Delivery System to PLC/PRF/5 Hepatocellular Carcinoma Model. International Journal of Nanomedicine, 0, Volume 17, 5099-5116.	3.3	4
3561	Novel insight into the mechanism underlying synergistic cytotoxicity from two components in 5-Fluorouracil-phenylalanine co-crystal based on cell metabolomics. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 180, 181-189.	2.0	2
3562	Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity. BMC Chemistry, 2022, 16, .	1.6	2
3563	Design, synthesis and biological characteristicsÂof pyrazolo[3,4-d]pyrimidine derivatives as potential VEGFR-2 inhibitors. Future Medicinal Chemistry, 2022, 14, 1649-1662.	1.1	2
3564	Carthami flos extract against carbon tetrachloride-induced liver fibrosis via alleviating angiogenesis in mice. Phytomedicine, 2023, 108, 154517.	2.3	10
3565	Cellular and molecular basis of therapeutic approaches to breast cancer. Cellular Signalling, 2023, 101, 110492.	1.7	10
3566	POCHODNE INDAZOLU JAKO ZWIÄ„ZKI O DZIAÅANIU PRZECIWNOWOTWOROWYM. , 2017, 15, 1-7.		0
3567	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Aheadâ€”A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 14117.	1.8	7
3568	Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment. Cells, 2022, 11, 3613.	1.8	3
3569	Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5127-5138.	1.2	3
3570	Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines, 2022, 10, 2890.	1.4	6
3571	Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML. Frontiers in Pediatrics, 0, 10, .	0.9	0
3573	Microfluidic preparation and optimization of sorafenib-loaded poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 147 Td (g Interface Science, 2023, 633, 383-395.	5.0	3
3574	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126.	1.5	44
3576	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Journal of Liver Cancer, 2023, 23, 1-120.	0.3	24

#	Article	IF	Citations
3577	Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study. Anticancer Research, 2022, 42, 6007-6018.	0.5	1
3578	Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	7
3579	Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1247-1261.	1.8	7
3580	Randomized phase <scp>II</scp> study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (<scp>STARGATE</scp>). Cancer Medicine, 2023, 12, 7784-7794.	1.3	4
3581	Predicting chemical structure using reinforcement learning with a stack-augmented conditional variational autoencoder. Journal of Cheminformatics, 2022, 14, .	2.8	1
3582	Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	27
3583	Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. Biomedicines, 2023, 11, 181.	1.4	4
3584	Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation. Frontiers in Oncology, 0, 12, .	1.3	2
3585	Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment. Pharmaceuticals, 2023, 16, 119.	1.7	4
3587	Secular Trends of Liver Cancer Mortality and Years of Life Lost in Wuhan, China 2010â€“2019. Current Oncology, 2023, 30, 938-948.	0.9	0
3588	Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?. Frontiers in Oncology, 0, 12, .	1.3	3
3589	Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
3590	Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer. Genes and Diseases, 2024, 11, 218-233.	1.5	6
3591	Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management. Cancers, 2023, 15, 179.	1.7	9
3592	NEAT1â€“SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines. Current Issues in Molecular Biology, 2023, 45, 1073-1085.	1.0	2
3593	Ferroptosisâ€modulating small molecules for targeting drugâ€resistant cancer: Challenges and opportunities in manipulating redox signaling. Medicinal Research Reviews, 2023, 43, 614-682.	5.0	20
3594	Impending Chemotherapeutic Impact of Arthrospira platensis Nanoparticles and/or Sorafenib against Hepatocellular Carcinoma through Modulation of Antioxidant Status, Tumor Marker Genes, and Anti-Inflammatory Signaling Pathways. Toxics, 2023, 11, 107.	1.6	1
3595	Synergistic effect of sorafenib with Platycladus orientalis (L) leaf extract on cervical cancer. Bioscience Journal, 0, 39, e39011.	0.4	0

#	Article	IF	Citations
3596	Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
3597	A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. Oncotarget, 2023, 14, 302-315.	0.8	1
3598	Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. Biomedicine and Pharmacotherapy, 2023, 161, 114452.	2.5	5
3599	Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells. Biochemical Pharmacology, 2023, 211, 115538.	2.0	1
3600	Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma. Current Opinion in Pharmacology, 2023, 70, 102365.	1.7	2
3601	Ca2+-Dependent Effects of the Selenium-Sorafenib Nanocomplex on Glioblastoma Cells and Astrocytes of the Cerebral Cortex: Anticancer Agent and Cytoprotector. International Journal of Molecular Sciences, 2023, 24, 2411.	1.8	7
3602	The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 2805.	1.8	6
3603	Exploring the CXCR4/CXCR7/CXCL12 Axis in Primary Desmoid Tumors. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 2248-2253.	0.9	0
3604	Liver Cancer and the Curative Potential of Nanomedicine. , 2023, , 283-306.		0
3605	Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality. , 0, , 66-77.		0
3607	Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma, 0, Volume 10, 267-279.	1.8	1
3608	BRAF v600Eâ€“mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. Npj Precision Oncology, 2023, 7, .	2.3	4
3609	Emerging roles of m6A RNA modification in cancer therapeutic resistance. Experimental Hematology and Oncology, 2023, 12, .	2.0	7
3611	Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	1
3612	Sorafenib Loaded Resealed Erythrocytes for the treatment of Hepatocellular Carcinoma. Recent Advances in Drug Delivery and Formulation, 2023, 17, .	0.3	0
3613	Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers, 2023, 3, 121-160.	0.8	2
3614	Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. Cancer Biomarkers, 2023, 36, 251-266.	0.8	0
3615	Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption. Frontiers in Oncology, 0, 13, .	1.3	3

#	Article	IF	Citations
3616	Evaluation of the Synergistic effect of Curcuma aromatica in combination with Sorafenib on a hepatoblastoma cell line in vitro. Research Journal of Pharmacy and Technology, 2023, , 245-249.	0.2	1
3617	Anti-Angiogenic Activity of Drugs in Multiple Myeloma. Cancers, 2023, 15, 1990.	1.7	2
3618	Evaluation of the anti-proliferative activity of 2-oxo-pyridine and 1â€²H-spiro-pyridine derivatives as a new class of EGFR^{Wt}and VEGFR-2 inhibitors with apoptotic inducers. RSC Advances, 2023, 13, 10440-10458.	1.7	10
3619	Effects of Voluntary Wheel Running Exercise on Chemotherapy-Impaired Cognitive and Motor Performance in Mice. International Journal of Environmental Research and Public Health, 2023, 20, 5371.	1.2	1
3620	A Review On Inhibitory Action of Tyrosine Kinase Inhibitors (TKI) by Curbing the ATP-Tyrosine Kinase Interactions. Current Signal Transduction Therapy, 2023, 18, .	0.3	0
3621	Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs. Frontiers in Oncology, 0, 13, .	1.3	1
3622	BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. Frontiers in Oncology, 0, 13, .	1.3	1
3623	Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. ACS Pharmacology and Translational Science, 2023, 6, 710-726.	2.5	2
3624	Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A singleâ€institution retrospective analysis. Pediatric Blood and Cancer, 2023, 70, .	0.8	1
3644	Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	68
3661	(Benz)imidazoles. , 2023, , 227-256.		0
3662	Studying the Role of ERK Inhibition in Glioblastoma Multiforme. , 2023, , 119-131.		0
3667	An updated literature on BRAF inhibitors (2018â€“2023). Molecular Diversity, 0, , .	2.1	1
3673	Current Pathophysiology, Treatment, and Future Perspective for Prostate Cancer. , 2023, , 1-22.		0
3681	Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML. , 2023, , 151-158.		0
3696	The role of CRAF in cancer progression: from molecular mechanisms to precision therapies. Nature Reviews Cancer, 2024, 24, 105-122.	12.8	3
3708	Radioiodine Refractory Thyroid Cancer. , 2023, , 165-188.		0